

# Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease

A Scientific Statement From the American Heart Association

**ABSTRACT:** Life expectancy and quality of life for those born with congenital heart disease (CHD) have greatly improved over the past 3 decades. While representing a great advance for these patients, who have been able to move from childhood to successful adult lives in increasing numbers, this development has resulted in an epidemiological shift and a generation of patients who are at risk of developing chronic multisystem disease in adulthood. Noncardiac complications significantly contribute to the morbidity and mortality of adults with CHD. Reduced survival has been documented in patients with CHD with renal dysfunction, restrictive lung disease, anemia, and cirrhosis. Furthermore, as this population ages, atherosclerotic cardiovascular disease and its risk factors are becoming increasingly prevalent. Disorders of psychosocial and cognitive development are key factors affecting the quality of life of these individuals. It is incumbent on physicians who care for patients with CHD to be mindful of the effects that disease of organs other than the heart may have on the well-being of adults with CHD. Further research is needed to understand how these noncardiac complications may affect the long-term outcome in these patients and what modifiable factors can be targeted for preventive intervention.

As survival to adulthood in individuals with congenital heart disease (CHD) has improved, adults with CHD are increasingly at risk for noncardiac complications.<sup>1,2</sup> The median age of adults with CHD has increased to 40 years, and the number of adults with CHD >65 years of age is steadily growing.<sup>3-5</sup> As patients age, common adult comorbidities such as diabetes mellitus (DM), coronary artery disease, and hypertension may have an impact on long-term outcomes.<sup>6,7</sup> Residual hemodynamic abnormalities or unrepaired CHD may place them at risk for hematologic, liver, and kidney disease. It has become increasingly important for practitioners who care for adults with CHD to understand not only the late cardiac sequelae of their patients' CHD but also the noncardiac problems that develop in adulthood. The purpose of this review is to provide a state-of-the-art update of noncardiac complications in adults with CHD.

## OVERVIEW

Extracardiac complications are increasingly prevalent in adults with CHD. The prevalence of noncardiac comorbidities such as DM and renal disease is significantly higher in a primary care population of adults with CHD compared with the general population.<sup>8</sup> Even adult patients with simple CHD may have a significant number

George K. Lui, MD, Chair  
Arwa Saidi, MB BCH, Vice Chair

Ami B. Bhatt, MD  
Luke J. Burchill, MD  
Jason F. Deen, MD  
Michael G. Earing, MD  
Michael Gewitz, MD,

FAHA  
Jonathan Ginns, MD  
Joseph D. Kay, MD  
Yuli Y. Kim, MD  
Adrienne H. Kovacs, PhD  
Eric V. Krieger, MD  
Fred M. Wu, MD  
Shi-Joon Yoo, MD, PhD  
On behalf of the American Heart Association Adult Congenital Heart Disease Committee of the Council on Clinical Cardiology and Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; and Council on Quality of Care and Outcomes Research

**Key Words:** AHA Scientific Statements ■ heart defects, congenital ■ heart diseases ■ prevention and control

© 2017 American Heart Association, Inc.

of comorbidities, including DM, stroke, pneumonia, and renal and hepatic dysfunction.<sup>9</sup>

Nearly all organ systems are affected in adults with CHD, and specific populations are at particular risk. In an outpatient study of >1000 adults with CHD, an abnormal glomerular filtration rate (GFR) was noted in ~50%.<sup>10</sup> Greater than 40% of adults with CHD have abnormal pulmonary function tests.<sup>11</sup> Both renal disease and lung disease have been associated with decreased survival in adults with CHD.<sup>10,11</sup> Hepatic dysfunction is an increasingly recognized complication of the Fontan procedure, but its impact remains poorly defined in other adults with CHD.<sup>12</sup> Genetic syndromes are commonly associated with CHD and may lead to unique endocrine and immunological complications.<sup>13</sup> Noncardiac causes of death in patients with Down syndrome include Alzheimer disease, respiratory infections, stroke, DM, and seizures.<sup>14</sup> Cyanotic patients with CHD represent some of the most complex patients, with potential complications affecting nearly all organ systems, including unique hematologic abnormalities. Finally, noncardiac complications are not limited to the physical domain. These individuals are at increased risk for psychological distress, neurocognitive deficits, and social challenges.

The presence of these noncardiac conditions affects the long-term outcomes of individuals with CHD. A recent large population study showed that pneumonia is the second leading cause of death in adults with CHD behind cardiac issues.<sup>15</sup> Other noncardiac causes of death in adults with CHD included cancer, hemorrhage (cerebral, pulmonary, and gastrointestinal), and cerebrovascular events.<sup>15,16</sup> In the German National Registry for CHD, patients who died were reported to have had more noncardiac comorbidities than living patients.<sup>17</sup> The most common comorbidities included renal (21%), lung (18%), and liver (6%) disease.<sup>17</sup> The number of adult patients with >2 noncardiac comorbidities associated with a hospitalization with CHD almost doubled between 1998 and 2010.<sup>18</sup> In a study of 342 adult CHD (ACHD) admissions to an intensive care unit, abnormal thyroid, creatinine, and bilirubin tests were highly predictive of both intensive care unit and hospital mortality.<sup>19</sup> Furthermore, comorbidities can be costly. A recent study demonstrated renal insufficiency as a primary driver of high resource use for ACHD hospitalizations, which account for only 10% of the admissions but make up one third of the total hospital charges.<sup>20</sup>


The impact of noncardiac comorbidities on both cardiac and noncardiac surgery is substantial. Preoperative chronic lung or liver dysfunction is a documented risk factor for increased mortality in adults with CHD undergoing cardiac operations.<sup>21</sup> For noncardiac surgery, adults with CHD are at increased risk of perioperative complications, perioperative mortality, longer length of stay, and higher hospital charges compared with the general population.<sup>22</sup> Specifically, adults with CHD un-

dergoing noncardiac surgery are more likely to develop acute renal failure, pneumonia and respiratory failure, and deep vein thrombosis (DVT)/pulmonary embolism (PE).<sup>22</sup>

The approach to managing noncardiac complications in ACHD requires a multidisciplinary team with expertise in subspecialties such as hepatology, immunology, pulmonology, and nephrology, as well as familiarity with complex CHD. The creation of multidisciplinary clinics such as single-ventricle programs may allow a group of providers to monitor, manage, and possibly initiate preventive strategies to mitigate the effects of end-organ involvement in patients with CHD.<sup>23</sup> It is recommended that adults with CHD be evaluated and cared for in regional ACHD programs.<sup>2</sup> After the publication of the ACHD guidelines by the American College of Cardiology and American Heart Association (AHA),<sup>2</sup> the percentage of adults with CHD receiving their cardiac surgery at dedicated ACHD centers increased from 46% to 71% in California.<sup>24</sup> Referral to regional ACHD programs is associated with lower mortality,<sup>25</sup> and it is imperative that centers allocate resources to provide comprehensive care to this population. To further decrease morbidity and mortality in patients with CHD, understanding and managing noncardiac complications becomes as important as knowing their cardiac history. This review covers some of the organ systems most frequently affected in the adult with CHD (Figure 1).

## RENAL Prevalence

Renal dysfunction has long been described in cyanotic CHD but is common among adults with all forms of CHD.<sup>26,27</sup> In a study cohort of 1102 young adults with CHD, 50% had impaired renal function, with 65% of cyanotic patients having at least mild renal insufficiency (GFR, 60–89 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>).<sup>10</sup> The prevalence of significant renal dysfunction in this study (GFR <60 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>) was 18-fold higher in adults with noncyanotic CHD and 35-fold higher in those with cyanotic CHD compared with the same-aged general population. Patients with Eisenmenger physiology had the highest prevalence of renal dysfunction at 18%. The prevalence of renal dysfunction increases as adults with CHD age. For instance, in patients with Fontan physiology, the prevalence of mild renal dysfunction increased from 10% at 13 to >50% by 26 years of age.<sup>10,28</sup> In addition, renal dysfunction is associated with higher rehospitalization rates, worse surgical outcomes, and increased mortality.<sup>4,10,27,29,30</sup> Adults with CHD with mild renal dysfunction have a 2-fold increase in 6-year mortality, whereas patients with moderate or severe renal dysfunction demonstrate a 5-fold increase.<sup>10</sup>



**Figure 1. Noncardiac complications in adults with congenital heart disease (CHD).**

## Pathogenesis

The heart and kidneys not only are connected by vasculature but also share a complex system of control mediated by neurohormones affecting hemodynamic parameters such as blood pressure and intravascular volume. Multiple signaling pathways communicate between the 2 organ systems, including the renin-angiotensin-aldosterone system, natriuretic peptides, and sympathetic nervous system. Renal disease has long been linked to acquired cardiovascular disease, to common risk factors such as hypertension and DM, and to chronic kidney disease (CKD)-specific risk factors such as chronic anemia, malnutrition, and vascular calcification.<sup>31</sup> These complex cardiac and renal interactions have been codified as cardiorenal syndromes. The most common type in the general population (type 2 cardiorenal syndrome), a condition of chronic cardiac dysfunction leading to kidney injury, is present in ≈63% of patients hospitalized with congestive heart failure<sup>32</sup> and occurs secondary to low cardiac output,<sup>33</sup>

impaired renal blood flow, and renal venous congestion.<sup>34</sup> These factors combined lead to neurohormonal activation and impaired renal autoregulation.<sup>35</sup> CHD not only shares the pathophysiological hemodynamic conditions with congestive heart failure states (impaired cardiac output and increased central venous pressure) but also likely causes the same neurohormonal dysregulation that has untoward effects on the kidney.<sup>36,37</sup> Patients with CHD also have unique risk factors for developing renal dysfunction that occur with cardiac surgery and cardiopulmonary bypass.<sup>38–40</sup> Cardiovascular surgery and cardiopulmonary bypass may limit renal blood flow, causing hypoxemic-ischemic injury, and are known to stimulate aldosterone and vasopressin release. The result is a transient decrease in GFR and acute kidney injury evidenced by an elevated creatinine measurement, which may be repetitive in the case of multiple cardiac surgeries, as is common in patients with CHD. This repeated acute kidney insult is associated with the development of CKD.<sup>41</sup>

Congenital renal anomalies commonly coexist with CHD, may lead to CKD, and may be seen in the VACTERL and CHARGE syndromes. These syndromes consist of vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities in VACTERL and coloboma of the eye, heart defects, atresia of the choanae, retardation of growth and development, and ear abnormalities in CHARGE. A small retrospective series reported that 30% of patients with CHD also had renal anomalies.<sup>42</sup> Although the true prevalence is likely lower, many pediatric cardiac centers actively screen patients with complex CHD for structural renal abnormalities. Renal artery stenosis is prevalent in nonsyndromic (familial supraaortic stenosis) and syndromic (Williams-Beuren syndrome) elastin insufficiency and may contribute to the development of hypertension in those individuals.<sup>43,44</sup> Patients with Williams-Beuren syndrome commonly develop severe hypercalcemia during infancy, although it is not clear if this promotes vascular calcification later in life.<sup>45</sup>

Cyanotic patients with CHD have unique risk factors for developing CKD. These include direct hypoxia leading to early renal tubular injury<sup>46,47</sup> and reactive erythrocytosis. This erythrocytosis induces secondary hyperviscosity leading to engorgement of the glomerular capillary beds, which in turn increases the efferent glomerular arteriolar resistance.<sup>10,48</sup> Eventually, glomerular shrinkage arises and leads to sclerosis. Furthermore, as a result of altered oncotic pressure dynamics in the postglomerular blood vessels, solute resorption and hence fluid retention are favored as glomerular sclerosis occurs.<sup>48</sup> Altered urate clearance with hyperuricemia is common in cyanotic patients; these abnormalities are usually well tolerated in the absence of gout.<sup>49</sup> Because of the presence of glomerular sclerosis and altered osmotic gradients, patients with cyanotic CHD may have significant microalbuminuria or proteinuria that occurs concurrently with azotemia.<sup>50,51</sup> The prevalence of frank proteinuria may be as high as 16% and carries clinical consequences such as increased incident thromboembolic complications.<sup>52</sup> In addition, cyanotic patients may develop secondary renal tubular acidosis with subsequent normal anion gap metabolic acidosis.<sup>53</sup>

## Management

Assessment of kidney function may be accomplished through standard methods of calculating GFR, relying on serum creatinine, age, sex, and race. Normal kidney function is defined as  $\geq 90 \text{ mL}\cdot\text{min}^{-1}\cdot 1.73 \text{ m}^{-2}$ . Because of the high prevalence of renal dysfunction and its indications for clinical mortality and morbidity in adults with CHD, assessment of renal function should be considered at regular intervals, particularly for cyanotic patients or those with Eisenmenger physiology,<sup>2</sup> with consideration for referral to nephrology. This may be

accomplished through creatinine measurement (serum or 24-hour urine) with subsequent calculation of GFR<sup>2</sup> and performed judiciously before procedures such as cardiac catheterization when intravenous contrast use is planned and during the postoperative period.<sup>2</sup> Current practice suggests that cyanotic adults with CHD with a reduction in GFR have a urinalysis to assess for the presence of proteinuria via measurement of a protein-to-creatinine ratio. Another measurement of CKD that may be a better predictor of GFR than serum creatinine is cystatin C.<sup>54–56</sup> Unlike serum creatinine, cystatin C is not affected by age, sex, race, or muscle mass.<sup>54</sup> Cystatin C and urinary biomarkers such as neutrophil gelatinase-associated lipocalin, interleukin-18, liver fatty acid binding protein, and kidney injury molecule-1 have been shown to be predictors of acute kidney injury after cardiac surgery in children and deserve further study in adults with CHD.<sup>54,57</sup> CKD in adults with CHD prompts a review of medications known to be associated with renal dysfunction, particularly those commonly used by adults with CHD such as angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory agents, diuretics, and some antiarrhythmic medications. Use of these known nephrotoxic agents in the setting of CKD warrants careful longitudinal surveillance of renal function. Interventional and surgical procedures ought to be meticulously planned with attention paid to the preprocedural hydration status with renal protection prophylaxis (volume expansion with isotonic saline) used when indicated.<sup>2</sup>

## LUNG Prevalence

Several studies have demonstrated that adults with CHD have reduced pulmonary function resulting from restrictive lung disease compared with healthy controls.<sup>58</sup> Forty-four percent of adults with CHD demonstrated a pattern on spirometry suggestive of restrictive lung disease, which is markedly higher than the 9% prevalence in the general adult population.<sup>59</sup> The prevalence of restrictive lung disease was highest in patients with a history of Fontan procedure (89%) and tetralogy of Fallot (TOF) repair (76%).<sup>59</sup> Forced vital capacity and forced expiratory volume in 1 second have been shown to be reduced in adults with CHD, a finding that is highly suggestive of abnormal pulmonary mechanics.<sup>60,61</sup>

Other pulmonary complications such as pulmonary hemorrhage, recurrent pneumonia, and PE are more common among adults with CHD.<sup>62</sup> Patients with Fontan physiology are at risk for a rare but debilitating complication: plastic bronchitis. The prevalence has been estimated to be 4% in children after Fontan palliation.<sup>63,64</sup> Thromboembolic events, particularly PE, are associated with significant morbidity and mortality in patients with Fontan physiology.<sup>65</sup> Patients with TOF/

pulmonary atresia, multiple aortopulmonary collaterals, and Eisenmenger syndrome are at risk for pulmonary hemorrhage. Hemoptysis can occur in up to 30% of patients with Eisenmenger syndrome.<sup>66,67</sup> Finally, pneumonia has been shown to be one of leading causes of death in adults with CHD.<sup>16</sup> Recurrent pneumonia in adults with CHD is discussed further in the section on infectious disease.

## Pathogenesis

Restrictive lung disease is characterized by reduced lung volumes, resulting from either an intrinsic cause such as an alteration in lung parenchyma or an extrinsic cause such as a disease of the pleura, chest wall, or neuromuscular apparatus.<sup>58</sup> The higher prevalence of restrictive lung physiology in adults with CHD is often secondary to an extrinsic pulmonary cause. The chest wall is an important component of normal respiratory function, and multiple thoracotomies can lead to a restrictive thoracic cage, which in turn disrupts normal chest wall mechanics and respiratory function.<sup>58</sup> A previous thoracotomy has been identified as a strong predictor of restrictive lung physiology.<sup>59</sup> Spinal deformities, including scoliosis and kyphosis, are significantly more common in patients after repair of CHD and may be related to previous thoracotomy or sternotomy.<sup>68</sup> Patients with TOF or Fontan physiology are likely to have undergone multiple previous surgeries and are most likely to have restrictive pulmonary mechanics.<sup>59,61</sup> Diaphragmatic weakness or paralysis is a sequela of congenital heart surgery that can be seen with routine chest x-ray and may further compromise respiratory mechanics. Finally, restrictive lung physiology in the adult with CHD may be related to neuromuscular causes. Respiratory and skeletal muscle weakness was common in young adults with complex CHD and similar to that found in adults with advanced heart failure from acquired disease.<sup>69</sup>

Intrinsic causes of restrictive lung disease include decreased pulmonary blood flow that may hinder growth and development of lung parenchyma, resulting in pulmonary hypoplasia.<sup>70</sup> This may partly explain the significantly higher prevalence of restrictive lung physiology in patients with TOF. Another intrinsic cause of restrictive lung physiology in adults with CHD may be pulmonary toxicity from amiodarone use.<sup>59</sup>

Obesity further exacerbates restrictive lung physiology in adults with CHD. Obesity has a clear impact on chest wall mechanics, may lead to a risk for further physical deconditioning with associated respiratory and skeletal muscle weakness, and is a risk for obstructive sleep apnea. Obstructive sleep apnea affects 9% to 24% of the general population.<sup>71</sup> Although the true prevalence of obstructive sleep apnea in the adult with CHD remains unknown, the potential detrimental effects on pulmonary physiology cannot be overlooked.

These effects include hypoxia, hypoxia-induced pulmonary vasoconstriction, and ultimately, pulmonary hypertension.<sup>71</sup> This is particularly worrisome given that as many as 10% of adults with CHD seen in clinic at baseline have pulmonary hypertension.<sup>67,72</sup>

## Impact

Abnormal lung function is a common and often under-recognized cause of both long-term morbidity and mortality in adults with CHD.<sup>11,59-61</sup> Restrictive lung physiology in particular is a major contributor to reduced exercise tolerance and functional capacity.<sup>59-61</sup> Abnormal lung function, previous cardiac surgery, and low heart rate reserve were associated with reduced exercise capacity in adults with CHD.<sup>59,61</sup> Restrictive lung physiology likely contributes to reduced exercise tolerance by resulting in a decreased ventilator capacity and higher ventilator demand. Thus, during exercise, these patients augment their minute ventilation by increasing their respiratory rate rather than tidal volume.<sup>73</sup> Increased dead space ventilation, decreased vital capacity, reduced respiratory muscle strength from decreased thoracic or lung compliance, and abnormal gas exchange likely also contribute to decreased exercise tolerance in these patients.<sup>73</sup> Abnormal ventilatory response during exercise has been demonstrated in adults with various CHD diagnoses.<sup>74</sup> This is particularly true in patients with restrictive lung physiology and is evidenced by markedly elevated minute ventilation in response to incremental increases in carbon dioxide production compared with healthy adults ( $\dot{V}_E/\dot{V}_{CO_2}$  slope).<sup>74</sup> This finding signifies that the ventilatory demand at any level of exercise for a patient with restrictive physiology is increased. In addition, there is concern for abnormal heart-lung interaction during exercise in patients with moderate restrictive lung dysfunction. Studies suggest that in the setting of restrictive lung disease, right ventricular dysfunction as a result of elevation in pulmonary pressures and reduced compliance from stiff lungs or chest wall are seen, resulting in restricted right ventricular diastolic filling during exercise.<sup>73</sup> At the same time, lung disease may also impair left ventricular performance. Abnormal ventilatory mechanics can alter left ventricular filling, increase left ventricular afterload, and result in reduced left ventricular function.<sup>75,76</sup> In addition to exercise intolerance, restrictive lung physiology has been associated with increased hospitalization, atrial arrhythmias, and mortality.<sup>59,74</sup> Adults with CHD who have a reduced forced vital capacity have a 1.6-fold increased risk of death compared with patients with normal lung function.<sup>11</sup>

## Management

An initial spirometric assessment of lung function is usually performed and followed serially to screen for

abnormal lung function in adults with CHD.<sup>77</sup> It can be performed as part of a standard cardiopulmonary exercise test. Although spirometry is a useful tool, its disadvantage is that it is only suggestive and not diagnostic of restrictive lung disease. Formal pulmonary function testing with body plethysmography is needed to confirm the diagnosis of restrictive lung disease by showing a reduction in total lung capacity.<sup>78,79</sup> Baseline and annual chest x-ray with baseline pulmonary function tests with diffusing capacity for carbon monoxide and high-resolution computed tomography (CT) as indicated can identify pulmonary disease in patients on amiodarone therapy.<sup>80</sup>

Effective treatment options exist for patients with restrictive lung function. Pulmonary rehabilitation with endurance training is an evidence-based, multidisciplinary, comprehensive intervention for patients with chronic respiratory disease who are symptomatic and often have impaired ability to perform their activities of daily living.<sup>81–83</sup> Pulmonary rehabilitation has been shown to improve exercise endurance and the quality of life in patients with restrictive lung physiology of various pathogeneses and even decrease hospital admissions.<sup>84–86</sup> To date, specific trials looking at the benefit of pulmonary rehabilitation in adults with CHD with restrictive lung physiology are limited. Studies of supervised pulmonary rehabilitation in the setting of pulmonary hypertension associated with CHD have been encouraging, demonstrating safety and improvement in both exercise tolerance and quality of life.<sup>87,88</sup> Given that the potential benefits outweigh the risks with relatively low cost, pulmonary rehabilitation may be considered in patients with moderate or severe restrictive lung physiology and exercise intolerance.

Other potentially beneficial treatment modalities in patients with moderate to severe restrictive lung disease include supplemental oxygen, nocturnal non-invasive inspiratory pressure support, and respiratory muscle training. Tobacco use is investigated during routine visits, and smoking cessation discussed. Polysomnography is recommended for the diagnosis of obstructive sleep apnea by the American College of Physicians in patients with unexplained daytime sleepiness and obesity; therefore, it is considered in adults with CHD who have risk factors for obstructive sleep apnea.<sup>89</sup> Finally, the presence of restrictive lung physiology needs to be taken into account when planning for interventional and surgical procedures that may require sedation or intubation or that may result in further insult to the chest wall and further alteration in respiratory mechanics.

Management of other pulmonary complications such as plastic bronchitis may require an individualized approach. Treatment of plastic bronchitis has included medical therapy (sildenafil, steroids, mucolytics, inhaled tissue plasminogen activator), interventions

aimed at lowering venous pressure, and transplantation.<sup>90</sup> Thoracic duct ligation and, more recently, percutaneous lymphatic procedures may offer symptomatic improvement.<sup>90</sup> Treatment of hemoptysis in the setting of Eisenmenger syndrome or multiple aortopulmonary collaterals is generally supportive in cases of self-limited episodes. However, severe episodes may require further evaluation with chest radiography and CT to assess the extent of intrapulmonary hemorrhage.<sup>91</sup> Aortography and embolization of culprit vessels with or without concomitant bronchoscopy may be considered in severe or recurrent episodes<sup>91</sup> and to rule out infection.

## LIVER

### Prevalence

The prevalence of liver disease among patients with CHD is poorly characterized and difficult to estimate because it is likely to vary between types of CHD and because liver disease is in many cases subclinical and undiagnosed. Research to date has focused predominantly on Fontan-associated liver disease (FALD). Retrospective reviews of liver histopathology in patients with Fontan physiology consistently show near-universal fibrosis both early and late after Fontan completion.<sup>92–95</sup> On noninvasive imaging, 57% to 67% of patients with Fontan physiology have ultrasound abnormalities of the liver, and 72% to 100% have abnormalities on CT or magnetic resonance (MR) imaging.<sup>96–99</sup> Epidemiologic data are limited in other CHD populations in which routine surveillance is uncommon and recognition therefore is less likely.

Manifestations of liver disease in association with CHD range from congestive hepatopathy to fibrosis with nodular regeneration and even cirrhosis.<sup>100</sup> Congenital portosystemic shunt (Abernethy malformation) is an exceedingly rare condition with <100 cases reported.<sup>101–103</sup> It is accompanied by CHD in 22% of cases, especially in the setting of polysplenia or left isomerism, and often presents with hyperammonemia, regenerative nodular liver lesions, and hepatocellular carcinoma. There are also a handful of genetic syndromes (eg, Alagille syndrome, Fas-associated death domain deficiency, orofacioidigital syndrome) of which primary liver disease and CHD are both features. Alagille syndrome, which is associated with cholestatic liver disease and cardiac anomalies such as pulmonary artery stenoses, hypoplasia, and atresia, as well as TOF and coarctation of the aorta (CoA), is perhaps the most common of these, affecting roughly 1 in 30 000 to 50 000 live births.<sup>104</sup>

### Pathogenesis

Contributing causes of liver disease in the ACHD population can be divided broadly into 2 categories: those

**Table 1. Types of Heart Disease That May Be Associated With Liver Disease**

Right-sided heart disease
Fontan physiology
TOF with residual pulmonary regurgitation
Complete transposition of the great arteries after atrial switch surgery
Pulmonary valve disease
Ebstein anomaly and other tricuspid valve disease
Eisenmenger syndrome
Pulmonary hypertension
Pericardial disease
Left-sided heart disease
Left ventricular outflow obstruction
Mitral valve disease
Ischemic and nonischemic cardiomyopathy
Cor triatriatum

TOF indicates tetralogy of Fallot.

related to hemodynamic derangements (ie, venous congestion, ischemic injury) and those related to non-hemodynamic factors (ie, viral hepatitis, drug-induced liver injury).

The unique circulation of the liver makes it especially vulnerable to injury in the setting of abnormal hemodynamics. As much as 70% of the blood supply of the liver is made up of nutrient-rich but oxygen-poor portal venous blood from the splanchnic circulation. Within the liver parenchyma, blood flows radially from the hepatic arterioles and portal venules through the sinusoids and into central veins, which coalesce and drain into the inferior vena cava. As the blood moves through the sinusoids, hepatocytes extract nutrients and oxygen. Thus, the hepatocytes closest to the central veins receive blood with the lowest oxygen and nutrient content and are most susceptible to injury from ischemia and congestion.<sup>105</sup>

Studies of patients without CHD show that decompensated heart failure results in compromised hepatic blood flow and therefore is associated with a greater risk of liver injury. However, decreased hepatic blood itself is rarely sufficient to cause liver injury. Rather, the combination of elevated central venous pressures and decreased cardiac output appears to be critical.<sup>106,107</sup> A classic example of this combination is the single-ventricle anatomy palliated to Fontan circulation. Patients with repaired TOF with residual pulmonary regurgitation, Ebstein anomaly with severe tricuspid regurgitation, complete transposition of the great arteries with obstructed systemic venous baffles, and Eisenmenger syndrome can also be affected by this combination of hemodynamic disturbances (Table 1). Left-sided heart disease can also lead to hepatic congestion as a result of pulmonary congestion and subsequent elevation

of central venous pressures. Acute hemodynamic disturbances during or after cardiac surgery can result in injury that may affect long-term liver health.<sup>108</sup> Finally, coagulation abnormalities have been described in children with cyanotic heart disease.<sup>109–111</sup> Chronic hypoxemia, sluggish flow in the hepatic microcirculation, and intrahepatic sinusoidal thrombosis all may contribute to ischemic hepatic injury in this setting.<sup>112</sup>

Although the risk of exposure to the hepatitis C virus through blood transfusion in the current era is only  $\approx 1$  in 2 million, it was not until mid-1992 that testing methods became sensitive enough to virtually eliminate the hepatitis C virus from the national blood supply. Therefore, chronic hepatitis C infection remains an important cause of liver disease in older patients with CHD. Studies of patients with CHD who underwent heart surgery before 1992 demonstrate hepatitis C virus exposure in 8.6% of patients and chronic infection in 4% to 5% of patients.<sup>113,114</sup>

In cases of frequent transfusion, iron overload can lead to cirrhosis, but this is not a common scenario among patients with CHD. More often, there may be medications used to treat arrhythmias (eg, amiodarone) or pulmonary vascular disease (eg, bosentan) that have hepatotoxic potential. Although these drugs are not contraindicated, appropriate consideration and surveillance are undertaken before these medications are started and while the patients are receiving treatment, particularly in patients with known advanced fibrosis or cirrhosis.

## Management

The key to management of liver disease in adults with CHD is early detection. Because of the paucity of strong evidence, the best strategy for the diagnosis and surveillance of liver disease remains unclear, and screening for liver disease in asymptomatic patients remains controversial.<sup>115</sup> Table 2 adapts the recommendations from the American Association for the Study of Liver Diseases and US Preventive Services Task Force for adults with CHD.

It is recommended that clinicians inquire about jaundice, nausea, vomiting, abdominal pain, and abdominal distension as part of the routine history. An abdominal examination for hepatomegaly, splenomegaly, ascites, and right upper quadrant tenderness is performed as part of the routine physical examination at each cardiac visit, particularly for patients with CHD at risk for liver disease.<sup>12,118,119</sup>

Abnormalities in biochemical laboratory values are common, particularly in patients with Fontan circulation, but tend to be mild for the vast majority of patients until their liver disease becomes advanced.<sup>120</sup> Abnormalities in transaminases, bilirubin, protein, and clotting factors are more common in patients with heart

**Table 2. Consideration for Liver Surveillance in Adults With CHD**

Physical examination for signs of liver disease. Signs can include an increased liver span consistent with hepatomegaly, splenomegaly, jaundice, right upper quadrant pain, or ascites.
Laboratory tests, including transaminases, GGT, alkaline phosphatase, bilirubin, albumin, total protein, INR, creatinine, and platelets every 1 to 2 y in patients with CHD at risk for liver disease, including all patients with Fontan circulation starting from 5 y after Fontan completion with frequency of testing increasing at 15 y after Fontan.
All patients who underwent heart surgery in or before 1992 should be screened for chronic hepatitis B and C infection. <sup>116</sup>
All patients with evidence of liver disease should be vaccinated against hepatitis A and B. Those previously vaccinated against hepatitis B should have serologies checked because some patients exhibit waning immunity in adulthood. <sup>117</sup>
Imaging of liver by ultrasound, MRI, or CT should be considered in patients with abnormal laboratory studies or signs of advanced liver disease. <sup>115</sup> It is reasonable to perform baseline abdominal imaging in patients with Fontan physiology 5 y after Fontan completion regardless of the presence of other abnormal findings.
Liver biopsy may assist in staging hepatic fibrosis and diagnosing cirrhosis but is susceptible to sampling error. Liver biopsy remains important in the evaluation of nodules seen on hepatic imaging in patients with liver disease caused by CHD.

CHD indicates congenital heart disease; CT, computed tomography; GGT,  $\gamma$ -glutamyltransferase; INR, international normalized ratio; and MRI, magnetic resonance imaging.

failure and in those with a combination of congestion and hypoxemia. In patients with only congestion or only hypoxemia, abnormal serum tests are seen less frequently. There has been interest in using biochemical markers of hepatic fibrosis (eg, hyaluronic acid, Forns index, FibroSure, or FibroTest) to screen for liver fibrosis in lieu of biopsy. However, most of these have been developed and validated to predict cirrhosis or advanced fibrosis for patients with hepatitis C and may or may not be useful for screening for liver disease in patients with CHD.<sup>121–124</sup>

Baseline laboratory studies to evaluate liver health are performed in patients with clinical evidence of liver disease or considered to be at risk for liver disease; that is, individuals with central venous hypertension or impaired cardiac output. This would include all patients with signs or symptoms of congestive heart failure and all patients with Fontan physiology starting 5 years after Fontan completion. These baseline liver studies include aspartate transaminase, alanine transaminase,  $\gamma$ -glutamyltransferase, alkaline phosphatase, bilirubin, albumin, total protein, and international normalized ratio, in addition to complete blood count and basic metabolic panel. It is recommended that patients with evidence of liver disease and all patients who underwent cardiac surgery in or before 1992 have serologies checked for hepatitis B and C. Frequency of subsequent testing should be individualized on the basis of clinical status.

Ultrasound, MR, and CT imaging offer greater sensitivity for assessing liver disease. Advantages and disadvantages of each modality are summarized in Table 3. MR

imaging and CT imaging of the liver generally demonstrate superior sensitivity and specificity compared with ultrasound but are considerably more expensive and may have a higher false-positive rate. In addition, regular CT imaging could result in significant exposure to ionizing radiation over the course of a patient's lifetime. Findings such as irregular liver contour, atrophy of the right liver lobe and medial segment, hypertrophy of the lateral segment and caudate lobe, heterogeneous enhancement of the liver parenchyma, and regenerative nodules may signal more advanced liver disease.<sup>125</sup> In addition, extrahepatic findings such as splenomegaly, ascites, or collaterals and varices may offer additional prognostic value.<sup>126</sup>

Any concerning changes on physical examination or laboratory testing are a prompt for imaging of the liver, preferably with MR. Whether to image the liver in an asymptomatic patient who is at risk for liver disease but without examination findings or serological tests suggestive of liver disease is open to debate. For patients with Fontan circulation who are at particularly high risk for liver disease, it is reasonable to perform baseline abdominal imaging starting 5 years after Fontan completion regardless of the presence of other abnormal findings. The frequency of subsequent abdominal imaging is based on individual patient status, but it should occur no less frequently than every 3 to 5 years. In patients with CHD at highest risk for liver disease, including all patients with Fontan physiology once they have reached 15 years after the completion of the Fontan procedure, abdominal imaging should be considered every 1 to 3 years.

Because hepatocellular carcinoma (HCC) has been reported in patients with long-standing heart disease, especially in those with Fontan circulation (see Oncology), more frequent imaging for nodules is an important component of surveillance in those with more advanced liver disease.<sup>127–131</sup> MR imaging with a hepatocyte-specific contrast agent has emerged as the preferred imaging modality for characterization of liver masses but may not be an option in the substantial subgroup of patients with CHD with pacemakers or defibrillators and may be limited in those with coils, vascular plugs, or other metallic devices.<sup>132</sup> Newer contrast-enhanced ultrasonography techniques recently have been approved for use in the United States and may increase the diagnostic accuracy of ultrasound for characterizing focal liver lesions.<sup>133</sup>

In any patient found to have advanced liver disease or cirrhosis (ie, those with laboratory evidence of liver disease, extrahepatic signs of "portal hypertension," or significant abnormalities on imaging), abdominal imaging by ultrasound or MR is performed every 6 months in conjunction with follow-up by a hepatologist to monitor the development of hepatocellular carcinoma.<sup>134</sup> The combined use of serum liver tumor marker  $\alpha$ -fetoprotein (AFP) and ultrasound increases detection rates for HCC in cirrhotic patients without CHD<sup>135</sup> but



**Table 3. Advantages and Disadvantages of Imaging Modalities for Detection of Liver Disease and Screening for HCC in Patients With CHD**

	Advantages	Disadvantages	Additional Notes
Ultrasound	Inexpensive Widely available Highly sensitive for differentiating cystic and solid lesions No ionizing radiation	Low sensitivity for detecting focal, solid liver lesions, particularly in the setting of diffuse disease Often unable to detect lesions <1 cm in size Low specificity High operator dependency	Use of contrast agents may improve characterization of hepatic tumors Useful for guiding liver parenchymal and some focal mass biopsies Elastography may overestimate degree of fibrosis and may not be useful for screening in CHD
CT	Best spatial resolution (submillimeter resolution)	Exposure to ionizing radiation dose Low sensitivity for detecting and characterizing lesions <1 cm in size Contrast contraindicated in renal failure Diffuse liver disease and fatty infiltration limit sensitivity for lesion detection	CT-guided liver mass biopsy useful in cases when ultrasound visualization is poor
MRI	High lesion-to-liver contrast High spatial resolution Better lesion detection and characterization than CT No ionizing radiation Unenhanced MRI superior to unenhanced CT	Contrast relatively contraindicated in renal failure (eGFR <30 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> ) High cost Long scan time Need for longer breath-holds Less widely available Unable to be used with many pacemakers and defibrillators	Hepatobiliary contrast media useful in characterizing specific liver tumors

CHD indicates congenital heart disease; CT, computed tomography; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; and MRI, magnetic resonance imaging.



also increases costs and is not recommended by the American Association for the Study of Liver Diseases for routine screening.<sup>134</sup> However, AFP in conjunction with imaging, particularly when a suspicious lesion is identified, may improve specificity for HCC in patients with liver disease specifically related to CHD and is reasonable to consider. Traditionally, liver biopsy has been considered the gold standard for staging hepatic fibrosis and for diagnosing cirrhosis and HCC. Histologically, the typical findings of liver disease associated with CHD are sinusoidal dilation, hepatic fibrosis coalescing into septa, and regenerative nodules. Cardiac cirrhosis refers to the condition in which bridging of adjacent central veins by fibrotic septa creates the appearance of “reverse lobulation” in which islands of relatively normal liver parenchyma surround a centrally located portal tract. This is in contrast to typical cirrhosis in which fibrous septa arise from and connect adjacent portal tracts.<sup>136</sup> Recently, however, the reliability and reproducibility of biopsy results have come into question. Intraobserver and interobserver variability has been demonstrated in multiple disease processes, and the patchy nature of fibrosis in congestive hepatopathy may be particularly susceptible to sampling error.<sup>95</sup> This may explain the poor correlation that has been described between histology and imaging findings, laboratory studies, and clinical outcomes in several studies of liver disease in patients with Fontan physiology.<sup>94,95,99</sup> Because of this, routine liver biopsy remains controversial, and consultation with a hepatologist may be helpful to weigh the

pros and cons. However, targeted liver biopsy still plays an important role in the evaluation of nodules seen on hepatic imaging in patients with liver disease resulting from CHD because differences in hepatic blood flow from the patient’s hemodynamic abnormalities may affect contrast uptake and enhancement and make accepted imaging characteristics of malignant nodules on CT and MR less reliable in this population.

Elastography, which can be performed with ultrasound or MR, is a noninvasive method for measuring liver stiffness that has been validated for the detection of advanced hepatic fibrosis in a host of liver diseases, although not specifically in congestive hepatopathy. Studies using a variety of methods have consistently shown increased liver stiffness in patients with CHD and non-CHD heart failure. However, these measurements likely overestimate the degree of liver fibrosis caused by hepatic congestion.<sup>137–139</sup> Thus, there is insufficient evidence to recommend routine elastography for surveillance of liver disease in the management of patients with CHD.

Generally, patients with cirrhosis undergo routine esophagogoduodenoscopy to screen for esophageal varices at the time of diagnosis of cirrhosis and every 1 to 3 years thereafter.<sup>140</sup> Guidelines recommend nonselective  $\beta$ -blockers such as nadolol or propranolol for patients found to have esophageal varices to lower portal pressures, thereby reducing the risk of variceal bleeding. In practice, although varices can be seen in patients with liver disease related to CHD, the incidence of variceal bleeding appears to be quite low as indicated by limited

data. In patients with Fontan physiology, documentation of an increased hepatic vein pressure gradient is relatively rare.<sup>95</sup> Therefore, the decision of whether to perform esophagoduodenoscopy is made with the input of a hepatologist on a case-by-case basis.

Management of liver disease in patients with CHD must focus on modification of the underlying hemodynamic derangements (ie, hepatic congestion and decreased cardiac output). It is recommended that hepatic venous pressure gradient be measured routinely during cardiac catheterization for any patients at risk for liver disease. The status of the liver is considered when the timing of cardiac interventions is determined. For example, cirrhosis and portal hypertension in patients without CHD predict additional complications after cardiac surgery, ventricular assist device placement, and cardiac transplantation. Therefore, the presence of cirrhosis or portal hypertension may adversely influence a patient's candidacy for heart transplantation.<sup>141–146</sup> Heart and liver transplantation has been reported in carefully selected patients with Fontan physiology.<sup>147</sup>

Preventive strategies include confirmation of hepatitis B immunity in patients who have undergone vaccination previously and immunization for hepatitis A and B for those who are not currently immune. Any patients found to be chronically infected with hepatitis C are referred for possible antiviral therapy. Patients are counseled to minimize alcohol intake and to maintain a healthy weight. Clinicians are reminded to use caution when considering potentially hepatotoxic drugs. Finally, identification of and collaboration with local or regional hepatologists with specific interest and expertise in CHD-related liver disease are essential.

## IMMUNOLOGY AND INFECTIOUS DISEASE

### Protein-Losing Enteropathy

#### *Prevalence and Pathogenesis*

Protein-losing enteropathy (PLE), defined as the abnormal loss of serum proteins from the gut, is seen in 5% to 15% of patients with a single ventricle after the Fontan operation.<sup>148–151</sup> A high level of clinical suspicion for PLE in patients with Fontan physiology is important because many patients remain asymptomatic during early stages of the disease. Others may present with chronic diarrhea or with secondary manifestations of hypoalbuminemia such as peripheral edema, ascites, clotting abnormalities, or recurrent infections. The diagnosis can be difficult in adult patients with Fontan physiology who may have other causes for edema, ascites, or hypoalbuminemia. The gold standard for diagnosis of PLE is demonstration of elevated fecal  $\alpha$ -1 antitrypsin, an endogenous marker for blood proteins in the intestinal tract. Patients with PLE generally have

$\alpha$ -1 antitrypsin clearance values  $>50$  mL/24 h or a spot fecal  $\alpha$ -1 antitrypsin concentration  $>100$  mg/mL.<sup>152</sup> Additional systemic complications include growth retardation, hypocalcemia, osteopenia, thromboembolism, and infections. Immune abnormalities associated with PLE include hypogammaglobulinemia (especially immunoglobulin G<sub>2</sub>),<sup>153</sup> lymphopenia,<sup>154</sup> and selective CD4 lymphocyte deficiency.<sup>155</sup> As a result of the combined effect of reduced lymphocytes and immunoglobulins, patients with Fontan physiology have been said to have a clinical phenotype akin to combined immunodeficiency. However, the clinical importance of these immune abnormalities is unclear, with no major opportunistic infections reported to date.<sup>156,157</sup> The pathophysiology of PLE is not well understood, although factors known to play an important role include chronic venous hypertension,<sup>150</sup> low cardiac output, increased mesenteric vascular resistance,<sup>158</sup> endothelial dysfunction, inflammation,<sup>159</sup> and loss of intestinal cell membrane integrity.

#### **Management**

PLE treatment varies widely but can be broadly categorized as intestinal directed therapies, cardiac directed therapies, and extracardiac directed therapies.<sup>150,160</sup> The treatment of PLE typically requires multiple strategies, but the efficacy of each treatment strategy remains unknown. Intestinal therapies comprise a low-fat/high-protein diet and medium-chain triglycerides, which act to reduce intestinal lymphatic flow and fluid losses. As PLE progresses, intestinal losses can exceed dietary intake. When diarrhea is severe and oral intake is poorly tolerated, parenteral nutrition may be considered, although thromboembolism and line sepsis are significant risks. Pharmacological strategies directed at reducing intestinal inflammation and protein losses include heparin<sup>161,162</sup> and steroids.<sup>158,163,164</sup> Long-term steroid therapy requires close monitoring and treatment of side effects such as depression, osteoporosis, infection, adrenal insufficiency, and DM.<sup>165</sup> Periodic serum albumin infusions with diuretics may provide short-term relief of symptoms but rarely offer resolution of PLE. Finally, intravenous immunoglobulin therapy may be considered in patients with PLE and severely reduced immunoglobulin levels.<sup>166</sup> Cardiac directed therapies include the use of surgery and catheter-based techniques for relief of Fontan obstruction, valve regurgitation, and atrial arrhythmias.

Transcatheter fenestration creation in the Fontan circuit may lower Fontan pressures for the short term,<sup>167</sup> although spontaneous closure and PLE recurrence are common.<sup>168</sup> Fontan fenestration adds a risk of thromboembolism to the patient. Pharmacological agents used to lower Fontan pressures include phosphodiesterase type 5 inhibitors<sup>169</sup> and inhaled prostacyclins. Extracardiac therapies include treatment of comorbid respiratory disease, obstructive sleep apnea, and high-output

states (anemia, thyroid dysfunction, sepsis). Cardiac transplantation leads to resolution of PLE in most<sup>170</sup> but not all patients. It has been shown that patients with failed Fontan circulation and impaired systolic function do better after transplantation than those with failed Fontan but preserved systolic function.<sup>171</sup> Concern surrounding high posttransplantation mortality in patients with Fontan physiology<sup>172–174</sup> has meant that transplantation is currently being offered to a highly select group of patients. Although older studies reported 5-year survival of only 50% after a diagnosis of PLE,<sup>149,167</sup> a more recent 2014 study reported 5- and 10-year survival of 88% and 72%, respectively,<sup>150</sup> suggesting that PLE outcomes have improved in the contemporary era or that the disease is diagnosed earlier in its course.

Despite receiving vaccination in childhood, patients with Fontan physiology with PLE often have nonprotective titers to the measles, mumps, and rubella and hepatitis B vaccinations, suggesting loss of immunity. Patients who do not have protective titers to hepatitis B may undergo repeat vaccination. Live vaccination with measles, mumps, and rubella is not recommended.

## Infectious Disease

### Prevalence

Patients with CHD have increased risks for complications of infectious diseases compared with the general population. Complications from infection are frequently direct manifestations of infections attacking cardiovascular structures made vulnerable from defective development or surgical interventions. In addition to structural heart disease, many patients with CHD are further predisposed to increased infection-related morbidity and mortality as a result of persistent circulatory and immune dysfunction. The risk of infection persists lifelong,<sup>175</sup> with even small unoperated ventricular septal defects having a risk of infective endocarditis (IE) that is 20 to 30 times that of the general population.<sup>176</sup> The increased lifetime risk of IE in most forms of CHD means that secondary antibiotic prophylaxis is important when contemplating extracardiac bacteremia-inducing procedures.<sup>177</sup> Cyanotic patients with CHD are also at higher risk for infections, particularly IE, pneumonia, and brain abscesses, and are another population in whom IE prophylaxis is paramount.

Patients with heterotaxy have abnormal arrangement of the thoraco-abdominal organs across the left-right axis of the body and a high prevalence of CHD. As a result of absence or hypofunction of the spleen, patients with heterotaxy are susceptible to infection with encapsulated bacteria; one quarter will experience significant sepsis by adulthood.<sup>178,179</sup> Primary ciliary dyskinesia is often associated with heterotaxy syndrome, which may further increase the susceptibility of patients with CHD to respiratory infections.<sup>180</sup> Examples of encapsulated bacteria are *Haemophilus influenzae* type

B, *Streptococcus pneumoniae*, *N meningitidis*, group B streptococcus, *Klebsiella pneumoniae*, *Salmonella typhi*, and *Escherichia coli*. *K pneumoniae* and *E coli* are the principal pathogens in patients <6 months of age, whereas *S pneumoniae* and *H influenzae* have been the predominant pathogens in patients >6 months of age, although successful *H influenzae* vaccination is altering this picture. Sepsis-related mortality is high and ranges from 27% to 82%.<sup>179,181–184</sup>

### Pathogenesis

There is a rising incidence of IE in transcatheter pulmonary valve replacement.<sup>185</sup> The incidence of IE in transcatheter pulmonary valve replacement (incidence of 3%/patient-year) may be even higher than that associated with traditional surgical approaches to pulmonary valve prosthesis.<sup>186</sup> Such concerns require ACHD clinicians to carefully select patients for whom transcatheter pulmonary valve replacement is appropriate and to properly prepare them for the procedure just as they would prepare a patient before surgical pulmonary valve replacement. In addition to the rising concerns surrounding transcatheter pulmonary valve replacement, recent insights into the changing microbiology of organisms associated with infections in patients with CHD require mention. *Staphylococcus aureus* still represents the most significant cause of morbidity among patients with CHD of all ages, but chlorhexidine-tolerant organisms have been noted with increasing prevalence in children with CHD and are likely to be found in the ACHD population.<sup>187</sup>

The use of extracardiac vascular grafts is not uncommon in patients with CHD, particularly in those who have had complex aortic arch treatment in childhood and those who need primary aortic aneurysm treatment with or without simultaneous aortic valve replacement. Patients with Marfan syndrome or those in whom the Ross operation for left ventricular outflow obstruction has been performed are noteworthy in this regard. A recently published AHA scientific statement reviews extracardiac vascular graft and endovascular infections, noting serious life-threatening infectious complications such as sepsis, anastomotic suture line disruption, mycotic emboli<sup>188</sup> and even death. The most common pathogenesis is intraoperative seeding of the graft by staphylococci, *Pseudomonas* species, or Gram-negative bacteria, but extracardiac graft infection can also occur as a result of wound infection or invasive procedures occurring at sites distant from the initial graft procedures, presumably by hematogenous spread. Extracardiac graft infection can be difficult to diagnose and requires a high degree of suspicion in patients who may have had vascular graft procedures months or years before clinical presentation. A full suite of imaging is usually required (echocardiography, MR, CT, positron emission tomography) to diagnose

**Table 4. Immunology and Infectious Disease Management in Patients With ACHD**

Pretreatment cultures of blood and sputum are of particular importance in ACHD, especially, but not exclusively, for those with associated immune compromise such as asplenia. Empirical use of antibiotics should be limited.
Fluoroquinolone treatment or combinational macrolide and $\beta$ -lactam therapy should be considered even for outpatient therapy and is even more strongly recommended for pneumonia and inpatient ICU treatment.
Pneumococcal polysaccharide (every 5 y) and meningococcal vaccination is recommended if there is any functional cardiovascular impairment or if there is any associated immune incompetence (eg, functional asplenia). <sup>117,190–192</sup>
Tdap vaccination may be considered once in adulthood for patients with heart disease. <sup>117</sup>
Influenza vaccination is recommended every year. <sup>117</sup>

ACHD indicates adult congenital heart disease; ICU, intensive care unit; and Tdap, tetanus, diphtheria, and acellular pertussis.

site involvement and complications in what often is an emergent setting.

Of the more common serious infectious disease issues facing adults with CHD, community-acquired pneumonia stands out, both because of its frequency in otherwise healthy adults and in view of the availability of effective strategies for its prevention. As previously mentioned, pneumonia is the most common noncardiac cause of death in adults with CHD, which is likely related to associated genetic disorders, associated immune compromise, or congenital abnormalities of the lung.<sup>15</sup> The other infection that stands out in adults with CHD is peritonitis, although no specific correlative or pathogenic findings have been documented. In the report from the CONCOR registry (Congenital Corvitia) of patients with CHD in the Netherlands, excess mortality was found in patients with ACHD compared with the general population, and among the causes, peritonitis was second only to IE as an infectious cause of death. This statistical finding was not related to any specific pathophysiological mechanism<sup>175</sup> but reminds clinicians of the need for careful consideration of peritonitis when evaluating a patient with CHD for possible systemic infection.

### Management

The Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of infectious disease in adults<sup>189</sup> highlight several considerations that are relevant for the ACHD population and are summarized in Table 4. Asplenic patients with fever or rigors should be advised to seek urgent medical evaluation. Daily antibiotic prophylaxis is recommended in asplenic children until 5 years of age.<sup>193</sup> In contrast, antibiotic prophylaxis is not recommended in asplenic adults.<sup>194</sup> Exceptions to this include adults with a history of severe pneumococcal sepsis, hypogammaglobulinemia, HIV, advanced liver disease, or history of transplantation. Immunocompromised adults

receive amoxicillin or penicillin 250 to 500 mg twice daily, adjusted according to body weight. Alternatives to penicillin vary by age and allergic history. Patients with heterotaxy with anatomic or functional asplenia should be vaccinated against *Neisseria meningitidis*, *H influenzae*, and *S pneumoniae*. In the clinical setting, influenza vaccine yearly and pneumococcal vaccine every 5 years are considered in all patients with CHD, especially those with heterotaxy. Current updated immunization schedules are reviewed elsewhere.<sup>117,190–192</sup>

## HEMATOLOGY

Hematologic abnormalities in CHD include anemia in patients with heart failure, erythrocytosis in cyanotic CHD, and coagulation abnormalities in patients with Fontan physiology. Anemic patients with CHD have increased mortality, even after accounting for functional class, renal dysfunction, and anticoagulation use, similar to what has been found in acquired heart failure.<sup>195–197</sup> Erythrocytotic patients are at risk for hyperviscosity complications, and those with coagulation abnormalities are at risk for hemorrhage and thrombosis.

### Cyanotic CHD: Secondary Erythrocytosis and Iron Deficiency

#### Prevalence

Patients with cyanotic CHD with adequate iron stores will have secondary erythrocytosis. Iron deficiency is common in patients with cyanotic CHD. The prevalence of iron deficiency depends on the definition used but is several-fold higher than found in the general population. In a study of patients with Eisenmenger syndrome (mean oxygen saturation, 84±8%), 22% were iron deficient (ferritin level <15 ng/mL or transferrin saturation <15%), and a history of phlebotomy was strongly associated with the presence of iron deficiency. In another sample of patients with Eisenmenger syndrome, 37% were iron deficient (ferritin level <20 ng/mL).<sup>198,199</sup>

#### Pathogenesis

Secondary erythrocytosis is an important adaptation to chronic cyanosis that allows adequate oxygen delivery in the setting of decreased oxygen tension.<sup>200</sup> In patients with adequate iron stores, the degree of erythrocytosis is inversely related in a linear fashion to the average oxygen saturation.<sup>201–203</sup> Rather than secondary erythrocytosis being considered a primary problem that needs treatment, it is a physiological marker of disease severity with attendant complications that may require management.

Erythrocytosis raises concern because of its associated hyperviscosity; however, secondary erythrocytosis causes less severe hyperviscosity than polycythemia vera, a myeloproliferative neoplasm in which all cell



lines are elevated. Blood viscosity is affected by multiple factors, including hemoglobin, hematocrit, packed cell volume, plasma viscosity, body temperature, and shear stress. Hematocrit is a stronger determinant of viscosity than hemoglobin.<sup>204,205</sup>

### Management

Hyperviscosity symptoms include headache, visual changes, myalgia, mucosal bleeding, and fatigue. Although blood viscosity is increased in patients with erythrocytosis, the relationship among hematocrit, viscosity, and symptoms is more complex. There is no specific hematocrit at which symptomatic hyperviscosity occurs; therefore, there is no indication to target a particular hematocrit level in patients without symptoms of hyperviscosity. Patients with cyanotic CHD should have annual testing that includes a complete blood count and assessment of iron stores.<sup>2</sup> Patients with symptoms of hyperviscosity are managed initially with oral or intravenous hydration. If hydration is ineffective at relieving symptoms, alternative explanations for the symptoms should be sought; patients with headaches or neurological symptoms have brain imaging to exclude abscess, and patients with joint complaints are evaluated for gout. Prophylactic phlebotomy to prevent symptomatic hyperviscosity is not recommended because it induces iron deficiency, reduces exercise tolerance, lowers oxygen-carrying capacity, and increases risk of cerebrovascular events.<sup>198,205–207</sup> Phlebotomy provides only transient relief of hyperviscosity symptoms; therefore, there are only 2 indications for phlebotomy: severe refractory hyperviscosity symptoms and preoperative phlebotomy for autologous blood donation if the hematocrit level is >65%.<sup>208</sup>

The diagnosis of iron deficiency in cyanotic CHD requires checking iron, ferritin, and transferrin saturation levels. Annual screening with these tests is recommended. Hypochromia and microcytosis, typical findings in iron deficiency, are rare in patients with cyanotic CHD because chronic cyanosis causes macrocytosis.<sup>199</sup> Microhematocrit centrifugation results in plasma trapping and falsely raises hematocrit, so testing should be performed with automated electronic particle counts.<sup>205</sup> Iron deficiency is treated to improve the associated relative anemia that inhibits oxygen-carrying capacity, leading to reduced exercise performance, fatigue, headache, or restless leg syndrome.<sup>205</sup> Concerns about uncontrolled erythrocytosis do not preclude iron repletion, which is done with periodic monitoring of iron levels and hematocrit. In a prospective study of iron repletion in patients with Eisenmenger syndrome, 150 to 200 mg elemental iron daily was safe and beneficial; despite an increase in hemoglobin from 19 to 20.4 mg/dL, there was no increase in symptomatic hyperviscosity. Iron supplementation improved 6-minute walk distance from 372±85 to 402±75 m and improved functional class.<sup>209</sup> This improvement in walk distance is similar to that seen with

advanced therapy for pulmonary arterial hypertension.<sup>210</sup> Patients with higher baseline hematocrit had smaller increases in red blood cell counts; therefore, no baseline hematocrit is considered too high for iron repletion. Diagnosis and treatment algorithms for iron deficiency in Eisenmenger syndrome have been published.<sup>209,211</sup> Oral iron replacement is cost-effective and widely available but can be limited by gastrointestinal side effects such as nausea and constipation. Intravenous iron replacement is more effective but carries the risk of anaphylaxis.

## Hyperuricemia and Gout

### Prevalence and Pathogenesis

Hyperuricemia is nearly universal in patients with cyanotic CHD, but clinical gout is relatively uncommon. Arthralgias, however, may be common. Hyperuricemia occurs as a result of increased production of uric acid and decreased renal clearance. Diuretics increase serum uric acid levels through hemoconcentration, decreased uric acid secretion, and increased reabsorption. Low fractional uric acid excretion is the primary mechanism of hyperuricemia in patients with cyanotic CHD.<sup>212,213</sup> Hyperuricemia is a marker of disease severity in cyanotic patients and is negatively correlated with cardiac index. Those with the highest uric acid levels had worse survival in a cohort of 94 patients with Eisenmenger syndrome.<sup>214</sup>

### Management

Hyperuricemia is diagnosed by testing serum uric acid, which should be done annually in cyanotic CHD.<sup>2</sup> Diagnosis of gout is difficult because patients with Eisenmenger syndrome often have pain resulting from hypertrophic osteoarthropathy and periostitis, which also cause bone pain and tenderness. Asymptomatic hyperuricemia does not require treatment. Colchicine can be used to treat gouty attacks, and xanthine oxidase inhibitors such as allopurinol or febuxostat can be used as prophylactic therapy in those with recurrent gout flares.

## Hemostasis

### Prevalence

Thrombosis is a common complication in adults with CHD; however, there are limited data on its prevalence. The majority of the literature has focused on the prevention and treatment of thrombosis in CHD in the pediatric population, including a scientific statement by the AHA.<sup>215</sup> Types of thrombotic complications associated with cyanosis are similar between pediatric and adult patients. However, adults with CHD are prone to arrhythmias, residual shunts, collaterals, and residual hemodynamic abnormalities that place them at increased risk for thromboembolic complications. Stroke incidence is higher in adults with CHD compared with the general population.<sup>216</sup>

Thromboembolic events contribute significantly to the morbidity and mortality of adults with Fontan

palliation.<sup>217</sup> Thrombosis occurs in 8% to 33% of patients with Fontan physiology, and incidentally discovered asymptomatic thrombosis is more common than clinically apparent thrombosis.<sup>65,218–221</sup> Thrombi can be seen in the venous pathway, the pulmonary arteries, the pulmonary venous atrium (particularly in the setting of atrial arrhythmias), or a ligated pulmonary artery stump. Thrombus is most commonly discovered in the first several years after surgery, and prevalence appears to diminish over time,<sup>222,223</sup> with a possible second peak in prevalence in later adulthood when hemodynamics deteriorate. Up to 7% of adult patients with Fontan physiology have a history of DVT, likely related to the high prevalence of chronic venous insufficiency in this population.<sup>220</sup>

### Pathogenesis

Eisenmenger syndrome patients are at simultaneous risk for thrombosis and hemorrhage. Unlike other forms of pulmonary arterial hypertension, Eisenmenger syndrome predisposes to bleeding resulting from alterations in platelet number, platelet function, and coagulation factors. Cyanotic patients often have a mild thrombocytopenia caused by ineffective thrombopoiesis and diminished platelet survival.<sup>205,224,225</sup> In addition, platelet dysfunction is reduced because of poor ADP-induced platelet aggregation.<sup>226</sup> Prothrombin time, partial thromboplastin time, and activated partial thromboplastin time are abnormal in ≈20% and are related to hepatic congestion, abnormalities in the vitamin K–dependent coagulation factors, and depletion of von Willebrand multimers.<sup>111,227,228</sup> In Eisenmenger syndrome, bleeding often presents as epistaxis, which is typically manageable, but can also present as hemoptysis, which can be catastrophic.<sup>212,229</sup>

A majority of patients with Fontan physiology have at least 1 abnormality in coagulation factors. After Fontan completion, factor VIII deficiency and protein C deficiency are the most common laboratory abnormalities (possibly predisposing to thrombosis), although alterations in nearly every coagulation factor have been described.<sup>230,231</sup> In addition, platelet activation and thrombin formation are enhanced and fibrinolysis is reduced, resulting in a prothrombotic state in most adult patients with Fontan physiology.<sup>218</sup> This is supported by the relatively high rate of thrombosis and the relatively low rates of clinical bleeding seen in adult patients with Fontan physiology. Defining coagulation abnormalities with standard laboratory testing is difficult; prothrombin time and partial thromboplastin time are often prolonged despite a procoagulant state. Testing of individual clotting factors is not routinely practiced.

Diagnosis of thromboembolism in patients with Fontan physiology poses a clinical challenge. D-dimer level may be a useful marker for systemic thromboembolism in patients with Fontan physiology.<sup>232</sup> DVT of the upper or lower extremity can be accurately diagnosed

or excluded with compression ultrasound. Unfortunately, thrombus in the Fontan pathway and pulmonary thrombosis or embolism are much more difficult to diagnose. Because there is no subpulmonary mixing chamber in the Fontan to homogenize contrast, CT pulmonary angiograms with a standard protocol have significant swirling artifact, heterogeneous contrast enhancement, and a high rate of false-positive results.<sup>233</sup> Nuclear lung perfusion scans are similarly unreliable because of asymmetric pulmonary blood flow patterns. Multidetector CT angiography with simultaneous upper and lower extremity contrast power injection with early- and late-phase image acquisition can improve diagnostic accuracy.<sup>234</sup> Thrombus in the pulmonary venous atrium or intracardiac portion of the Fontan can be visualized by transesophageal echocardiography or alternatively CT or cardiac MR imaging.

Because of elevated hematocrit and decreased plasma volume in Eisenmenger syndrome, the use of standard laboratory testing leads to falsely prolonged prothrombin and activated partial thromboplastin times resulting from an inappropriate ratio between plasma and citrate anticoagulant. In patients with a hematocrit >55%, it is advisable that tubes with reduced sodium citrate be used to maintain a ratio of blood to anticoagulant of 9:1.<sup>235–237</sup> With appropriate citrate levels, laboratory testing includes platelet count, prothrombin time, and partial thromboplastin time.

### Management

Because of the ongoing risk of life-threatening bleeding and thrombosis in Eisenmenger syndrome, whether to anticoagulate this population is a therapeutic dilemma.<sup>238</sup> Anticoagulation appears to increase the rate of major bleeding; the rate of hemorrhage in Eisenmenger patients treated with anticoagulation was 16% in 1 study (compared with 0% in those not receiving anticoagulation), and fatal bleeding events were reported. Overall, the study did not show that anticoagulation affected survival.<sup>239</sup> Neither American nor European guidelines have made a recommendation for or against routine anticoagulation use in Eisenmenger syndrome, although many centers reserve its use for those with documented acute or chronic thrombosis.<sup>2,240</sup>

Given the high rate of thrombotic complications in patients with Fontan physiology, lifelong thromboprophylaxis is desirable, and a meta-analysis of nonrandomized data suggested that thromboprophylaxis reduced thrombotic complications.<sup>241</sup> There is no consensus as to whether antiplatelet therapy is adequate or therapeutic anticoagulation is needed in the absence of previous thromboembolism or arrhythmia, but limited data suggest equal efficacy of either strategy.<sup>241,242</sup> The relative safety and efficacy of non-vitamin K antagonist oral anticoagulants in adults with CHD have not been established, but multicenter trials are ongoing.

**Table 5. Genetic Syndromes With Cardiac Disorders and Associated Endocrinopathies**

Syndrome	CHD Association	Endocrine Associations	Recommendations
Alagille	TOF, peripheral PS	Short stature Osteoporosis	Tests: consider DEXA scan <sup>246</sup> Treatment: calcium and vitamin D supplementation <sup>246</sup>
DiGeorge (22q11.2 deletion)	Conotruncal abnormalities (TOF, IAA, DORV), AVC, VSD, PDA, PS, vascular ring	Hypothyroidism (25%) Hyperthyroidism (5%) Hypoparathyroidism (80%) Normal reproductive fitness	Tests: CBC, BMP, TSH, Ca, Mg, PTH, LFT, lipids, HbA <sub>1c</sub> annually <sup>247</sup> Treatment: calcium and vitamin D supplementation <sup>247</sup>
Down	AVC, TOF, VSD, PDA	DM (3- to 10-fold increased risk) Obesity Hypothyroidism (up to 25%) Hyperthyroidism (<5%) Hyperlipidemia Osteoporosis	Tests: lipids and TSH every 5 y; FPG/HbA <sub>1c</sub> every 3 y if >45 y of age or sooner if risk factors are present; DEXA scan every 2 y* or if any risk factors are present <sup>14</sup>
Kabuki	Coarctation of the aorta, ASD, VSD	Congenital hypothyroidism Growth hormone deficiency	Tests: consider TSH <sup>248</sup>
Marfan	Dilated aortic root, mitral valve prolapse	Possible osteoporosis <sup>249</sup>	Tests: consider DEXA scan <sup>249</sup>
Noonan <sup>250</sup>	Pulmonic stenosis, hypertrophic cardiomyopathy	Delayed puberty Reduced fertility in male patients Short stature	Tests: no specific endocrine screening
Turner	Bicuspid aortic valve, CoA, dilated aorta	Hypogonadism Hypothyroidism (24%) Hyperthyroidism (2.5%) Hyperlipidemia Impaired glucose tolerance and DM (50%) Osteopenia and osteoporosis Short stature	Tests: DEXA scan every 3–5 y; TSH, LFTs, lipids, OGTT/HbA <sub>1c</sub> annually <sup>251</sup> Treatment: discuss risk/benefit of estrogen replacement <sup>251</sup>
Williams-Beuren	Supravalvular aortic stenosis, supravalvular PS, peripheral PS, coronary artery abnormalities, midaortic syndrome, renal artery stenosis	Impaired glucose tolerance and DM (75%) Osteopenia and osteoporosis (45%) Subclinical hypothyroidism (15%–30%) Hypercalcemia	Tests: BMP, Ca every 1–2 y; spot urine Ca/Cr ratio annually; TSH every 3 y; OGTT/HbA <sub>1c</sub> every 5 y; DEXA every 5 y <sup>252,253</sup> Treatment: care with calcium supplementation given predisposition to hypercalcemia <sup>252,253</sup>

AVC indicates atrioventricular canal; BMP, basic metabolic panel; CBC, complete blood count; CHD, congenital heart disease; CoA, coarctation of the aorta; Cr, creatinine; DEXA, dual-energy x-ray absorptiometry; DM, diabetes mellitus; DORV, double-outlet right ventricle; FPG, fasting plasma glucose; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; IAA, interrupted aortic arch; LFT, liver function test; OGTT, oral glucose tolerance test; PDA, patent ductus arteriosus; PS, pulmonic stenosis; PTH, parathyroid hormone; TOF, tetralogy of Fallot; TSH, thyroid-stimulating hormone; and VSD, ventricular septal defect.

\*Adults with Down syndrome ≥40 years of age living in institutions and ≥45 years of age living in the community.

## ENDOCRINE

Endocrinopathies are often associated with specific syndromes in patients with CHD. For example, thyroid disorders and DM are frequently encountered in Down, Turner, and Williams-Beuren syndromes. DiGeorge syndrome (22q11.2 deletion syndrome) is associated with hypocalcemia and thyroid disease. However, disorders of calcium metabolism are not isolated to patients with genetic syndromes. Patients with Fontan physiology and patients with advanced heart failure are especially at risk for low vitamin D, elevated parathyroid hormone, and abnormal bone density.<sup>243,244</sup> As adults with CHD age, they may develop cardiovascular risk factors for atherosclerotic disease such as obesity, DM, hyperlipidemia, and metabolic syndrome. It is essential for the ACHD practitioner to partner with an endocrinolo-

gist familiar with CHD-related endocrinopathies and metabolic disorders.

## Thyroid

### Prevalence and Pathogenesis

Hypothyroidism, which affects almost 10% of the ACHD population, is one of the most common endocrine abnormalities in CHD.<sup>245</sup> It is particularly associated with cyanosis, genetic syndromes (particularly Down syndrome), and the use of amiodarone (Table 5). The prevalence of hypothyroidism in children and adults with Down syndrome has been reported to be as high as 4% to 18%.<sup>254–256</sup> The incidence increases over time and may relate to inadequate thyroid tissue or the increased incidence of autoimmunity in Down syndrome.<sup>257</sup> Adults with TOF and syndromic features have an elevated prev-

absence of thyroid dysfunction (20%), similar to those with 22q11.2 deletion at 21% to 25%,<sup>247,258</sup> which may be related to abnormal thyroid development from neural crest cells. The incidence of hypothyroidism in Turner syndrome is 24% to 31%.<sup>251,259</sup> In adults with CHD taking amiodarone, the incidence of hypothyroidism is 12% to 15%.<sup>260,261</sup> Amiodarone-induced hyperthyroidism occurs in 14% to 21% of treated patients with ACHD,<sup>260-262</sup> which is higher than the 2% to 10% incidence in unselected populations.<sup>263-265</sup> Risk factors for amiodarone-induced hyperthyroidism in CHD include female sex, low body mass index (BMI), complex cyanotic CHD, Fontan palliation, lower age, goiter, heart failure, and dose >200 mg/d.<sup>260,261,266</sup> There is a small but important incidence of thyrotoxicosis in patients receiving prostacyclin therapy for pulmonary hypertension, and this is a consideration in an otherwise stable patient presenting with acute decompensation on this therapy.<sup>267</sup> Abnormal autoimmunity accounts for increased rates of hyperthyroidism in Down, Turner, and 22q11.2 deletion syndromes (Table 5).

### Diagnosis/Management

There is controversy about routine thyroid screening in the asymptomatic general population.<sup>268</sup> The American Association of Clinical Endocrinologists recommends that screening be considered in patients at risk for thyroid disorders.<sup>268</sup> Therefore, one can consider routine thyroid screening in adults with CHD who have a higher prevalence of thyroid disorders such as patients with Down syndrome. Guidelines by the Heart Rhythm Society recommend testing of thyroid-stimulating hormone and free thyroxine every 6 months or sooner on the basis of clinical symptoms in patients receiving amiodarone.<sup>80,269</sup> The management of thyroid dysfunction in medically complicated individuals occurs in collaboration with an endocrinologist. Overall management of hypothyroidism is not different in the adult with CHD, although several important issues are noted. The incidence of atrial arrhythmias is significantly increased in the adult patient with CHD<sup>270</sup>; therefore, gradual up-titration of thyroid replacement is warranted. Thyroid dysfunction is a risk factor for poor outcome in patients with ACHD undergoing cardiac surgery and should be carefully assessed before surgery.<sup>19</sup> Amiodarone-induced thyrotoxicosis is treated as it would be in the general population. Given the high mortality associated with intravenous prostaglandin-associated hyperthyroidism, treatment as an inpatient or in the intensive care unit is advised.

## Calcium Hemostasis and Bone Health

### Prevalence and Pathogenesis

Disordered bone, calcium, and vitamin D metabolism may lead to increased rates of bone disease and predispose to fractures. Particular at-risk populations include

patients with a single ventricle with Fontan palliation (especially with a history of PLE) and patients with advanced heart failure or cyanosis.<sup>243</sup> Those suffering from PLE or treated with corticosteroids appear to be at highest risk.<sup>271</sup> Low vitamin D and elevated parathyroid hormone levels appear to be associated with CHD.<sup>272-274</sup> It is well established that adults with advanced heart failure have lower bone mass and vitamin D levels,<sup>244</sup> with approximately half of patients with severe heart failure having osteopenia or osteoporosis, so it is of concern that a significant number of patients with complex CHD at such a young age have demonstrated markers of abnormal bone density/function because this may be a harbinger of osteopenia, osteoporosis, and fracture risk later in life. Patients with Down syndrome are at increased risk for low bone mineral density and fractures.<sup>275</sup> Turner syndrome is associated with increased risk of osteoporosis, linked to estrogen deficiency (Table 5). Patients with 22q11.2 deletion syndrome can have hypoparathyroidism, resulting in hypocalcemia and tetany, which occurs in infancy but can occur at any time throughout the life span, with ≈80% experiencing this at some point.<sup>276</sup> Hypocalcemia can cause seizures and arrhythmias.

The causes of low bone mineral density, low vitamin D, and elevated parathyroid hormone in Fontan, cyanotic, advanced heart failure, and Down/Turner syndrome patients are myriad. Hypoxemia, reduced activity, reduced sunlight exposure, use of long-term corticosteroids for treatment of PLE, and abnormal diet all may contribute.

### Diagnosis/Management

Population-based screening remains controversial for the detection of osteoporosis. The Association of Clinical Endocrinologists recommends screening all women ≥65 years of age, younger perimenopausal or postmenopausal women with clinical risk factors for fracture, and any adult with a history of fracture not caused by severe trauma.<sup>277</sup> Further study is needed in adults with CHD of bone density and vitamin D deficiency. Many clinical risk factors for fracture, including advanced age, reduced physical activity, malabsorption, glucocorticoid therapy, and secondary osteoporosis from chronic liver disease, may be applicable to patients with CHD with Fontan palliation or advanced heart failure. It is reasonable to follow guideline-based screening with dual-energy x-ray absorptiometry in adults with CHD. Assessment of serum calcium, vitamin D, and possibly parathyroid hormone concentration can be considered in adults with CHD.

Management includes calcium supplementation, vitamin D supplementation, an exercise plan that includes weight-bearing exercise, and regular monitoring by and review with an endocrinologist. The use of antiresorptive therapy has not been well studied in this group of patients. A high index of suspicion for frac-



tures is maintained because this may provide a clue to underlying bone pathology.

## Obesity and Metabolic Syndrome

### Prevalence and Pathogenesis

Currently, it is estimated that 69% of US adults are at least overweight (BMI, 25–29.9 kg/m<sup>2</sup>) and ~35% are obese (BMI ≥30 kg/m<sup>2</sup>).<sup>278</sup> Of great concern to the physician caring for adults with CHD is the increased cardiovascular morbidity and mortality associated with obesity and the metabolic syndrome superimposed on the sequelae of CHD.<sup>279</sup>

The prevalence of obesity in adults with CHD appears to be comparable to that of the general population, with an estimated prevalence of 40% to 54%.<sup>280,281</sup> In those undergoing redo cardiac surgery, obesity was present in 30%.<sup>282</sup> In terms of specific CHD lesions, data from several cohorts suggest a high rate of overweight and obesity in patients with Fontan physiology in the United States at 30% to 39%,<sup>283–285</sup> associated with pre-Fontan weight and Hispanic ethnicity. These findings mirror documented rates of overweight and obesity in children with various forms of CHD in the United States at 26% to 30%.<sup>286–288</sup>

Rates of metabolic syndrome are higher in adults with CHD compared with the general population. In a cohort-based study in the United States, metabolic syndrome was present in 15% of adults with CHD versus 7% in controls.<sup>289</sup> This finding was driven by a much higher prevalence of hypertriglyceridemia, low high-density lipoprotein, and fasting hyperglycemia in the adults with CHD. A Korean study showed a similarly higher rate of metabolic syndrome in the surgically corrected ACHD group of 37% versus 24% in control subjects.<sup>290</sup> Cyanotic CHD was protective against metabolic syndrome in this cohort.

The causes of overweight/obesity and metabolic syndrome are likely multifactorial. Adults with CHD may be more sedentary because of restrictions placed by physicians leading to deconditioning or by intrinsic physical limitations related to underlying defects.<sup>291</sup> It is postulated that abnormal growth patterns during childhood, characterized by initial low body mass followed by a rapid “catch-up” growth phase after palliation and subsequent emphasis on weight gain on the part of both families and providers, may lead to an increased risk of atherosclerotic cardiovascular disease later in life.<sup>292,293</sup>

As in the rest of the population, obesity appears to exert a negative impact on outcomes in adults with CHD. Postoperative complications with longer length of stay and postoperative arrhythmias have been reported in obese patients with CHD undergoing pulmonary valve replacement.<sup>294</sup> The untoward effects of increased afterload on ventricular function are of particular sig-

**Table 6. Screening for Atherosclerotic Cardiovascular Risk Factors in Adults With CHD**

	Testing	Frequency
Diet and physical activity	NA	Yearly <sup>296</sup>
Tobacco	NA	Yearly <sup>296</sup>
Hypertension	Office blood pressure measurement and/or ambulatory/home blood pressure monitor	Yearly <sup>297</sup>
Obesity	Weight, height, and BMI	Yearly <sup>298</sup>
Dyslipidemia	Fasting lipid panel	Every 5 y <sup>299</sup>
DM	Fasting plasma glucose, oral glucose tolerance test, or hemoglobin A <sub>1c</sub>	Every 3 y in adults ≥45 y of age or ≤45 y of age with BMI ≥25 kg/m <sup>2</sup> and risk factors for DM <sup>300</sup>
PAD	Ankle-brachial index	Insufficient evidence but can consider in patients with DM or an additional cardiovascular risk factor <sup>301</sup>

BMI indicates body mass index; CHD, congenital heart disease; DM, diabetes mellitus; NA, not available; and PAD, peripheral artery disease.

Adapted from Lui et al.<sup>7</sup> Copyright © 2014, The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

nificance for those with systemic right or single ventricles. Of concern is the correlation between obesity and symptomatic heart failure, accelerated liver disease, and mortality in adult patients with Fontan physiology.<sup>295</sup>

### Management

Routine assessment of weight, BMI, and waist circumference on a yearly basis is appropriate (Table 6).<sup>298</sup> Management of obesity involves a comprehensive discussion and plan for calorie restriction, intense face-to-face or over-the-phone counseling, physical activity, and long-term maintenance.<sup>298</sup> Referral to a nutrition professional for counseling is likely to be beneficial. Bariatric surgery for the treatment of obesity may be appropriate in individuals with a BMI ≥40 kg/m<sup>2</sup> or ≥35 kg/m<sup>2</sup> with obesity-related comorbid conditions.<sup>298</sup> Further consultation with a bariatric surgeon may be beneficial with consideration for the risk for perioperative and postoperative hypoxia. Management of the metabolic syndrome includes recommendations for exercise, lifestyle modification, and management of its individual components of obesity, insulin resistance, hypertension, and dyslipidemia.

## Diabetes Mellitus

### Prevalence and Pathogenesis

DM prevalence rates in the general US population have increased from 3.5% in 1980 to a current estimate of

9%.<sup>302</sup> Data from several studies suggest that there is an increased risk for DM in adults with CHD. A single-center study showed rates of fasting hyperglycemia of 40% in adults with CHD versus 9% in matched controls.<sup>289</sup> A population-based study from Denmark showed new onset of DM in 4% between 30 and 45 years of age with a hazard ratio of 1.35 of new DM in adults with CHD compared with the general population.<sup>303</sup> This study noted that this risk was concentrated in individuals with repaired cyanotic CHD (hazard ratio, 2.85), although the reasons remain unclear. Impaired glucose tolerance and prediabetes have been demonstrated in almost 40% of adults with CHD.<sup>304,305</sup> Patients with Down, Turner, and Williams-Beuren syndromes have markedly increased risk of DM (Table 5). The causes of these important differences from the general population are hard to determine from available data but may relate to increased rates of obesity and reduced physical exercise. The impact of DM on patients with CHD has been suggested to increase morbidity and mortality compared with diabetic individuals without CHD.<sup>306</sup>

### Diagnosis/Management

The diagnosis and management of DM are beyond the scope of this review. Screening for DM with fasting plasma glucose, oral glucose tolerance test, or hemoglobin A<sub>1c</sub> is recommended at 3-year intervals by the American Diabetes Association in adults  $\geq 45$  years of age or in those  $< 45$  years of age who have a BMI  $\geq 25$  kg/m<sup>2</sup> and an additional risk factor for DM (Table 6).<sup>300</sup> In adults with CHD, DM screening has been recommended in all those  $\geq 40$  years of age with a BMI  $\geq 25$  kg/m<sup>2</sup> with or without risk factors.<sup>307</sup> Physician emphasis on healthy weight, diet, and increased exercise is an important part of management. There are no specific limitations on standard dietary and medical therapy for adults with concomitant DM and CHD, and usual goals for reducing hemoglobin A<sub>1c</sub> are pursued. It is appropriate to consider the degree of reactive erythrocytosis and the hemoglobin concentration in the interpretation of hemoglobin A<sub>1c</sub> in cyanotic patients, and in this situation, afriuctosamine level may be useful.

### Lipid Abnormalities

#### Prevalence and Pathogenesis

Dyslipidemia has been studied in several cohorts of adults with CHD, with estimates ranging from 27% to 60% with abnormal lipid levels.<sup>4,289,305,307</sup> Lipoprotein(a) levels were found to be similar to those in the general cohort.<sup>308</sup> A Korean study found low-density lipoprotein to be higher and high-density lipoprotein lower in patients with CHD than in a control group.<sup>290</sup> Low high-density lipoprotein and high triglycerides may be related to the same factors promoting metabolic syn-

drome in these patients.<sup>289</sup> Although data remain limited to single centers or administrative databases, the prevalence of dyslipidemia appears to be similar to that in the general population.<sup>307</sup>

### Diagnosis/Management

The diagnosis and management of hyperlipidemia are well established in the general population and are reviewed elsewhere.<sup>299,309</sup> Certain CHD populations such as those with CoA or transposition of the great arteries after arterial switch operation may be at increased atherosclerotic cardiovascular risk and warrant aggressive risk factor modification.<sup>307</sup> The role of conventional medical therapy is not well established in ACHD, although atorvastatin and ramipril were found to lower serum markers of vascular inflammation in a cohort of normotensive patients with CoA, in whom these markers are known to be abnormal.<sup>310,311</sup>

## ONCOLOGY

### Prevalence

Cancer is the fourth leading cause of mortality after heart failure, pneumonia, and sudden cardiac death in a large registry of adults with CHD, with an increasing proportion of death resulting from noncardiac causes with older age.<sup>16</sup> Indeed, cancer was a predictor of all-cause mortality in an analysis of adult patients with CHD  $> 65$  years of age,<sup>4</sup> highlighting the need to address age-related noncardiac morbidities such as malignancy in this population.

The prevalence of cancer in adults with CHD in Quebec is 1.6 to 2 times higher than that in the general Canadian population.<sup>312</sup> A population-based study from Taiwan of 31 961 individuals with a CHD diagnosis identified from a national database showed an increased risk of cancer compared with the general population (standardized incidence ratio, 1.45; 95% confidence interval, 1.25–1.67).<sup>313</sup> Death caused by cancer is higher in adults with CHD. A large study of 10 964 patients who underwent pediatric cardiac surgery in Finland between 1953 and 2009 with up to 60 years of follow-up demonstrated that death caused by neoplasm was more common in patients with CHD compared with the general population, particularly among female patients who underwent surgery between 1990 and 2009.<sup>15</sup>

### Pathogenesis

The use of low-dose ionizing radiation from medical diagnostics and procedures is a risk factor for carcinogenesis, and its use in the management of CHD has increased steadily over time. In a population-based study in Quebec of children and adults with CHD, the number of cardiac procedures associated with low-dose ionizing

radiation increased from 18.5 to 51.9 per 1000 patients with CHD per year from 1990 to 2005 ( $P < 0.0001$ ), driven primarily by a growing number of diagnostic catheterizations.<sup>314</sup> Age at the time of first exposure of radiation in children decreased from 5 years to 9.6 months during the study period, reflecting increasing accessibility and general acceptance of these types of procedures as standard of care.<sup>314</sup>

## Genetic Causes

A risk factor for CHD and malignancy may be shared genetic linkage. There is a strong association between congenital malformations and cancer that is particularly well established in Down syndrome.<sup>315–318</sup> In an analysis of 15905 patients with CHD from a Danish national registry followed up to 31 years, the observed increase in the overall risk of cancer compared with the general population was driven by individuals with Down syndrome.<sup>319</sup>

Other syndromes associated with congenital anomalies and increased cancer risk include Noonan syndrome, Fanconi anemia, and 22q11.2 deletion syndrome. Germline gene mutation of protein tyrosine phosphatase nonreceptor type 11 gene (*PTPN11*) in Noonan syndrome and other genetic disorders of the renin-angiotensin system–mitogen-activated protein kinase signaling pathway (RASopathies) has been linked to leukemia and solid tumors.<sup>320–322</sup> Fanconi anemia is an autosomal and X-linked recessive condition characterized by bone marrow failure and high risk of leukemia and solid tumors with multisystem involvement, including CHD (ventricular septal defect, patent ductus arteriosus, pulmonic or aortic valve stenosis, CoA and arch anomalies, TOF) in 6% to 10%.<sup>323,324</sup> The deletion of 22q11.2 is a common genetic syndrome associated with conotruncal CHD that also may form the basis for tumorigenesis.<sup>325,326</sup>

Teratogenesis and carcinogenesis may share a common basis for some cancer sites,<sup>318</sup> and putative mechanisms include point mutations in specific genes that may lead to both cancer and congenital anomalies or mutations in a developmental gene early in embryogenesis.<sup>316</sup> However, children born with congenital defects are at higher risk for cancer early in life,<sup>327</sup> and the mechanism for childhood malignancy in these cases may be distinct from malignancy diagnosed later in adulthood.<sup>316</sup>

## Low-Dose Ionizing Radiation and Malignancy in CHD

The vast majority of research on oncological issues and CHD has focused on radiation exposure, especially that sustained in childhood, which may play a significant role in later-onset malignancy. The BEIR (Biological Ef-

fects of Ionizing Radiation) VII report from the National Research Council of the National Academies advocates a linear no-threshold hypothesis that states that there is no threshold below which radiation cannot cause malignancy and describes a linear increase of malignancy with radiation dose.<sup>328</sup> Low-dose ionizing radiation for medical use is acknowledged as a risk factor for the development of cancer.<sup>329–331</sup> Specifically, a positive correlation between exposure to low-dose ionizing radiation and incidence cancer risk has been demonstrated in adults with CHD.<sup>332</sup>

Age at the time of radiation exposure is a critical determinant of cancer risk. Adults with CHD have often been exposed to studies using radiation in childhood. Historically, cardiac catheterization was the primary modality for CHD diagnosis before the advent of echocardiography in the 1980s. Children have been estimated to have a higher risk of cancer compared with adults because they have more rapidly dividing cells, more closely spaced organs leading to radiation outside the area of interest, and longer life expectancy.<sup>328,333</sup>

Cardiac catheterization and CT scans account for the majority of radiation in the management of CHD, specifically 81% to 95% in contemporary pediatric cardiology practice.<sup>333,334</sup> In a cohort of 337 children  $\leq 6$  years of age who had undergone cardiac surgery, cardiac catheterizations represented 1.5% of all testing associated with radiation but accounted for 60% of the total radiation exposure. Populations at risk for more exposure to low-dose ionizing radiation procedures and repetitive imaging are children, especially those with complex CHD, and those with genetic syndromes.<sup>314,335,336</sup> Johnson et al<sup>334</sup> demonstrated a wide range of radiation exposure depending on CHD complexity: 0.19 mSv (95% confidence interval, 0.07–29.28) for atrial septal defect repair compared with 28.93 mSv (95% confidence interval, 0.08–76.93) for those who underwent the Norwood operation. The lifetime exposure for an adolescent with CHD is estimated to be  $\approx 20$  mSv.<sup>337</sup>

The data on long-term outcomes on incidence of and mortality from cancer in patients with CHD exposed to ionizing radiation in childhood are mixed.<sup>338–340</sup> To adequately quantify risk from doses of radiation  $\leq 10$  mSv, decades of follow-up in millions of people would be required because of the low incidence of cancer.<sup>341</sup> To address these epidemiological limitations, other surrogate markers for carcinogenic end point have been examined. Both short- and long-term damage in the form of circulating lymphocytes as biomarkers of genetic damage from cardiac catheterization has been shown.<sup>333,342</sup> Adolescents who were exposed to ionizing radiation at  $< 1$  year of age had up to a 3-fold increase in chromosomal aberration in circulating lymphocytes years after exposure.<sup>337</sup> An excess number of  $\gamma$ -H2AX foci (a marker of breaks in double-stranded DNA that is considered one of the most dangerous chromosomal alterations

from exposure to ionizing radiation) have been shown to occur after pediatric cardiac catheterization.<sup>343</sup>

Solid cancer incidence in atomic bomb survivors varies by sex, age at exposure, and attained age.<sup>344</sup> The BEIR VII report estimates that the lifetime attributable risk (LAR) of cancer incidence associated with a single cardiac catheterization is 2.1% (1 in 476) in female patients and 0.8% (1 in 1250) in male patients.<sup>345</sup> In a recent study, organ-specific radiation dose from a variety of catheterization procedures in children ranged from an LAR of <1 in 2000 for atrial septal defect closure to 1 in 150 for transcatheter valve replacements.<sup>346</sup> Of particular importance was the strong modification of LAR cancer incidence depending on survival, with a lower LAR incidence by 7-fold for those with a life expectancy of 50 years. Women are at particular risk, and breast cancer is of particular concern especially after transcatheter valve replacement.<sup>346</sup>

## Special Populations

There are increasingly more reports of HCC in patients with Fontan physiology in the literature.<sup>119,127,347–349</sup> The liver in the Fontan circulation is at risk for FALD (see Liver), which is characterized by congestion, fibrosis, and cirrhosis, which ultimately places these patients at risk for HCC.<sup>120</sup> In addition to being subjected to the physiological alterations characteristic of Fontan physiology (increased central venous pressure and low cardiac output), the liver in the patient with a single ventricle is vulnerable to a number of insults to the liver that begin well before Fontan completion (hypoxia, low output state, and perioperative insult).<sup>350,351</sup>

Neuroendocrine tumors such as pheochromocytoma and paraganglioma have been documented in the setting of cyanotic CHD going back to the 1960s.<sup>352–355</sup> Chronic hypoxia was hypothesized to be the trigger on the basis of observations of a higher incidence in high-altitude dwellers.<sup>356</sup> A number of genes have been identified that are associated with these neoplasms, including mitochondrial succinate dehydrogenase (SDH) complex subunits A, SDHB, SDHC, SDHD, and SDH5 and Von Hippel Lindau tumor suppressor genes.<sup>357</sup> More recently, there is evidence supporting a putative molecular mechanism linking hypoxia and neuroendocrine tumorigenesis, or the (pseudo) hypoxia hypothesis.<sup>358,359</sup> SDH and Von Hippel Lindau gene mutations lead to dysregulation of hypoxia-inducible genes, activating a pathway of chronic hypoxic stimulation, which results in cellular proliferation, angiogenesis, apoptosis, and metastasis.<sup>359</sup>

## Management

Radiation-induced solid cancers tend to occur at ages at which they are normally diagnosed in the general population.<sup>344</sup> Although radiation-induced leukemia manifests

within 3 to 5 years after radiation exposure, solid tumors generally appear at least 10 to 15 years after exposure and often are not diagnosed until adulthood.<sup>360</sup> The most common types of cancer in adults with CHD mirror those of the general population: breast, colorectal, and uterine for women and prostate, colorectal, and bladder for men.<sup>312</sup> For these reasons, age-appropriate cancer screening for adults with CHD is recommended (Table 7).

In addition to age-appropriate cancer screening, certain types of cancers associated with medical radiation are worth mentioning given the proximity of these organs to the heart. Specific organs that are particularly radiosensitive in children are thyroid, breast, bone marrow, brain, and skin.<sup>360</sup> Thyroid cancer is particularly sensitive to radiation, and a linear dose-response relationship has been demonstrated, with younger age at exposure and female patients at particular risk.<sup>371</sup> Breast cancer risk is also linearly related to dose and age at exposure, with this risk persisting up to 50 years after radiation exposure.<sup>372,373</sup>

Patients should be educated on low-dose ionizing radiation associated with medical studies and procedures. Risks of not performing cardiac studies that involve low-dose ionizing radiation are weighed against a small risk of inducing malignancy, and patients ought to be involved in the decision-making process. This conversation is more challenging with a younger population such as adult CHD survivors because radiation-induced malignancies have a biological latency of ≈10 to 40 years.<sup>374</sup> The LAR of cancer incidence is higher with younger age at exposure according to models of cancer risk outlined in the BEIR VII report.<sup>328</sup> Life expectancy is a strong modifier of cancer risk and taken into account in these discussions.<sup>346</sup>

There are no practice guidelines on the surveillance of HCC in patients with Fontan physiology. Table 2 summarizes recommendations for surveillance of FALD. The American Association for the Study of Liver Diseases practice guideline for the management of HCC does not address cardiac cirrhosis or FALD.<sup>134</sup> The guideline does suggest that it is cost-effective to screen for HCC if the risk exceeds 1.5%/y in patients with hepatitis C.<sup>134</sup> An incidence of 1.5%/y to 5%/y for HCC has been suggested in patients with Fontan physiology.<sup>127</sup> Therefore, guideline-based screening for HCC may be reasonable in FALD, which in cirrhotic patients is based largely on ultrasound examination. CT or MR imaging may be recommended at the discretion of the hepatologist or if a liver nodule >1 cm is identified. The role of AFP remains controversial. The American Association for the Study of Liver Diseases no longer recommends the use of AFP as a screening tool,<sup>134</sup> but AFP in conjunction with imaging may improve the specificity for HCC in patients with Fontan physiology. Management of HCC is not well defined in FALD but may include transarterial chemoembolization, percutaneous ablation, surgical resection, and liver transplantation.<sup>134</sup>

**Table 7. Recommendations for Cancer Screening**

	USPSTF	ACS
Breast	Women* 50–74 y of age: biennial screening mammography is recommended. Women* 40–49 y of age: individual decision but women with parent, sibling, or child with breast cancer are at higher risk and may benefit from earlier screening. <sup>361</sup>	Women with average risk who are 45–54 y of age: annual screening mammography. Women with average risk who are ≥55 y of age: biennial screening mammography or the opportunity to continue annual screening. Women should have the opportunity to be screened annually between 40 and 44 y of age. Women should continue screening mammography as long as their health is overall good and life expectancy at least 10 y. Clinical breast examination among average-risk women is not recommended. <sup>362</sup>
Colorectal	Adults 50–75 y of age: screening is recommended by stool-based tests or direct visualization with frequency depending on method. Adults 76–85 y of age: individual decision taking into account overall health and screening history. <sup>363</sup>	ACS/US Multisociety Task Force on Colorectal Cancer/American College of Radiology 2008 guidelines recommend that clinicians help patients choose between stool-based test and direct visualization and emphasize prevention rather than screening. <sup>364</sup> Adults ≥50 y of age with average risk: consider flexible sigmoidoscopy every 5 y, colonoscopy every 10 y, double-contrast barium enema every 5 y, CT colonography every 5 y or guaiac-based fecal occult blood test every 5 y, fecal immunochemical test every year, stool DNA test every 3 y.
Prostate	Recommendation against PSA-based screening. <sup>365</sup>	Individual decision to screen. For those who decide to be screened, PSA testing with or without DRE for average-risk men beginning at 50 y of age. Screening discussion may begin at 40–45 y of age for high-risk population (blacks and those with first-degree relative with prostate cancer before 65 y of age). <sup>366</sup>
Lung	Adults 55–80 y of age: annual screening is recommended with LDCT for those who have 30–pack-y history and currently smoke or have quit within past 15 y. <sup>367</sup>	Adults 55–74 y of age: annual screening is recommended with LDCT for those who have 30–pack-y history of smoking and currently smoke or have quit within past 15 y or 50 y of age with cumulative risk >5% over next 5 y. <sup>368</sup>
Cervical	Women† 21–65 y of age: Pap smear every 3 y Women† 30–65 y of age: Pap smear and screening for HPV every 5 y <sup>369</sup>	ACS/American Society for Colposcopy and Cervical Pathology/American Society for Clinical Pathology 2012 guidelines recommend Pap smear every 3 y for women 21–29 y of age and Pap smear plus screening for HPV every 5 y for women 30–65 y of age. <sup>370</sup>

ACS indicates American Cancer Society; CT, computed tomography; DRE, digital rectal examination; HPV, human papilloma virus; LDCT, low-dose computed tomography; PSA, prostate-specific antigen; and USPSTF, US Preventive Services Task Force.

\*These recommendations apply to asymptomatic women ≥40 years of age who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation (such as a *BRCA1* or *BRCA2* gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age.

†This recommendation statement applies to women who have a cervix, regardless of sexual history. This recommendation statement does not apply to women who have received a diagnosis of a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who are immunocompromised (such as those who are HIV positive).

## VASCULAR

Vascular disease is made up of a heterogeneous set of disorders that may accompany CHD in adulthood. Both arterial and venous vasculature can be affected with involvement of systemic and pulmonary circulations, including aortic, cerebral, and peripheral vascular beds. Pathogenetic factors include genetic syndromes, anatomic malformations, previous vascular interventions, and various physiological disturbances.

### Cerebrovascular Disease

#### Prevalence and Pathogenesis

The risk of cerebrovascular disease, including stroke and transient ischemic attacks, exists across myriad ACHD diagnoses.<sup>216</sup> Among adults with CHD, 1 in 11 men and 1 in 15 women experience a stroke between 18 and 64 years of age.<sup>216</sup> Stroke incidence is higher than in the

general population, especially at a younger age. The cumulative risk of ischemic stroke is higher than that of hemorrhagic stroke in this population. Individuals with heart failure, DM, and recent myocardial infarction may be at greatest risk for ischemic stroke.<sup>216</sup>

The pathogenesis of cerebrovascular disease among adults with CHD may relate to inherent coagulation abnormalities such as in patients with a single ventricle<sup>110</sup> but may also relate to structural arterial findings in CoA or other CHD associated with vascular arteriopathy.<sup>375</sup> Embolic phenomenon must be considered in the ACHD population, especially in individuals with mechanical valves, right-to-left shunt lesions, and atrial arrhythmias, particularly in the presence of depressed ventricular function or akinetic segments.<sup>376</sup>

Atrial arrhythmias delineate a subset of individuals with increased risk of thromboembolism in adults with CHD. Nearly 75% of individuals with an atriopulmonary Fontan and atrial fibrillation or flutter have intracardiac

thrombi, with lower, although still concerning, rates of thrombus formation ( $\approx 10\%$ – $15\%$ ) in those with lateral tunnel or right atrium to right ventricular outflow tract connections.<sup>377</sup> Nearly 16% of these patients had documented stroke, and 5% of patients had PEs during follow-up, although fortunately the risk of thromboembolism associated with cardioversion in the setting of anticoagulation is very low.

Subarachnoid hemorrhage from ruptured intracranial aneurysm is a rare but devastating phenomenon in ACHD. Studies have suggested that adults with CoA have a 5-fold higher prevalence of intracranial aneurysms ( $\approx 10\%$  versus  $\approx 2\%$ ), occurring at an earlier age, than in the general population.<sup>378</sup> Diagnosis is more common at an older age in the CoA population (median age of individuals with aneurysm versus without aneurysm, 37 versus 23 years).<sup>379</sup> Individuals with CoA and hypertension appear to have a 2-fold higher incidence of intracranial aneurysm, suggesting increased hypertension with age or perhaps a pathophysiological factor influencing aneurysm formation, although much more data are needed to assess correlation.<sup>379</sup> More recent studies suggest that in children treated early for CoA, there is no clear association of CoA and intracranial aneurysm, but they perhaps still support the possibility that hypertension may contribute to aneurysm development in adults with CoA.<sup>379,380</sup>

### Management

Atrial arrhythmias are common in ACHD, and there is a high incidence of stroke in those with atrial fibrillation. In those groups with a higher incidence of atrial fibrillation, rhythm monitoring, often longer term, at regular intervals is essential for diagnosing asymptomatic atrial fibrillation in order to recommend rhythm management when indicated and anticoagulation, considering the high risk of thromboembolism. One recent study revealed that the mean pre-event CHA<sub>2</sub>DS<sub>2</sub>-VASc (Congestive Heart Failure, Hypertension, Age, Diabetes, Previous Stroke/Transient Ischemic Attack and Vascular Disease) score was 1 in an at-risk ACHD population with atrial fibrillation, suggesting that this scoring system may underperform in stroke risk stratification in adults with CHD.<sup>376</sup> Another retrospective multicenter cohort study of patients with CHD with documented sustained atrial arrhythmias revealed that antiplatelet therapy was administered to 38%, anticoagulation to 54%, and neither to 8% with 85% freedom from thromboembolic events at 15 years and no difference between anticoagulation and antiplatelet therapy.<sup>381</sup> Thromboembolic events were predicted by disease complexity but not by CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc scores, and the HAS-BLED (Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding, Labile INR, Elderly, Drugs or Alcohol) score was useful in predicting major bleeds.<sup>381</sup>

In addition to anticoagulation in individuals with atrial arrhythmia and cerebrovascular accident risk, individuals with right-to-left intracardiac shunts have a high stroke rate, so anticoagulation as part of the management algorithm should be discussed with an ACHD multidisciplinary team. Paradoxical embolic events are also common in adults with Ebstein anomaly with severe tricuspid regurgitation and are strongly associated with atrial septal defect. In patients with Ebstein anomaly and atrial septal defect or patent foramen ovale, shunt closure can be considered to reduce the risk of possible paradoxical embolic events if physiology allows.<sup>382</sup> The patient with a fenestration in the Fontan pathway is also at risk for paradoxical embolism. Cerebrovascular imaging with both MR and CT offers unique information and is undertaken in collaboration with neurology or neuroradiology for optimal data collection. Further research is needed to consider screening with MR angiography for vasculopathy in adults with CHD.<sup>379,380</sup>

## Peripheral Venous and Arterial Disease

### Prevalence and Pathogenesis

Venous insufficiency presents primarily in the Fontan circulation but also in other elevated right-sided heart pressure states. The prevalence of venous reflux is 5-fold higher in patients with Fontan physiology compared with healthy control subjects and does not correlate with clinical venous insufficiency (only half of patients with Fontan physiology with observed venous reflux demonstrate clinical signs of venous disease).<sup>383</sup> Individuals with a single right ventricle, those dependent on antiarrhythmic medications, and those with a family history of venous disease are at highest risk of documented venous insufficiency.<sup>383</sup> The medial malleolar area, as with chronic venous insufficiency in any individual, should be clinically assessed for CEAP (clinical, etiological, anatomic, pathophysiological) class V and VI ulceration because it may provide a source for bacteremia in this population. Patients with previous venous intervention such as right-sided heart cardiac hemodynamic catheterizations and in some cases femoral vein ligation may be at particular risk for chronic venous insufficiency.<sup>220</sup>

Unfortunately, DVTs and PEs are less well-defined but common vascular disease associations seen in adults with CHD. There is an increased risk of DVT in patients with interrupted inferior vena cava; therefore, the left isomerism or polysplenia syndrome requires that particular attention be paid to DVT risk assessment.<sup>384</sup> Vascular access challenges from early and multiple procedures, including recurrent catheterizations and sometimes cut-downs for improved access to the vasculature in a child, must be assessed in any adult with repaired CHD.

Peripheral artery disease (PAD) may occur with age in the ACHD population in correlation with classic atherosclerotic risk factors (tobacco use, dyslipidemia, DM) and may coexist with coronary artery disease, atrial fibrillation, cerebrovascular disease, and renal disease. Therefore, in an adult with CHD and PAD, assessment of these associated conditions is essential. Unique to the ACHD population, individuals with recurrent childhood arterial access for cardiovascular assessment, especially the CoA population, may be at higher risk of focal arterial stenoses. Additional contributors to PAD in the adult with CHD can include hyperviscosity, phlebitis, previous surgery or cannulation site, and coagulopathy. PAD is generally chronic in presentation. If acute symptoms occur, imaging and assessment of causes for embolic events leading to acute limb ischemia must be done rapidly. Although less common, vascular infection ought to be considered in the immediate post-procedural setting and as a contributor to peripheral vascular disease but is generally accompanied by classic infectious presentation. In the aging ACHD population, atrial fibrillation, valvular disease, recent myocardial infarction, and atherosclerotic disease may all contribute to increasing rates of PAD in the next decade.

### **Diagnosis and Management**

Lower extremity ultrasound is the diagnostic modality of choice for the assessment of venous insufficiency and venous thromboembolism. Dedicated lower extremity muscle training and venous compression stockings may benefit patients with chronic venous insufficiency.<sup>220</sup> CT angiographic evaluation for PE may be difficult to perform and interpret, especially when there is an abnormal pulmonary flow pattern, and is best performed in a regional ACHD center. Noninvasive testing such as pulse wave velocity and ankle-brachial index can be diagnostic (Table 6), in addition to classic PAD presentation, including intermittent claudication with symptoms precipitated by walking and relieved at rest. However, the development of collateral circulation over time may reduce recognizable symptoms; therefore, exercise ankle-brachial index assessment is useful in adults with coarctation to uncover asymptomatic decreased lower extremity perfusion.

## **Aortopathy**

### **Prevalence and Pathogenesis**

Dilatation of the aortic root and the ascending aorta is frequently encountered in adults with CHD. Aortic dilation associated with CoA, bicuspid aortic valve, and genetic syndromes with connective tissue disorders such as Marfan, Loeys-Dietz, vascular Ehlers-Danlos, and Turner syndromes is generally well recognized and is not addressed here. However, primary aortic dilation also is seen in association with conotruncal abnormali-

ties such as TOF, pulmonary atresia with ventricular septal defect, double-outlet right ventricle, or truncus arteriosus. Genetic predisposition, hemodynamic effects, and intrinsic arterial wall abnormalities (fibrosis, elastic fiber fragmentation, cystic medial necrosis) likely together contribute to aortic dilation in the conotruncal population.<sup>385,386</sup> A right-sided aortic arch, male sex, history of an aortopulmonary shunt, and complete repair at older age have been associated with late aortic dilatation.<sup>387</sup> Aortic dissection late after TOF repair is rare and appears to occur only in severely dilated aortas or at areas of previous surgical shunt.<sup>388–390</sup>

In individuals after particular congenital cardiac surgeries, there is a risk of aortic root dilation. These include the Ross operation for aortic valve disease in which the native aortic root is replaced by a pulmonary autograft, the arterial switch operation for D-transposition of the great arteries, and the initial stages of single-ventricle repair with systemic outflow tract reconstruction (eg, Norwood procedure). The aortic root is referred to as a neo-aortic root in these postoperative patients because it consists mainly of pulmonary arterial root tissue. This pulmonary arterial tissue appears to respond to the high-pressure left-sided system with progressive dilation by the time the individual reaches adulthood. A dilated neo-aortic root is seen in half of patients with arterial switch operation<sup>391</sup> and in nearly all patients after hypoplastic left heart syndrome<sup>392</sup> in adulthood. Aortic insufficiency without stenosis, older age at the time of surgical correction, and, for patients with arterial switch operation, presence of a ventricular septal defect, previous pulmonary artery banding, and the association with coexisting CoA are associated with increased neo-aortic dilatation.<sup>393,394</sup>

### **Diagnosis and Management**

The standard for aortic assessment in CHD remains echocardiography before cardiac MR or CT.<sup>395</sup> For each of these ACHD populations at risk for aortic dilation, including the postsurgical populations, active aortic surveillance is recommended at an ACHD center for follow-up. New aortic regurgitation on physical examination may signal aortic root dilation and would warrant echocardiography if recent imaging has not been undertaken. The 2008 American College of Cardiology/AHA guidelines for ACHD recommend aortic imaging every 5 years in patients with CoA. However, other disease states can be imaged at intervals deemed appropriate by the ACHD clinician and team.<sup>2</sup>

## **Endothelial Dysfunction and Arterial Stiffness**

### **Prevalence and Pathogenesis**

Arterial compliance and endothelial function have increasingly entered the research realm in ACHD. Just as

many diagnoses carry clinical manifestations of arterial vascular disease, the subclinical assessment of the pathophysiology is revealing unique abnormalities in many of the seemingly heterogeneous congenital diagnoses.<sup>396–398</sup> To date, CoA is the best-studied vascular phenotype and presents the panoply of challenges in vascular assessment and management. Individuals with CoA have endothelial dysfunction that persists despite successful repair in many individuals, including those without hypertension. There may be a subset of patients with normal endothelial function,<sup>399</sup> suggesting that a subset of individuals with CoA may have a more concerning vascular risk profile. The contribution of endothelial dysfunction to coronary arterial disease is not yet known, but there are existing markers of subclinical atherosclerosis, including increased carotid and femoral intima-media thickness in the adult CoA population.<sup>400</sup> Central aortic stiffness is also markedly increased and associated with increased left ventricular mass in normotensive young subjects after successful early repair of CoA,<sup>401</sup> and fluid dynamics modeling has revealed that ventricular-vascular coupling hemodynamics determine the effects of intervention on myocardial strain.<sup>402</sup>

Patients after Fontan palliation are another population at risk for endothelial dysfunction.<sup>403,404</sup> The lack of pulsatility in the lung alters the endothelium-dependent vasorelaxation response of the pulmonary arteries, which can have profound effects on vascular recruitment and lung vessel growth.<sup>405,406</sup> The consequences of these changes may adversely influence pulmonary vascular resistance. Furthermore, impaired endothelial function and increased arterial stiffness may also contribute to increased systemic vascular resistance in patients with Fontan physiology.<sup>407</sup>

These data, although not yet clinically applicable en masse, provide valuable new mechanisms to evaluate vascular physiology in ACHD that may influence future clinical practice.

## Hypertension

### *Prevalence and Pathogenesis*

There may be an increased risk of hypertension in the ACHD population compared with the general population,<sup>8</sup> especially among men.<sup>280</sup> Quebec CHD database figures showed a prevalence of 47% in a CHD population comprising people >65 years of age.<sup>4</sup> Adults with CHD and renal abnormalities (cyanotic CHD, heart failure with renal insufficiency) and patients with CoA, who may have systemic hypertension despite abolition of a coarctation gradient, are particularly at-risk populations. Nearly 60% of individuals with CoA develop hypertension.<sup>408</sup> Obesity is associated with the development of hypertension, insulin resistance, dyslipidemia, sleep apnea, autonomic imbalance, and increased inflammatory cytokines.<sup>307</sup>

## Management

Management of hypertension in the adult with CHD mirrors the general adult guidelines for blood pressure management.<sup>409</sup> Diagnostic evaluation includes assessment of target organ damage and noncongenital reasons for hypertension. Urinalysis, blood glucose levels, hematocrit, lipid panel, basic metabolic panel, and calcium levels are obtained. Identifiable causes of hypertension such as sleep apnea, nonsteroidal anti-inflammatory drug use, CKD, endocrine causes, reno-vascular disease, and CoA should be considered. The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among people with CHD remain uncertain. SPRINT (Systolic Blood Pressure Intervention *Trial*) revealed that among adults without CHD (>50 years of age) and at high risk for cardiovascular events but without DM, targeting a systolic blood pressure of <120 compared with <140 mm Hg resulted in lower rates of fatal and nonfatal major cardiovascular events and death resulting from any cause.<sup>410</sup> Current guidelines for blood pressure goals may be extrapolated to adults with CHD, with particular attention to those individuals in whom a lower afterload (eg, systemic right ventricle, single ventricle, aortic dilation) would be beneficial. However, in SPRINT, rates of hypotension, syncope, electrolyte abnormalities, and acute kidney injury were higher with intensive treatment, and attention to the risk of those adverse events in individuals with CHD, especially the moderate to complex diagnoses, is important when blood pressure goals are extrapolated.<sup>410</sup> Lifestyle modifications include a focus on salt intake and attention to obtaining a healthy BMI because obesity increases the risk of premature vascular disease, DM, and hypertension.<sup>307</sup> Physical activity should be encouraged as tolerated, and actual exercise prescriptions should provide clear guidelines for patients. Changes in aortic stiffness, diameter, and wave reflection that can occur with aging may lead to increased ventricular afterload, resulting in potential adverse effects in late systolic ejection and diastolic relaxation. In these individuals, blood pressure management, afterload reduction, and prevention of adverse ventricular remodeling may help clinicians target the correct medical regimen for their individual patient. Management with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in combination with a mineralocorticoid receptor blocker such as spironolactone or eplerenone may have a cardioprotective benefit.<sup>411</sup>

## PSYCHOSOCIAL

### Prevalence

Adults with CHD are at increased risk of psychological distress, neurocognitive deficits, and social challenges.



Three North American studies published between 2000 and 2009 that incorporated clinical interviews reported that approximately one third of adults with CHD had mood or anxiety disorders.<sup>412–414</sup> Traditionally, depression is the psychiatric disorder that has received the majority of attention within general cardiology and congenital cardiology,<sup>2,415</sup> although anxiety is increasingly recognized. In patients with CHD presenting for psychological services, anxiety concerns were observed to be more prominent than mood disturbance.<sup>416</sup> In another sample, 20% of patients with CHD reported symptoms consistent with posttraumatic stress disorder.<sup>417</sup> Thus, it is important to be mindful of the potential for both mood and anxiety disorders when considering the psychological impact of living with CHD.

Children and adolescents with CHD are at elevated risk of neurodevelopmental deficits, and the frequency and severity increase with greater disease complexity.<sup>418</sup> Young patients with CHD have an increased prevalence of neurodevelopmental disabilities, deficits in behavior, language and speech disorders, and attention-deficit/hyperactivity disorder and increased use of special services.<sup>418,419</sup> Deficits in executive functioning are common<sup>420,421</sup> and present challenges in planning and behavioral regulation. A rich body of research in the pediatric CHD setting exists, although we know far less about neurocognitive outcomes of adults with CHD.<sup>307,422,423</sup> Although intelligence scores for adults with CHD generally fall within the normal range,<sup>424–426</sup> deficits in executive functioning have been observed.<sup>427,428</sup> It has been suggested that the manifestation of pediatric-onset neurocognitive deficits might become more evident in adulthood and that adult-onset factors (eg, heart failure, arrhythmias) might negatively affect cognitive functioning.<sup>423</sup>

Consistent with a psychosocial conceptualization, the social impact of living with a chronic medical condition should not be minimized. It is not uncommon for adults with CHD to report difficulties with social interactions, conflicting social expectations, and “feeling different” from their peers.<sup>429,430</sup> Recalled parental overprotection has been associated with heart-focused anxiety in adulthood.<sup>431</sup> Furthermore, loneliness and social anxiety have been linked to low mood and generalized anxiety among adults with CHD.<sup>414</sup> Higher education, employment, independent living, and being married have been associated with better quality of life among adults with CHD.<sup>432,433</sup> As a group, however, adults with CHD, particularly those with more complex forms, tend to have lower educational attainment and higher rates of unemployment.<sup>434–436</sup>

Furthermore, there may be specific challenges associated with romantic relationships, sexuality, and family planning.<sup>437</sup> Compared with healthy peers, adults with CHD are less likely to be involved in romantic relationships.<sup>438</sup> Many patients are embarrassed by surgical

scarring.<sup>439</sup> Among adults with CHD with implantable cardioverter-defibrillators, greater shock anxiety has been associated with poorer sexual functioning.<sup>440</sup> Therefore, CHD has the potential to affect patients' education, employment, relationships, and sexuality and thus overall psychosocial well-being.

## Pathogenesis

The pathogenesis of psychosocial distress in adulthood for individuals with CHD is multifactorial. The time period during which individuals with CHD transition from adolescence to young adulthood is one in which mental health warrants particular attention. In the general population, three quarters of mental health disorders present by the age of 24 years.<sup>441</sup> Young adults with CHD may face a number of unique biopsychosocial challenges.<sup>442</sup> This list includes factors related to medical care (eg, ongoing medical surveillance, transitioning from pediatric to adult care, adjusting to implanted cardiac devices, making treatment decisions, preparing for repeat intervention, declining physical health), cognitive challenges (eg, lower academic abilities and achievement, negative thinking), and social functioning (eg, loneliness, social anxiety, parental overprotection, body image concerns, autonomy).<sup>414,430,431,442–447</sup> No definitive conclusions can be drawn with regard to whether psychosocial distress differs by age, sex, or defect complexity.<sup>430</sup> Perceptions of health might be more germane to emotional well-being than objective health status.<sup>414,448</sup> With regard to neurodevelopmental outcomes, the causes are again multifactorial and include circulatory abnormalities that affect the heart and brain development, medical and surgical intervention, and comorbid syndromes or genetic disorders.<sup>418</sup>

Furthermore, a subgroup of patients have genetic syndromes that place them at greatly elevated risk of mental health disorders. Individuals with conotruncal heart defects have a higher prevalence of 22q11.2 deletion syndrome, and this genetic syndrome in turn is associated with significantly higher rates of mental health disorders, including schizophrenia.<sup>449,450</sup>

## Management

Effective management entails the identification of individuals experiencing clinically significant psychosocial distress and the provision of targeted interventions. Within empirical studies, there is known variability in the surveys that researchers have used to assess psychosocial distress, a situation that has certainly contributed to inconsistent findings.<sup>451</sup> Published guidelines for both coronary artery disease and CHD have recommended screening for depressive symptoms during clinical encounters.<sup>2,452</sup> However, as previously described, an exclusive focus on depression will fail to

identify patients with anxiety problems. Furthermore, there is no clear evidence that routine screening for depression in cardiac patients improves mood or cardiac outcomes.<sup>453</sup> Before the implementation of formal screening programs, it is important to ensure that there are adequate resources to score the chosen measure, discuss results with patients, and provide mental health care to patients with both elevated distress and an interest in treatment.

The "4 As" have been suggested as a strategy for regional ACHD programs to address the psychosocial challenges faced by many of their patients.<sup>442</sup> The 4 components are the following: (1) ask patients about specific challenges, (2) advise about common challenges that are likely to occur and ways they can be managed, (3) assist the patient through education and brief problem solving, and (4) arrange referrals to mental health professionals as appropriate. Within this approach, mental health professionals are 1 part of a comprehensive approach, and all CHD care providers (physicians, advanced care providers, and nurses) have the opportunity to provide proactive care. It is of benefit for all providers in the healthcare team to demonstrate increased psychosocial awareness and to initiate proactive discussions that normalize common concerns.<sup>442</sup>

Quantitative and qualitative research has indicated that, as a group, adults with CHD are interested in mental health treatment and opportunities for peer support.<sup>430,454</sup> We anticipate that adults with CHD will increasingly advocate for attention to their mental healthcare needs in recognition that living with a lifelong cardiac condition affects more than a person's heart.

Many patients would benefit from mental health evaluation and treatment. However, most adults with CHD with mood or anxiety disorders do not receive treatment.<sup>412-414</sup> Regional ACHD centers must determine the most appropriate and feasible approach for the identification and management of psychosocial distress in their patients. Although the optimal approach is the integration of mental health professionals within care teams, this is not always realistic, and other options include collaborating with mental health professionals within a program's hospital or university or identifying providers in the local community.<sup>443</sup>

Specific approaches to psychotherapy (talk therapy) include cognitive behavioral therapy, interpersonal therapy, acceptance and commitment therapy, and mindfulness-based interventions. A study to determine the feasibility of conducting a randomized controlled trial of a group coping skills intervention has been introduced.<sup>455</sup> Among children with CHD, there are no clear relationships between physical activity and the psychosocial domain of quality of life.<sup>456</sup> However, because physical activity has proven benefits for adults identified as being depressed or anxious,<sup>457</sup> the encouragement


of medically appropriate physical activity, with potential for both physical and psychosocial benefits, appears appropriate.

In a sample of 134 respondents who were asked about preferences for future mental health treatment, 41% preferred psychotherapy, 9% preferred pharmacotherapy, and 34% found either approach acceptable.<sup>454</sup> Thus, although psychotherapy may be generally preferred, pharmacotherapy represents another approach to be considered for adults with CHD, particularly for those who prefer this modality or for whom access to psychotherapy is limited. Compared with other types of antidepressants, selective serotonin reuptake inhibitors have been shown to be safest in treating depression in adults with cardiovascular disease.<sup>458-460</sup>

Within the pediatric CHD setting, algorithms for the screening, surveillance, and management of neurodevelopmental deficits and disorders have been proposed, and many pediatric cardiology centers have established neurodevelopmental follow-up clinics.<sup>418</sup> Opportunities for comprehensive neurocognitive assessment are currently much rarer in the adult care environment. What is likely more feasible, but admittedly requires additional time in already busy clinic visits, is inquiry about the patient's academic history (eg, previous diagnosis with a learning disorder or attention-deficit/hyperactivity disorder, history of special education classes) and employment history (eg, difficulty obtaining or maintaining employment).<sup>423</sup> A thoughtful consideration of the use of medications for attention-deficit/hyperactivity disorder is required on an individual patient basis.<sup>461</sup> Education and vocational education, in adolescence and young adulthood, are warranted.

## NONCARDIAC SURGERY

CHD is a heterogeneous group of defects leading to unique risk factors for surgery among the different cardiac lesions. The combination of complex heart disease and associated noncardiac conditions places adults with CHD at greater risk than the general population for noncardiac surgery.<sup>22,462-464</sup> Guidelines for perioperative cardiovascular risk assessment in the general population focus primarily on the risks posed by ischemic heart disease, which is relatively uncommon in adults with CHD.<sup>465</sup> As discussed throughout this document, adults with CHD have multiorgan involvement, which places them at risk for perioperative complications. Although patients with CHD are at increased risk when undergoing noncardiac surgery, up to 74% of noncardiac surgeries in ACHD patients occur at non-ACHD centers.<sup>466</sup> Ideally, elective noncardiac surgery would take place in a regional ACHD center with specialists familiar with and experienced in the management of those with CHD (Figure 2).<sup>2</sup>



**Figure 2. Stepwise approach to perioperative cardiac assessment in adults with congenital heart disease (CHD).**

ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; and NO, nitric oxide. Adapted from Warnes et al.<sup>2</sup> Copyright © 2008, American Heart Association, Inc.



## Preoperative Evaluation

A comprehensive preoperative assessment is essential in the care of adults with CHD undergoing noncardiac surgery. Residual cardiac abnormalities such as ventricular dysfunction, valvular dysfunction, pulmonary hypertension, arrhythmia, or shunts place patients with CHD at high risk for intraoperative and postoperative complications.<sup>467–469</sup> Before any elective surgery, a complete understanding of the patient's previous cardiac surgeries and current cardiac physiology is required to better perform adequate risk assessment for the upcoming surgery. Inadequate preoperative assessment and optimization accounts for up to 40% of the adverse events in adults with CHD who undergo noncardiac surgery.<sup>470</sup> Patients with certain complex cardiac lesions such as severe pulmonary hypertension or Eisenmenger syndrome have a very high risk for adverse outcomes during noncardiac surgery, with mortality ranging from 4% to 10% in the modern era.<sup>462,471,472</sup> Those with Fontan palliation for single-ventricle anatomy have also been

shown to have a much higher than normal complication rate, with some series having complication rates as high as 31%.<sup>463</sup>

Preoperative risk assessment before noncardiac surgery in the patient without CHD emphasizes the use of functional capacity to determine the patient's risk for perioperative complications.<sup>465,473</sup> However, many adults with CHD have adapted to lifelong decreased functional capacity by self-restricting activity and report that their functional status is unchanged or fine when questioned. Exercise testing can objectively measure functional capacity and cardiac reserve and has an increased role in preoperative evaluation of patients with CHD compared with in the general population.

Arrhythmias are common in the perioperative setting, with ≈50% of adults with CHD having some rhythm disturbance.<sup>474</sup> Antiplatelet or therapeutic anticoagulants are often used for stroke prevention in patients with CHD with arrhythmias, residual shunts, prosthetic

valves, or previous thromboembolism. The risks of withholding these agents and subsequent thromboembolic events must be considered for each noncardiac surgery. The 2014 American College of Cardiology/AHA guidelines on perioperative cardiovascular evaluation provide an algorithm for antiplatelet management in patients with previous coronary intervention who are undergoing noncardiac surgery.<sup>465</sup> For patients with mechanical heart valves, bridging anticoagulation may be appropriate in the setting of mechanical atrioventricular valve or mechanical aortic valve with  $\geq 1$  additional risk factors (eg, atrial fibrillation, previous thromboembolism, systemic ventricular dysfunction, hypercoagulable condition, or an older-generation prosthetic aortic valve).<sup>465</sup> Vitamin K and fresh-frozen plasma can reverse warfarin for urgent or emergent noncardiac surgery. In patients with CHD with arrhythmias, residual shunts, or aortic prosthetic valves without risk factors, antiplatelet or vitamin K antagonists may be discontinued 2 to 3 days before surgery. Factor Xa inhibitors should be discontinued at least 48 hours before major surgery.<sup>465</sup> The 2014 American College of Cardiology/AHA guidelines suggest monitoring activated partial thromboplastin time for dabigatran and prothrombin time for apixaban and rivaroxaban.<sup>465</sup>

The pulmonary sequelae of CHD can complicate the perioperative management and increase surgical risk. In 1 study, 56% of adults who underwent heart surgery in childhood had restrictive lung disease, which affects ventilator management and extubation.<sup>59</sup> Certain complex lesions such as heterotaxy syndrome have cilia dysmotility, increasing the risk of postoperative pneumonia and prolonged ventilation.<sup>475-477</sup>

Many patients have had surgeries that intentionally sacrificed a subclavian artery (classic Blalock-Thomas-Taussig shunt, subclavian flap repair of CoA). These patients often have spuriously low blood pressure in the affected arm. Hence, intraoperative and postoperative blood pressure monitoring must use an appropriate extremity to accurately reflect central aortic pressure. Communication with the anesthesiology, surgical, and nursing teams is critical to ensure that blood pressures accurately reflect central pressures and that patients are not inadvertently administered vasoactive agents as a result of misleading vital signs.

Many adults with complex CHD have occluded femoral veins or arteries resulting from catheterizations performed in childhood. In addition, systemic venous anatomy may be unusual in the setting of heterotaxy syndrome, a Mustard baffle, or a Glenn shunt. If venous or arterial access is needed for intraoperative monitoring, such anatomy should be documented before surgery. If unknown, preoperative noninvasive imaging is appropriate.

Many patients with CHD have a pacemaker. Epicardial pacing systems are common, and these devices may be located below the diaphragm, requiring accurate knowledge of the device position before abdominal

surgery to avoid damage to or infection in the pacing system. For patients who are pacemaker dependent, reprogramming of the device to potentially slightly higher heart rates can be desirable. Pacemakers should be programmed to safe surgical modes to avoid inhibition of the device from electric impulses such as from the electric cautery system.

Patients with CHD are at higher risk for perioperative infections and may require antibiotic prophylaxis for endocarditis as outlined by the AHA guidelines.<sup>463</sup> Most gastrointestinal or genitourinary tract procedures no longer require antibiotic prophylaxis.<sup>177</sup>

## Perioperative Management

Patients with cyanotic heart disease or pulmonary arterial hypertension have extremely high risk, and if surgery is truly elective, it is usually best avoided. Mortality for these patients after noncardiac surgery remains as high as 7% to 10%.<sup>462,471</sup> Those with CHD of moderate complexity but excellent preoperative functional capacity and no more than mild systemic ventricular dysfunction are at lower risk.

For patients with Eisenmenger syndrome, providers must consider the multiple organ systems affected by chronic cyanosis, expected fluid shifts, and bleeding risks. Because of multiple collaterals that develop within tissues, platelet dysfunction, and alterations in the coagulation cascade, cyanotic patients have increased surgical bleeding.<sup>212</sup> Although routine phlebotomy has been mostly abandoned in Eisenmenger syndrome, a role remains for preoperative phlebotomy to decrease surgical risk. Those with a hematocrit above  $\approx 65\%$  should have preoperative isovolumic phlebotomy to reduce intraoperative bleeding and to decrease viscosity, with the removed blood stored for autotransfusion if needed during surgery.<sup>478</sup> Because patients with Eisenmenger syndrome have relatively fixed pulmonary vascular resistance, vigilance and avoidance of conditions that worsen pulmonary vascular resistance are paramount, including the avoidance of hypothermia, metabolic acidosis, hypercarbia, and hypovolemia. Placement of an arterial line to identify such changes early should be considered. Pulmonary arterial catheters may trigger an arrhythmia and cause paradoxical embolism from microthrombi or in situ pulmonary thrombi. Because patients with Eisenmenger syndrome have relatively fixed pulmonary resistance and pulmonary pressure is equal to a noninvasively measure blood pressure, risks often outweigh benefit.<sup>238,479</sup> Central venous catheters also pose risk because these patients are prothrombotic, leading to potential catastrophe if venous thromboembolism occurs in the pulmonary circulation or in the systemic circulation via a residual intracardiac shunt. These risks and benefits of central venous pressure monitoring and ease of intravenous fluid and medication infusion by central line are assessed and

considered. To avoid air emboli in all venous access, meticulous care with air filters and air vigilance protocols is required. With any hypotension, increased cyanosis will be seen with increased right-to-left shunting; therefore, a thoughtful plan is needed for which agents to use for the induction and maintenance of anesthesia. Some centers will elect to admit these patients the evening before surgery to allow continuous maintenance fluid in the setting of restricted oral intake before surgery.

Patients with Fontan palliation pose unique challenges. The anesthesia team must avoid hypercarbia and acidosis because they increase pulmonary vascular resistance or pulmonary pressures, maintain adequate inferior vena cava pressure, and avoid hypovolemia. Oxygen can still be a potent vasodilator in many of these patients, so higher supplemental oxygen levels are recommended, with the ready availability of inhaled nitric oxide to treat low cardiac output.

Low airway pressure is desirable because higher intrathoracic pressures for prolonged periods will decrease cardiac output in Fontan circulation. Anesthesiologists and respiratory therapists are encouraged to minimize positive end-expiratory pressure to the lowest level required to avoid atelectasis, hypercarbia, and hypoxia. Laparoscopic surgery can be dangerous in patients with Fontan physiology if intra-abdominal pressure rises too high. Whereas intra-abdominal pressures of <15 mmHg do not appear to adversely affect cardiac performance in patients with 2-ventricle circulation,<sup>480–482</sup> a similar threshold for those with Fontan physiology is not known. Case reports have shown that laparoscopic surgery can be performed with acceptable risk if intra-abdominal pressures are <10 mmHg in patients with Fontan physiology.<sup>483</sup> Additional care is needed to prevent carbon dioxide embolization to the lungs, which is not tolerated well in these patients, and to avoid paradoxical embolization, which can occur through a persistent Fontan fenestration or right-to-left shunting from venous collaterals.<sup>484–486</sup> Because abdominal insufflation can lead to hypercarbia or increased intrathoracic pressures, either of which may lead to a drop in cardiac output, intra-arterial lines are frequently placed. Central venous access is used for longer procedures with larger volume shifts to allow rapid fluid resuscitation and central venous pressure measurements. Such patients usually also receive preoperative intravenous hydration secondary to their relative volume depletion in the fasting state. Neuraxial anesthetic techniques can be safe in patients with Fontan physiology, which may be particularly useful for obstetric and gynecologic surgery, although careful titration of these agents is needed.<sup>487</sup>

### Postoperative Management

Postoperative monitoring and care are as important as the preoperative assessment and intraoperative management

because 50% of adverse events after noncardiac surgery are related to postoperative issues.<sup>470</sup> Common postoperative complications such as bleeding, fever, thromboembolism, infection, or pulmonary edema may affect the patient with CHD with cardiac and noncardiac comorbidities with greater impact than in the average patient. Many patients require either postoperative diuresis or volume resuscitation, depending on the underlying cardiac physiology and the perioperative blood loss. Adults with CHD require close surveillance focused on monitoring for postoperative arrhythmias; postural hypotension, which may exacerbate a right-to-left shunt; pain management; and fluid shifts.<sup>2,462</sup> Patients with Eisenmenger syndrome require observation in the intensive care unit for 12 to 24 hours after noncardiac surgery to address acute changes in pulmonary and systemic resistance.

The reinitiation of anticoagulation and antiplatelets after noncardiac surgery depends on the relative risk of bleeding versus thrombosis. For patients at high risk of thromboembolism, early ambulation and pneumatic compression may prevent DVT. Intravenous heparin and oral anticoagulants can be resumed as soon as determined safe by the surgical team. In patients with a lower risk of thrombotic complications, these agents may be resumed safely several days after the procedure.

### SUMMARY

Noncardiac complications contribute significantly to the morbidity and mortality of adults with CHD. As these individuals grow in number and age, we need to identify preventive strategies with intervention at an earlier age to mitigate the development of later noncardiac complications. Many patients with repaired simple CHD are now in their six or seventh decade of life or later, whereas most patients with complex CHD such as the Fontan circulation are relatively younger. Single-ventricle programs provide an opportunity to care for these individuals with a multidisciplinary team that includes clinicians with expertise in neurodevelopment, hepatology, and nephrology. Although we have made progress, many research questions remain, and considerable work still needs to be done. For example, the role of biomarkers in CHD and their relationships with noncardiac conditions are not well known. Whereas animal models demonstrate that angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists have important antifibrotic effects in end organs (including kidneys, heart, and liver), it is unknown whether these medications confer a protective effect when introduced early. Other questions include the incidence of IE in transcatheter valves, the effectiveness of non-vitamin K antagonist oral anticoagulants in ACHD, risk stratification of patients for pulmonary function tests and noncardiac surgery, and

cancer screening for complex CHD. The effect of chemotherapy on the congenitally abnormal heart is not known. Do patients with right ventricular dysfunction warrant closer monitoring in the setting of chemotherapy? Furthermore, the impact of psychosocial factors on quality of life, mortality, and morbidity warrants investigation. In summary, adults with CHD often have complex multisystemic disease for which both cardiac outcomes and noncardiac complications warrant clinical attention and empirical investigation; an interdisciplinary approach is required across the life span of these patients.

## ACKNOWLEDGMENTS

The authors acknowledge Julia Close, MD; David Garcia, MD; Robin Kremsdorf, MD; Salila Kurra, MD; and Anna Rutherford, MD, MPH, for their expert review of the Oncology, Hematology, Renal, Endocrine, and Liver sections, respectively.

## FOOTNOTES

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on

June 27, 2017, and the American Heart Association Executive Committee on August 21, 2017. A copy of the document is available at <http://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 843-216-2533 or e-mail [kelle.ramsay@wolterskluwer.com](mailto:kelle.ramsay@wolterskluwer.com).

The American Heart Association requests that this document be cited as follows: Lui GK, Saidi A, Bhatt AB, Burchill LJ, Deen JF, Earing MG, Gewitz M, Ginns J, Kay JD, Kim YY, Kovacs AH, Krieger EV, Wu FM, Yoo S-J; on behalf of the American Heart Association Adult Congenital Heart Disease Committee of the Council on Clinical Cardiology and Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; and Council on Quality of Care and Outcomes Research. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. *Circulation*. 2017;136:eXXX–eXXX. DOI: 10.1161/CIR.0000000000000535.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at [http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines\\_UCM\\_300404\\_Article.jsp](http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp). A link to the "Copyright Permissions Request Form" appears on the right side of the page.

*Circulation* is available at <http://circ.ahajournals.org>.

## DISCLOSURES

### Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
George K. Lui	Stanford University School of Medicine	None	None	None	None	None	Medical Advisory Board, Adult Congenital Heart Association*	None
Arwa Saidi	University of Florida, Gainesville	None	None	None	None	None	Medical Advisory Board, Adult Congenital Heart Association*	None
Ami B. Bhatt	Massachusetts General Hospital, Harvard Medical School	None	None	None	None	None	None	None
Luke J. Burchill	Oregon Health Science University, Knight Cardiovascular Institute	None	None	None	None	None	None	None

(Continued)

Writing Group Disclosures Continued

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Jason F. Deen	Seattle Children's Hospital, University of Washington	None	None	None	None	None	None	None
Michael G. Earing	Medical College of Wisconsin, Children's Hospital of Wisconsin	None	None	Actelion Pharmaceuticals*	None	None	None	None
Michael Gewitz	New York Medical College, Maria Fareri Children's Hospital	None	None	None	None	None	None	None
Jonathan Ginns	Columbia University Medical Center	None	None	None	None	None	None	None
Joseph D. Kay	University of Colorado, Denver	None	None	None	None	None	None	None
Yuli Y. Kim	Hospital of the University of Pennsylvania	None	None	None	None	None	None	None
Adrienne H. Kovacs	Oregon Health & Science University, Knight Cardiovascular Institute	Canadian Institutes of Health Research*; Heart and Stroke Foundation*; Labatt Family Heart Centre Innovation Fund*; Peter Munk Cardiac Centre Innovation Fund*; Actelion Pharmaceuticals*; National Institutes of Health*	None	None	None	None	None	None
Eric V. Krieger	University of Washington, Seattle, and Seattle Children's Hospital	None	None	None	None	None	None	None
Fred M. Wu	Boston Adult Congenital Heart Service, Brigham and Women's Hospital & Boston Children's Hospital	None	None	None	None	None	None	None
Shi-Joon Yoo	Hospital for Sick Children	None	None	None	None	3D HOPE Medical*; 3D Print Heart*; IMIB-CHD*	None	None



This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10,000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.  
 \*Modest.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Roger A. de Freitas	Ann & Robert H. Lurie Children's Hospital of Chicago	None	None	None	None	None	None	None
Leigh C. Reardon	Ahmanson/UCLA Adult Congenital Heart Disease Center	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10,000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

Downloaded from <http://circ.ahajournals.org/> by guest on October 16, 2017

## REFERENCES

1. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI, Somerville J, Williams RG, Webb GD. Task force 1: the changing profile of congenital heart disease in adult life. *J Am Coll Cardiol*. 2001;37:1170–1175.
2. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). *Circulation*. 2008;118:e714–e833. doi: 10.1161/CIRCULATIONAHA.108.190690.
3. Khairy P, Ionescu-Ittu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. *J Am Coll Cardiol*. 2010;56:1149–1157. doi: 10.1016/j.jacc.2010.03.085.
4. Afilalo J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Marelli AJ. Geriatric congenital heart disease: burden of disease and predictors of mortality. *J Am Coll Cardiol*. 2011;58:1509–1515. doi: 10.1016/j.jacc.2011.06.041.
5. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. *Circulation*. 2007;115:163–172. doi: 10.1161/CIRCULATIONAHA.106.627224.
6. Roche SL, Silversides CK. Hypertension, obesity, and coronary artery disease in the survivors of congenital heart disease. *Can J Cardiol*. 2013;29:841–848. doi: 10.1016/j.cjca.2013.03.021.
7. Lui GK, Fernandes S, McElhinney DB. Management of cardiovascular risk factors in adults with congenital heart disease. *J Am Heart Assoc*. 2014;3:e001076. doi: 10.1161/JAHA.114.001076.
8. Billett J, Cowie MR, Gatzoulis MA, Vonder Muhll IF, Majeed A. Comorbidity, healthcare utilisation and process of care measures in patients with congenital heart disease in the UK: cross-sectional, population-based study with case-control analysis. *Heart*. 2008;94:1194–1199. doi: 10.1136/hrt.2007.122671.
9. Rodriguez FH 3rd, Moodie DS, Parekh DR, Franklin WJ, Morales DL, Zafar F, Graves DE, Friedman RA, Rossano JW. Outcomes of hospitalization in adults in the United States with atrial septal defect, ventricular septal defect, and atrioventricular septal defect. *Am J Cardiol*. 2011;108:290–293. doi: 10.1016/j.amjcard.2011.03.036.
10. Dimopoulos K, Diller GP, Koltzida E, Pijuan-Domench A, Papadopoulos SA, Babu-Narayan SV, Salukhe TV, Piepoli MF, Poole-Wilson PA, Best N, Francis DP, Gatzoulis MA. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. *Circulation*. 2008;117:2320–2328. doi: 10.1161/CIRCULATIONAHA.107.734921.
11. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro A, Tutarel O, Marino P, Wustmann K, Charalambides M, Silva M, Swan L, Dimopoulos K, Gatzoulis MA. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. *Circulation*. 2013;127:882–890. doi: 10.1161/CIRCULATIONAHA.112.126755.
12. Asrani SK, Asrani NS, Freese DK, Phillips SD, Warnes CA, Heimbach J, Kamath PS. Congenital heart disease and the liver. *Hepatology*. 2012;56:1160–1169. doi: 10.1002/hep.25692.
13. Fort P, Lifshitz F, Bellisario R, Davis J, Lanes R, Pugliese M, Richman R, Post EM, David R. Abnormalities of thyroid function in infants with Down syndrome. *J Pediatr*. 1984;104:545–549.
14. Ross WT, Olsen M. Care of the adult patient with Down syndrome. *South Med J*. 2014;107:715–721. doi: 10.14423/SMJ.0000000000000193.
15. Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late causes of death after pediatric cardiac surgery: a 60-year population-based study. *J Am Coll Cardiol*. 2016;68:487–498. doi: 10.1016/j.jacc.2016.05.038.
16. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, Babu-Narayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. *Circulation*. 2015;132:2118–2125. doi: 10.1161/CIRCULATIONAHA.115.017202.
17. Engelings CC, Helm PC, Abdul-Khaliq H, Asfour B, Bauer UM, Baumgartner H, Kececioglu D, Körten MA, Diller GP, Tutarel O. Cause of death in adults with congenital heart disease: an analysis of the German National Register for Congenital Heart Defects. *Int J Cardiol*. 2016;211:31–36. doi: 10.1016/j.ijcard.2016.02.133.
18. O'Leary JM, Siddiqi OK, de Ferranti S, Landzberg MJ, Opatowsky AR. The changing demographics of congenital heart disease hospitalizations in the United States, 1998 through 2010. *JAMA*. 2013;309:984–986. doi: 10.1001/jama.2013.564.
19. Price S, Jaggar SI, Jordan S, Trenfield S, Khan M, Sethia B, Shore D, Evans TW. Adult congenital heart disease: intensive care management and outcome prediction. *Intensive Care Med*. 2007;33:652–659. doi: 10.1007/s00134-007-0544-z.
20. Bhatt AB, Rajabali A, He W, Benavidez OJ. High resource use among adult congenital heart surgery admissions in adult hospitals: risk factors and association with death and comorbidities. *Congenit Heart Dis*. 2015;10:13–20. doi: 10.1111/chd.12169.
21. Abarbanell GL, Goldberg CS, Devaney EJ, Ohye RG, Bove EL, Charpie JR. Early surgical morbidity and mortality in adults with congenital heart disease: the University of Michigan experience. *Congenit Heart Dis*. 2008;3:82–89. doi: 10.1111/j.1747-0803.2008.00170.x.
22. Maxwell BG, Wong JK, Kin C, Lobato RL. Perioperative outcomes of major noncardiac surgery in adults with congenital heart disease. *Anesthesiology*. 2013;119:762–769. doi: 10.1097/ALN.0b013e3182a56de3.
23. Rychik J. The relentless effects of the Fontan paradox. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu*. 2016;19:37–43. doi: 10.1053/j.pcsu.2015.11.006.
24. Fernandes SM, Chamberlain LJ, Grady S Jr, Saynina O, Opatowsky AR, Sanders L, Wise PH. Trends in utilization of specialty care centers in California for adults with congenital heart disease. *Am J Cardiol*. 2015;115:1298–1304. doi: 10.1016/j.amjcard.2015.02.013.
25. Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A. Specialized adult congenital heart disease care: the impact of policy on mortality. *Circulation*. 2014;129:1804–1812. doi: 10.1161/CIRCULATIONAHA.113.005817.
26. Spear GS. The glomerulus in cyanotic congenital heart disease and primary pulmonary hypertension: a review. *Nephron*. 1964;1:238–248.
27. Flanagan MF, Hourihan M, Keane JF. Incidence of renal dysfunction in adults with cyanotic congenital heart disease. *Am J Cardiol*. 1991;68:403–406.
28. Sharma S, Ruebner RL, Furth SL, Dodds KM, Rychik J, Goldberg DJ. Assessment of kidney function in survivors following Fontan palliation. *Congenit Heart Dis*. 2016;11:630–636. doi: 10.1111/chd.12358.
29. Ohuchi H, Ikado H, Noritake K, Miyazaki A, Yasuda K, Yamada O. Impact of central venous pressure on cardiorenal interactions in adult patients with congenital heart disease after biventricular repair. *Congenit Heart Dis*. 2013;8:103–110. doi: 10.1111/j.1747-0803.2012.00717.x.
30. Kwiatkowski DM, Price E, Axelrod DM, Romfh AW, Han BS, Sutherland SM, Krawczeski CD. Incidence, risk factors, and outcomes of acute kidney injury in adults undergoing surgery for congenital heart disease. *Cardiol Young*. 2017;27:1068–1075. doi: 10.1017/S1047951116002067.
31. Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, Leon MB, Stone GW, Kirtane AJ, Karpaliotis D, Bokhari S, Hardy MA, Dube G, Mohan S, Ratner LE, Cohen DJ, Ali ZA. Diagnosis and management of cardiovascular disease in advanced and end-stage renal disease. *J Am Heart Assoc*. 2016;5:e003648. doi: 10.1161/JAHA.116.003648.
32. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P; Acute Dialysis Quality Initiative (ADQI) Consensus Group. Cardio-renal syndromes: report from the Consensus Conference of the Acute Dialysis Quality Initiative. *Eur Heart J*. 2010;31:703–711.
33. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. relationship of cardiac index to kidney function. *Drugs*. 1990;39(suppl 4):10–21.
34. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. *J Am Coll Cardiol*. 2009;53:582–588. doi: 10.1016/j.jacc.2008.08.080.
35. Magri P, Rao MA, Cangianiello S, Bellizzi V, Russo R, Mele AF, Andreucci M, Memoli B, De Nicola L, Volpe M. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. *Circulation*. 1998;98:2849–2854.
36. Ohuchi H, Takasugi H, Ohashi H, Yamada O, Watanabe K, Yagihara T, Echigo S. Abnormalities of neurohormonal and cardiac autonomic nervous activities relate poorly to functional status in Fontan patients. *Circulation*. 2004;110:2601–2608. doi: 10.1161/01.CIR.0000145545.83564.51.
37. Tulevski II, Groenink M, van Der Wall EE, van Veldhuisen DJ, Boomsma F, Stoker J, Hirsch A, Lemkes JS, Mulder BJ. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure over-



- load: correlation between plasma neurohormones and right ventricular dysfunction. *Heart*. 2001;86:27–30.
38. Welke KF, Dearani JA, Ghanayem NS, Beland MJ, Shen I, Ebels T. Renal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. *Cardiol Young*. 2008;18(suppl 2):222–225. doi: 10.1017/S1047951108002953.
  39. Taylor ML, Carmona F, Thiagarajan RR, Westgate L, Ferguson MA, del Nido PJ, Rajagopal SK. Mild postoperative acute kidney injury and outcomes after surgery for congenital heart disease. *J Thorac Cardiovasc Surg*. 2013;146:146–152. doi: 10.1016/j.jtcvs.2012.09.008.
  40. Esch JJ, Salvin JM, Thiagarajan RR, Del Nido PJ, Rajagopal SK. Acute kidney injury after Fontan completion: risk factors and outcomes. *J Thorac Cardiovasc Surg*. 2015;150:190–197. doi: 10.1016/j.jtcvs.2015.04.011.
  41. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med*. 2014;371:58–66. doi: 10.1056/NEJMr1214243.
  42. San Agustín JT, Klena N, Granath K, Panigrahy A, Stewart E, Devine W, Strittmatter L, Jonassen JA, Liu X, Lo CW, Pazour GJ. Genetic link between renal birth defects and congenital heart disease [published correction appears in *Nat Commun*. 2016;7:11910]. *Nat Commun*. 2016;7:11103. doi: 10.1038/ncomms11103.
  43. Collins RT 2nd. Cardiovascular disease in Williams syndrome. *Circulation*. 2013;127:2125–2134. doi: 10.1161/CIRCULATIONAHA.112.000064.
  44. Merla G, Brunetti-Pierri N, Piccolo P, Micale L, Loviglio MN. Supravalvular aortic stenosis: elastin arteriopathy. *Circ Cardiovasc Genet*. 2012;5:692–696. doi: 10.1161/CIRCGENETICS.112.962860.
  45. Sindhar S, Lugo M, Levin MD, Danback JR, Brink BD, Yu E, Dietzen DJ, Clark AL, Purgert CA, Waxler JL, Elder RW, Pober BR, Kozel BA. Hypercalcemia in patients with Williams-Beuren Syndrome. *J Pediatr*. 2016;178:254–260.e4. doi: 10.1016/j.jpeds.2016.08.027.
  46. Dittrich S, Haas NA, Bührer C, Müller C, Dähner I, Lange PE. Renal impairment in patients with long-standing cyanotic congenital heart disease. *Acta Paediatr*. 1998;87:949–954.
  47. Agras PI, Derbent M, Ozcay F, Baskin E, Turkoglu S, Aldemir D, Tokel K, Saatci U. Effect of congenital heart disease on renal function in childhood. *Nephron Physiol*. 2005;99:p10–p15. doi: 10.1159/000081797.
  48. Inatomi J, Matsuoka K, Fujimaru R, Nakagawa A, Iijima K. Mechanisms of development and progression of cyanotic nephropathy. *Pediatr Nephrol*. 2006;21:1440–1445. doi: 10.1007/s00467-006-0220-5.
  49. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease: hematologic derangements, renal function, and urate metabolism. *Cardiol Clin*. 1993;11:689–699.
  50. Martínez-Quintana E, Rodríguez-González F, Fábregas-Brouard M, Nieto-Lago V. Serum and 24-hour urine analysis in adult cyanotic and noncyanotic congenital heart disease patients. *Congenit Heart Dis*. 2009;4:147–152. doi: 10.1111/j.1747-0803.2009.00273.x.
  51. Martínez-Quintana E, Rodríguez-González F. Medium-term follow-up of renal function in hypoxaemic congenital heart disease patients. *Cardiol Young*. 2016;26:1137–1143. doi: 10.1017/S1047951115001948.
  52. Martínez-Quintana E, Rodríguez-González F. Proteinuria and clinical outcome in CHD patients. *Cardiol Young*. 2015;25:1054–1059. doi: 10.1017/S1047951114001541.
  53. Vida VL, Mack R, Barnoya J, Larrazabal LA, Lou R, Castañeda AR. The association of renal tubular acidosis and cyanotic congenital heart disease. *J Thorac Cardiovasc Surg*. 2005;130:1466–1467. doi: 10.1016/j.jtcvs.2005.06.040.
  54. Cooper DS, Kwiatkowski DM, Goldstein SL, Krawczeski CD. Acute kidney injury and cardiorenal syndromes in pediatric cardiac intensive care. *Pediatr Crit Care Med*. 2016;17(suppl 1):S250–S256. doi: 10.1097/PCC.0000000000000820.
  55. Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. *Clin J Am Soc Nephrol*. 2010;5:1552–1557. doi: 10.2215/CJN.02040310.
  56. Zappitelli M, Greenberg JH, Coca SG, Krawczeski CD, Li S, Thiessen-Philbrook HR, Bennett MR, Devarajan P, Parikh CR; Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) Consortium. Association of definition of acute kidney injury by cystatin C rise with biomarkers and clinical outcomes in children undergoing cardiac surgery. *JAMA Pediatr*. 2015;169:583–591. doi: 10.1001/jamapediatrics.2015.54.
  57. Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piyaphanee N, Ma Q, Bennett M, Devarajan P. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. *J Am Coll Cardiol*. 2011;58:2301–2309. doi: 10.1016/j.jacc.2011.08.017.
  58. Cohen SB, Ginde S, Bartz PJ, Earing MG. Extracardiac complications in adults with congenital heart disease. *Congenit Heart Dis*. 2013;8:370–380. doi: 10.1111/chd.12080.
  59. Ginde S, Bartz PJ, Hill GD, Danduran MJ, Biller J, Sowinski J, Tweddell JS, Earing MG. Restrictive lung disease is an independent predictor of exercise intolerance in the adult with congenital heart disease. *Congenit Heart Dis*. 2013;8:246–254. doi: 10.1111/chd.12010.
  60. Fredriksen PM, Veldtman G, Hechter S, Therrien J, Chen A, Warsi MA, Freeman M, Liu P, Siu S, Thaulow E, Webb G. Aerobic capacity in adults with various congenital heart diseases. *Am J Cardiol*. 2001;87:310–314.
  61. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. *Circulation*. 2005;112:828–835. doi: 10.1161/CIRCULATIONAHA.104.529800.
  62. Healy F, Hanna BD, Zinman R. Pulmonary complications of congenital heart disease. *Paediatr Respir Rev*. 2012;13:10–15. doi: 10.1016/j.prrv.2011.01.007.
  63. Caruthers RL, Kempa M, Loo A, Gulbransen E, Kelly E, Erickson SR, Hirsch JC, Schumacher KR, Stringer KA. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. *Pediatr Cardiol*. 2013;34:256–261. doi: 10.1007/s00246-012-0430-5.
  64. Schumacher KR, Singh TP, Kuebler J, Aprile K, O'Brien M, Blume ED. Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study. *J Am Heart Assoc*. 2014;3:e000865. doi: 10.1161/JAHA.114.000865.
  65. Marrone C, Galasso G, Piccolo R, de Leva F, Paladini R, Piscione F, Santoro G. Antiplaquet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. *Pediatr Cardiol*. 2011;32:32–39. doi: 10.1007/s00246-010-9808-4.
  66. Dimopoulos K, Giannakoulas G, Wort SJ, Gatzoulis MA. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. *Curr Opin Cardiol*. 2008;23:545–554. doi: 10.1097/HCO.0b013e3283126954.
  67. Engelfriet PM, Duffels MG, Möller T, Boersma E, Tijssen JG, Thaulow E, Gatzoulis MA, Mulder BJ. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. *Heart*. 2007;93:682–687. doi: 10.1136/hrt.2006.098848.
  68. Herrera-Soto JA, Vander Have KL, Barry-Lane P, Myers JL. Retrospective study on the development of spinal deformities following sternotomy for congenital heart disease. *Spine (Phila Pa 1976)*. 2007;32:1998–2004. doi: 10.1097/BRS.0b013e318131b225.
  69. Greutmann M, Le TL, Tobler D, Biaggi P, Oechslin EN, Silversides CK, Granton JT. Generalised muscle weakness in young adults with congenital heart disease. *Heart*. 2011;97:1164–1168. doi: 10.1136/hrt.2010.213579.
  70. De Troyer A, Yernault JC, Englert M. Lung hypoplasia in congenital pulmonary valve stenosis. *Circulation*. 1977;56(pt 1):647–651.
  71. Watson NF, Bushnell T, Jones TK, Stout K. A novel method for the evaluation and treatment of obstructive sleep apnea in four adults with complex congenital heart disease and Fontan repairs. *Sleep Breath*. 2009;13:421–424. doi: 10.1007/s11325-009-0260-8.
  72. Duffels MG, Engelfriet PM, Berger RM, van Loon RL, Hoendermis E, Vriend JW, van der Velde ET, Bresser P, Mulder BJ. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. *Int J Cardiol*. 2007;120:198–204. doi: 10.1016/j.ijcard.2006.09.017.
  73. Hsia CC. Cardiopulmonary limitations to exercise in restrictive lung disease. *Med Sci Sports Exerc*. 1999;31(suppl):S28–S32.
  74. Dimopoulos K, Okonko DO, Diller GP, Broberg CS, Salukhe TV, Babu-Narayan SV, Li W, Uebing A, Bayne S, Wensel R, Piepoli MF, Poole-Wilson PA, Francis DP, Gatzoulis MA. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. *Circulation*. 2006;113:2796–2802. doi: 10.1161/CIRCULATIONAHA.105.594218.
  75. Buda AJ, Pinsky MR, Ingels NB Jr, Daughters GT 2nd, Stinson EB, Alderman EL. Effect of intrathoracic pressure on left ventricular performance. *N Engl J Med*. 1979;301:453–459. doi: 10.1056/NEJM197908303010901.

76. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. *Chest*. 1998;113:576–583.
77. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J*. 2005;26:319–338. doi: 10.1183/09031936.05.00034805.
78. Crapo RO. Pulmonary-function testing. *N Engl J Med*. 1994;331:25–30. doi: 10.1056/NEJM199407033110107.
79. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26:948–968. doi: 10.1183/09031936.05.00035205.
80. Epstein AE, Olshansky B, Naccarelli GV, Kennedy JJ Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. *Am J Med*. 2016;129:468–475. doi: 10.1016/j.amjmed.2015.08.039.
81. Goldstein RS, Hill K, Brooks D, Dolmage TE. Pulmonary rehabilitation: a review of the recent literature. *Chest*. 2012;142:738–749. doi: 10.1378/chest.12-0188.
82. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med*. 2006;173:1390–1413. doi: 10.1164/rccm.200508-1211ST.
83. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, Zuwallack R, Herrerias C. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. *Chest*. 2007;131(suppl):4S–42S. doi: 10.1378/chest.06-2418.
84. Markovitz GH, Cooper CB. Rehabilitation in non-COPD: mechanisms of exercise limitation and pulmonary rehabilitation for patients with pulmonary fibrosis/restrictive lung disease. *Chron Respir Dis*. 2010;7:47–60. doi: 10.1177/1479972309348654.
85. Mascolo MC, Truwit JD. Role of exercise evaluation in restrictive lung disease: new insights between March 2001 and February 2003. *Curr Opin Pulm Med*. 2003;9:408–410.
86. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. *J Cardiopulm Rehabil*. 2006;26:237–243.
87. Becker-Grünig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, Gorenlfo M, Tiede H, Schranz D, Hager A, Kaemmerer H, Miera O, Ulrich S, Speich R, Uiker S, Grünig E. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. *Int J Cardiol*. 2013;168:375–381. doi: 10.1016/j.ijcard.2012.09.036.
88. Mereles D, Ehlken N, Kreuzer S, Ghofrani S, Hoepfer MM, Halank M, Meyer FF, Karger G, Buss J, Juenger J, Holzappel N, Opitz C, Winkler J, Herth FJ, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation*. 2006;114:1482–1489. doi: 10.1161/CIRCULATIONAHA.106.618397.
89. Qaseem A, Dallas P, Owens DK, Starkey M, Holty JE, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2014;161:210–220. doi: 10.7326/M12-3187.
90. Dori Y, Keller MS, Rome JJ, Gillespie MJ, Glatz AC, Dodds K, Goldberg DJ, Goldfarb S, Rychik J, Itkin M. Percutaneous lymphatic embolization of abnormal pulmonary lymphatic flow as treatment of plastic bronchitis in patients with congenital heart disease. *Circulation*. 2016;133:1160–1170. doi: 10.1161/CIRCULATIONAHA.115.019710.
91. Gatzoulis MA, Webb GD, Daubeney PEF. *Diagnosis and Management of Adult Congenital Heart Disease*. 2nd ed. Philadelphia, PA: Elsevier/Churchill Livingstone; 2011.
92. Johnson JA, Cetta F, Graham RP, Smyrk TC, Driscoll DJ, Phillips SD, John AS. Identifying predictors of hepatic disease in patients after the Fontan operation: a postmortem analysis. *J Thorac Cardiovasc Surg*. 2013;146:140–145. doi: 10.1016/j.jtcvs.2012.09.005.
93. Schwartz MC, Sullivan LM, Glatz AC, Rand E, Russo P, Goldberg DJ, Rome JJ, Cohen MS. Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery. *Pediatr Cardiol*. 2013;34:135–142. doi: 10.1007/s00246-012-0402-9.
94. Surrey LF, Russo P, Rychik J, Goldberg DJ, Dodds K, O'Byrne ML, Glatz AC, Rand EB, Lin HC. Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation. *Hum Pathol*. 2016;57:106–115. doi: 10.1016/j.humpath.2016.07.006.
95. Wu FM, Jonas MM, Opatowsky AR, Harmon A, Raza R, Ukomadu C, Landzberg MJ, Singh MN, Valente AM, Egidy Assenza G, Perez-Atayde AR. Portal and centrilobular hepatic fibrosis in Fontan circulation and clinical outcomes. *J Heart Lung Transplant*. 2015;34:883–891. doi: 10.1016/j.healun.2015.01.993.
96. Bae JM, Jeon TY, Kim JS, Kim S, Hwang SM, Yoo SY, Kim JH. Fontan-associated liver disease: spectrum of US findings. *Eur J Radiol*. 2016;85:850–856. doi: 10.1016/j.ejrad.2016.02.002.
97. Pundi K, Pundi KN, Kamath PS, Cetta F, Li Z, Poterucha JT, Driscoll DJ, Johnson JN. Liver disease in patients after the Fontan operation. *Am J Cardiol*. 2016;117:456–460. doi: 10.1016/j.amjcard.2015.11.014.
98. Lindsay I, Johnson J, Everitt MD, Hoffman J, Yetman AT. Impact of liver disease after the Fontan operation. *Am J Cardiol*. 2015;115:249–252. doi: 10.1016/j.amjcard.2014.10.032.
99. Wu FM, Kogon B, Earing MG, Aboulhosn JA, Broberg CS, John AS, Harmon A, Sainani NI, Hill AJ, Odze RD, Johncilla ME, Ukomadu C, Gauvreau K, Valente AM, Landzberg MJ; Alliance for Adult Research in Congenital Cardiology (AARCC) Investigators. Liver health in adults with Fontan circulation: a multicenter cross-sectional study. *J Thorac Cardiovasc Surg*. 2017;153:656–664. doi: 10.1016/j.jtcvs.2016.10.060.
100. Ford RM, Book W, Spivey JR. Liver disease related to the heart. *Transplant Rev (Orlando)*. 2015;29:33–37. doi: 10.1016/j.ttre.2014.11.003.
101. Ratnasamy C, Kurbegov A, Swaminathan S. Cardiac anomalies in the setting of the Abernethy malformation of the portal vein. *Cardiol Young*. 2007;17:212–214. doi: 10.1017/S1047951106001375.
102. Murray CP, Yoo SJ, Babyn PS. Congenital extrahepatic portosystemic shunts. *Pediatr Radiol*. 2003;33:614–620. doi: 10.1007/s00247-003-1002-x.
103. Newman B, Feinstein JA, Cohen RA, Feingold B, Kreutzer J, Patel H, Chan FP. Congenital extrahepatic portosystemic shunt associated with heterotaxy and polysplenia. *Pediatr Radiol*. 2010;40:1222–1230. doi: 10.1007/s00247-009-1508-y.
104. Kamath BM, Bason L, Piccoli DA, Krantz ID, Spinner NB. Consequences of JAG1 mutations. *J Med Genet*. 2003;40:891–895.
105. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. *Clin Liver Dis*. 2011;15:1–20. doi: 10.1016/j.cld.2010.09.010.
106. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. *Medicine (Baltimore)*. 2003;82:392–406. doi: 10.1097/01.md.0000101573.54295.bd.
107. Henrion J, Descamps O, Luwaert R, Schapira M, Parfony A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. *J Hepatol*. 1994;21:696–703.
108. Mitchell IM, Pollock JC, Jamieson MP. The effects of congenital heart disease and cardiac surgery on liver blood flow in children. *Perfusion*. 1995;10:210–218. doi: 10.1177/026765919501000403.
109. Odegard KC, McGowan FX Jr, DiNardo JA, Castro RA, Zurakowski D, Connor CM, Hansen DD, Neufeld EJ, del Nido PJ, Laussen PC. Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. *J Thorac Cardiovasc Surg*. 2002;123:459–465.
110. Odegard KC, McGowan FX Jr, Zurakowski D, DiNardo JA, Castro RA, del Nido PJ, Laussen PC. Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. *Ann Thorac Surg*. 2002;73:1770–1777.
111. Henriksson P, Väreth G, Lundström NR. Haemostatic defects in cyanotic congenital heart disease. *Br Heart J*. 1979;41:23–27.
112. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). *Hepatology*. 1995;21:1232–1237.
113. Wang A, Book WM, McConnell M, Lyle T, Rodby K, Mahle WT. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to screening in 1992. *Am J Cardiol*. 2007;100:1307–1309. doi: 10.1016/j.amjcard.2007.05.059.
114. Cox DA, Ginde S, Tweddell JS, Earing MG. Outcomes of a hepatitis C screening protocol in at-risk adults with prior cardiac surgery. *World J Pediatr Congenit Heart Surg*. 2014;5:503–506. doi: 10.1177/2150135114547587.
115. Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of

- an AASLD clinical workshop. *Hepatology*. 2004;39:1204–1212. doi: 10.1002/hep.20169.
116. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2013;159:349–357. doi: 10.7326/0003-4819-159-5-201309030-00672.
  117. Kim DK, Bridges CB, Harriman KH; Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. *Ann Intern Med*. 2016;164:184–194. doi: 10.7326/M15-3005.
  118. Bradley E, Hendrickson B, Daniels C. Fontan liver disease: review of an emerging epidemic and management options. *Curr Treat Options Cardiovasc Med*. 2015;17:51. doi: 10.1007/s11936-015-0412-z.
  119. Josephus Jitta D, Wagenaar LJ, Mulder BJ, Guichelaar M, Bouman D, van Melle JP. Three cases of hepatocellular carcinoma in Fontan patients: review of the literature and suggestions for hepatic screening. *Int J Cardiol*. 2016;206:21–26. doi: 10.1016/j.ijcard.2015.12.033.
  120. Wu FM, Ukomadu C, Odze RD, Valente AM, Mayer JE Jr, Earing MG. Liver disease in the patient with Fontan circulation. *Congenit Heart Dis*. 2011;6:190–201. doi: 10.1111/j.1747-0803.2011.00504.x.
  121. Ginde S, Hohenwarter MD, Foley WD, Sowinski J, Bartz PJ, Venkatapuram S, Weinberg C, Tweddell JS, Earing MG. Noninvasive assessment of liver fibrosis in adult patients following the Fontan procedure. *Congenit Heart Dis*. 2012;7:235–242. doi: 10.1111/j.1747-0803.2012.00632.x.
  122. Ofei SY, Garipey C, Hanje J, Sisk T, Daniels CJ, Zaidi AN. Liver fibrosis in adults with Fontan palliation: do common screening studies predict disease severity? *Int J Cardiol*. 2015;181:174–175. doi: 10.1016/j.ijcard.2014.12.031.
  123. Baek JS, Bae EJ, Ko JS, Kim GB, Kwon BS, Lee SY, Noh CI, Park EA, Lee W. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. *Heart*. 2010;96:1750–1755. doi: 10.1136/hrt.2010.201772.
  124. Wu FM, Earing MG, Aboulhosn JA, Johncilla ME, Singh MN, Odze RD, Ukomadu C, Gauvreau K, Landzberg MJ, Valente AM; Alliance for Adult Research in Congenital Cardiology (AARCC) Investigators. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients. *J Heart Lung Transplant*. 2017;36:211–219. doi: 10.1016/j.healun.2016.07.011.
  125. Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K, Usuki N, Shimamatsu K, Kage M, Kojiro M. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis: a multicenter collaborative study. *Intervirology*. 2008;51(suppl 1):17–26. doi: 10.1159/000122595.
  126. Elder RW, McCabe NM, Hebson C, Veledar E, Romero R, Ford RM, Mahle WT, Kogon BE, Sahu A, Jokhadar M, McConnell ME, Book WM. Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. *Int J Cardiol*. 2013;168:3764–3769. doi: 10.1016/j.ijcard.2013.06.008.
  127. Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. *N Engl J Med*. 2013;368:1756–1757. doi: 10.1056/NEJMc1214222.
  128. Barberis VI, Briili S, Dimopoulou M, Barbetseas J, Stefanadis C. Hepatocellular carcinoma with right atrial extension in a young patient with congenitally unguarded tricuspid orifice. *Echocardiography*. 2006;23:417–420. doi: 10.1111/j.1540-8175.2006.00226.x.
  129. Elder RW, Parekh S, Book WM. More on hepatocellular carcinoma after the Fontan procedure. *N Engl J Med*. 2013;369:490. doi: 10.1056/NEJMc1306854.
  130. McCabe N, Farris AB, Hon H, Ford R, Book WM. Hepatocellular carcinoma in an adult with repaired tetralogy of Fallot. *Congenit Heart Dis*. 2013;8:E139–E144. doi: 10.1111/j.1747-0803.2012.00700.x.
  131. Song PS, Koh KC, Yoo BC, Paik SW, Lee JH, Choi MS, Ryu DR, Lee JY. A case of hepatocellular carcinoma complicating cardiac cirrhosis caused by constrictive pericarditis [in Korean]. *Korean J Gastroenterol*. 2005;45:436–440.
  132. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. *AJR Am J Roentgenol*. 2010;195:29–41. doi: 10.2214/AJR.10.4538.
  133. Strobel D, Seitz K, Blank W, Schuler A, Dietrich C, von Herbay A, Friedrich-Rust M, Kunze G, Becker D, Will U, Kratzer W, Albert FW, Pachmann C, Dirks K, Strunk H, Greis C, Bernatik T. Contrast-enhanced ultrasound for the characterization of focal liver lesions: diagnostic accuracy in clinical practice (DEGUM multicenter trial). *Ultraschall Med*. 2008;29:499–505. doi: 10.1055/s-2008-1027806.
  134. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011;53:1020–1022. doi: 10.1002/hep.24199.
  135. Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. *Am J Gastroenterol*. 2015;110:836–844; quiz 845.
  136. Sherlock S. The liver in heart failure: relation of anatomical, functional, and circulatory changes. *Br Heart J*. 1951;13:273–293.
  137. Kutty SS, Peng Q, Danford DA, Fletcher SE, Perry D, Talmon GA, Scott C, Kugler JD, Duncan KF, Quiros-Tejeira RE, Kutty S; Liver Adult-Pediatric-Congenital-Heart-Disease Dysfunction Study (LADS) Group. Increased hepatic stiffness as consequence of high hepatic afterload in the Fontan circulation: a vascular Doppler and elastography study. *Hepatology*. 2014;59:251–260. doi: 10.1002/hep.26631.
  138. Poterucha JT, Johnson JN, Qureshi MY, O'Leary PW, Kamath PS, Lennon RJ, Bonnicksen CR, Young PM, Venkatesh SK, Ehman RL, Gupta S, Smyrk TC, Dearani JA, Warnes CA, Cetta F. Magnetic resonance elastography: a novel technique for the detection of hepatic fibrosis and hepatocellular carcinoma after the Fontan operation. *Mayo Clin Proc*. 2015;90:882–894. doi: 10.1016/j.mayocp.2015.04.020.
  139. Wu FM, Opatowsky AR, Raza R, Harney S, Ukomadu C, Landzberg MJ, Valente AM, Breitbart RE, Singh MN, Gauvreau K, Jonas MM. Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis. *Congenit Heart Dis*. 2014;9:438–447. doi: 10.1111/chd.12159.
  140. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol*. 2015;63:743–752. doi: 10.1016/j.jhep.2015.05.022.
  141. Bizouarn P, Ausseur A, Desseigne P, Le Turnier Y, Nougarede B, Train M, Michaud JL. Early and late outcome after elective cardiac surgery in patients with cirrhosis. *Ann Thorac Surg*. 1999;67:1334–1338.
  142. Hayashida N, Shoujima T, Teshima H, Yokokura Y, Takagi K, Tomoeda H, Aoyagi S. Clinical outcome after cardiac operations in patients with cirrhosis. *Ann Thorac Surg*. 2004;77:500–505. doi: 10.1016/j.athoracsur.2003.06.021.
  143. Klemperer JD, Ko W, Krieger KH, Connolly M, Rosengart TK, Altorki NK, Lang S, Isom OW. Cardiac operations in patients with cirrhosis. *Ann Thorac Surg*. 1998;65:85–87.
  144. Lin CH, Lin FY, Wang SS, Yu HY, Hsu RB. Cardiac surgery in patients with liver cirrhosis. *Ann Thorac Surg*. 2005;79:1551–1554. doi: 10.1016/j.athoracsur.2004.11.004.
  145. Hsu RB, Lin FY, Chou NK, Ko WJ, Chi NH, Wang SS. Heart transplantation in patients with extreme right ventricular failure. *Eur J Cardiothorac Surg*. 2007;32:457–461. doi: 10.1016/j.ejcts.2007.05.015.
  146. Reinhartz O, Farrar DJ, Hershon JH, Avery GJ Jr, Hausslein EA, Hill JD. Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation. *J Thorac Cardiovasc Surg*. 1998;116:633–640. doi: 10.1016/S0022-5223(98)70171-0.
  147. Hollander SA, Reinhartz O, Maeda K, Hurwitz M, Rosenthal DN, Bernstein D. Intermediate-term outcomes after combined heart-liver transplantation in children with a univentricular heart. *J Heart Lung Transplant*. 2013;32:368–370. doi: 10.1016/j.healun.2012.11.023.
  148. Crupi G, Locatelli G, Tiraboschi R, Villani M, De Tommasi M, Parenzan L. Protein-losing enteropathy after Fontan operation for tricuspid atresia (imperforate tricuspid valve). *Thorac Cardiovasc Surg*. 1980;28:359–363. doi: 10.1055/s-2007-1022109.
  149. Feldt RH, Driscoll DJ, Offord KP, Cha RH, Perrault J, Schaff HV, Puga FJ, Danielson GK. Protein-losing enteropathy after the Fontan operation. *J Thorac Cardiovasc Surg*. 1996;112:672–680. doi: 10.1016/S0022-5223(96)70051-X.
  150. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. *J Am Coll Cardiol*. 2014;64:54–62. doi: 10.1016/j.jacc.2014.04.025.
  151. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study: PLE Study Group. *J Thorac Cardiovasc Surg*. 1998;115:1063–1073.
  152. Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ. Intestinal clearance of alpha 1-antitrypsin: a sensitive method for the detection of protein-losing enteropathy. *Gastroenterology*. 1981;81:777–780.

153. Garty BZ. Deficiency of CD4+ lymphocytes due to intestinal loss after Fontan procedure. *Eur J Pediatr*. 2001;160:58–59.
154. Waldmann TA, Wochner RD, Laster L, Gordon RS Jr. Allergic gastroenteropathy: a cause of excessive gastrointestinal protein loss. *N Engl J Med*. 1967;276:762–769.
155. Cheung YF, Tsang HY, Kwok JS. Immunologic profile of patients with protein-losing enteropathy complicating congenital heart disease. *Pediatr Cardiol*. 2002;23:587–593. doi: 10.1007/s00246-001-0078-z.
156. Magdo HS, Stillwell TL, Greenhawt MJ, Stringer KA, Yu S, Fifer CG, Russell MW, Schumacher KR. Immune abnormalities in Fontan protein-losing enteropathy: a case-control study. *J Pediatr*. 2015;167:331–337. doi: 10.1016/j.jpeds.2015.04.061.
157. Morsheimer MM, Rychik J, Forbes L, Dodds K, Goldberg DJ, Sullivan K, Heimall JR. Risk factors and clinical significance of lymphopenia in survivors of the Fontan procedure for single-ventricle congenital cardiac disease. *J Allergy Clin Immunol Pract*. 2016;4:491–496. doi: 10.1016/j.jaip.2015.11.034.
158. Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. *Am J Cardiol*. 2002;90:672–674.
159. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. *Ann Thorac Surg*. 2006;82:695–700. doi: 10.1016/j.athoracsur.2006.02.048.
160. Johnson JN, Driscoll DJ, O'Leary PW. Protein-losing enteropathy and the Fontan operation. *Nutr Clin Pract*. 2012;27:375–384. doi: 10.1177/0884533612444532.
161. Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. *J Pediatr*. 1997;130:474–478.
162. Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. *Mayo Clin Proc*. 1998;73:777–779. doi: 10.4065/73.8.777.
163. Rothman A, Snyder J. Protein-losing enteropathy following the Fontan operation: resolution with prednisone therapy. *Am Heart J*. 1991;121(pt 1):618–619.
164. Therrien J, Webb GD, Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? *Heart*. 1999;82:241–243.
165. John AS, Phillips SD, Driscoll DJ, Warnes CA, Cetta F. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation. *Congenit Heart Dis*. 2011;6:653–656. doi: 10.1111/j.1747-0803.2011.00518.x.
166. Zaupper LB, Nielsen BW, Herlin T. Protein-losing enteropathy after the total cavopulmonary connection: impact of intravenous immunoglobulin. *Congenit Heart Dis*. 2011;6:624–629. doi: 10.1111/j.1747-0803.2011.00568.x.
167. Mertens L, Dumoulin M, Gewillig M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. *Br Heart J*. 1994;72:591–592.
168. Vyas H, Driscoll DJ, Cabalka AK, Cetta F, Hagler DJ. Results of transcatheter Fontan fenestration to treat protein losing enteropathy. *Catheter Cardiovasc Interv*. 2007;69:584–589. doi: 10.1002/ccd.21045.
169. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. *Ann Thorac Surg*. 2006;82:e39–e40. doi: 10.1016/j.athoracsur.2006.08.043.
170. Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, Hsu D, Canter CE, Kirklin JK, Morrow WR; Pediatric Heart Transplant Study. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. *Circulation*. 2006;114:273–280.
171. Griffiths ER, Kaza AK, Wyler von Ballmoos MC, Loyola H, Valente AM, Blume ED, del Nido P. Evaluating failing Fontans for heart transplantation: predictors of death. *Ann Thorac Surg*. 2009;88:558–563. doi: 10.1016/j.athoracsur.2009.03.085.
172. Chen JM, Davies RR, Mital SR, Mercando ML, Addonizio LJ, Pinney SP, Hsu DT, Lamour JM, Quaegebeur JM, Mosca RS. Trends and outcomes in transplantation for complex congenital heart disease: 1984 to 2004. *Ann Thorac Surg*. 2004;78:1352–1361. doi: 10.1016/j.athoracsur.2004.04.012.
173. Doumouras BS, Alba AC, Foroutan F, Burchill LJ, Dipchand AI, Ross HJ. Outcomes in adult congenital heart disease patients undergoing heart transplantation: a systematic review and meta-analysis. *J Heart Lung Transplant*. 2016;35:1337–1347. doi: 10.1016/j.healun.2016.06.003.
174. Jayakumar KA, Addonizio LJ, Kichuk-Christant MR, Galantowicz ME, Lamour JM, Quaegebeur JM, Hsu DT. Cardiac transplantation after the Fontan or Glenn procedure. *J Am Coll Cardiol*. 2004;44:2065–2072. doi: 10.1016/j.jacc.2004.08.031.
175. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ. Mortality in adult congenital heart disease. *Eur Heart J*. 2010;31:1220–1229. doi: 10.1093/eurheartj/ehq032.
176. Berglund E, Johansson B, Dellborg M, Sorensson P, Christersson C, Nielsen NE, Rinnstrom D, Thilen U. High incidence of infective endocarditis in adults with congenital ventricular septal defect [published online ahead of print July 21, 2016]. *Heart*. doi: 10.1136/heartjnl-2015-309133. <http://www.heart.bmj.com/cgi/pmidlookup?view=long&pmid=27443390>.
177. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in *Circulation*. 2007;116:e376–e377]. *Circulation*. 2007;116:1736–1754. doi: 10.1161/CIRCULATIONAHA.106.183095.
178. Chiu SN, Shao PL, Wang JK, Chen HC, Lin MT, Chang LY, Lu CY, Lee PI, Huang LM, Wu MH. Severe bacterial infection in patients with heterotaxy syndrome. *J Pediatr*. 2014;164:99–104.e1. doi: 10.1016/j.jpeds.2013.08.051.
179. Waldman JD, Rosenthal A, Smith AL, Shurin S, Nadas AS. Sepsis and congenital asplenia. *J Pediatr*. 1977;90:555–559.
180. Kennedy MP, Omran H, Leigh MW, Dell S, Morgan L, Molina PL, Robinson BV, Minnix SL, Olbrich H, Severin T, Ahrens P, Lange L, Morillas HN, Noone PG, Zariwala MA, Knowles MR. Congenital heart disease and other heterotaxial defects in a large cohort of patients with primary ciliary dyskinesia. *Circulation*. 2007;115:2814–2821. doi: 10.1161/CIRCULATIONAHA.106.649038.
181. Nagel BH, Williams H, Stewart L, Paul J, Stümper O. Splenic state in surviving patients with visceral heterotaxy. *Cardiol Young*. 2005;15:469–473. doi: 10.1017/S1047951105211320.
182. Schutze GE, Mason EO Jr, Barson WJ, Kim KS, Wald ER, Givner LB, Tan TQ, Bradley JS, Yogev R, Kaplan SL. Invasive pneumococcal infections in children with asplenia. *Pediatr Infect Dis J*. 2002;21:278–282.
183. Wu MH, Wang JK, Lue HC. Sudden death in patients with right isomerism (asplenisism) after palliation. *J Pediatr*. 2002;140:93–96. doi: 10.1067/mpd.2002.120510.
184. Prendiville TW, Barton LL, Thompson WR, Fink DL, Holmes KW. Heterotaxy syndrome: defining contemporary disease trends. *Pediatr Cardiol*. 2010;31:1052–1058. doi: 10.1007/s00246-010-9764-z.
185. Uebing A, Rigby ML. The problem of infective endocarditis after transcatheter pulmonary valve implantation. *Heart*. 2015;101:749–751. doi: 10.1136/heartjnl-2014-307287.
186. Van Dijk I, Budts W, Cools B, Eyskens B, Boshoff DE, Heying R, Frerich S, Vanagt WY, Troost E, Gewillig M. Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants. *Heart*. 2015;101:788–793. doi: 10.1136/heartjnl-2014-306761.
187. McNeil JC, Ligon JA, Hulten KG, Dreyer WJ, Heinle JS, Mason EO, Kaplan SL. *Staphylococcus aureus* infections in children with congenital heart disease. *J Pediatric Infect Dis Soc*. 2013;2:337–344. doi: 10.1093/jpids/pit037.
188. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O'Gara PT, Lockhart PB, Darouiche RO, Ramlawi B, Derdeyn CP, Bolger AF, Levison ME, Taubert KA, Baltimore RS, Baddour LM; on behalf of the American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and Stroke Council. Vascular graft infections, mycotic aneurysms, and endovascular infections: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e412–e460. doi: 10.1161/CIR.0000000000000457.
189. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A,

- Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(suppl 2):S27–S72. doi: 10.1086/511159.
190. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2013;62:1–28.
  191. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR; Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged  $\geq 10$  years at increased risk for serogroup b meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015 [published correction appears in *MMWR Morb Mortal Wkly Rep*. 2015;64:806]. *MMWR Morb Mortal Wkly Rep*. 2015;64:608–612.
  192. Strikas RA; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP); ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years: United States, 2015. *MMWR Morb Mortal Wkly Rep*. 2015;64:93–94.
  193. Committee on Infectious Diseases; American Academy of Pediatrics; Kimberlin DW, Brady MT, Jackson MA, Long SS. Immunization in immunocompromised children. In: *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.
  194. Rubin LG, Schaffner W. Clinical practice: care of the asplenic patient. *N Engl J Med*. 2014;371:349–356. doi: 10.1056/NEJMc1314291.
  195. Collins N, Piran S, Harrison J, Azevedo E, Oechslin E, Silversides CK. Prevalence and determinants of anemia in adults with complex congenital heart disease and ventricular dysfunction (subaortic right ventricle and single ventricle physiology). *Am J Cardiol*. 2008;102:625–628. doi: 10.1016/j.amjcard.2008.04.034.
  196. Dimopoulos K, Diller GP, Giannakoulas G, Petraco R, Chamaidi A, Karaoli E, Mullen M, Swan L, Piepoli MF, Poole-Wilson PA, Francis DP, Gatzoulis MA. Anemia in adults with congenital heart disease relates to adverse outcome. *J Am Coll Cardiol*. 2009;54:2093–2100. doi: 10.1016/j.jacc.2009.06.050.
  197. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. *Circulation*. 2006;113:2454–2461. doi: 10.1161/CIRCULATIONAHA.105.583666.
  198. Diller GP, Dimopoulos K, Broberg CS, Kaya MG, Naghota US, Uebing A, Harries C, Goktekin O, Gibbs JS, Gatzoulis MA. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. *Eur Heart J*. 2006;27:1737–1742. doi: 10.1093/eurheartj/ehl116.
  199. Kaemmerer H, Fratz S, Braun SL, Koelling K, Eicken A, Brodherr-Heberlein S, Pietrzik K, Hess J. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. *Am J Cardiol*. 2004;94:825–828. doi: 10.1016/j.amjcard.2004.06.014.
  200. Broberg CS. Challenges and management issues in adults with cyanotic congenital heart disease. *Heart*. 2016;102:720–725. doi: 10.1136/heartjnl-2015-308042.
  201. Gidding SS, Stockman JA 3rd. Erythropoietin in cyanotic heart disease. *Am Heart J*. 1988;116(pt 1):128–132.
  202. Broberg CS, Jayaweera AR, Diller GP, Prasad SK, Thein SL, Bax BE, Burman J, Gatzoulis MA. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. *Am J Cardiol*. 2011;107:595–599. doi: 10.1016/j.amjcard.2010.10.019.
  203. Gidding SS, Bessel M, Liao YL. Determinants of hemoglobin concentration in cyanotic heart disease. *Pediatr Cardiol*. 1990;11:121–125.
  204. Broberg CS, Bax BE, Okonko DO, Rampling MW, Bayne S, Harries C, Davidson SJ, Uebing A, Khan AA, Thein S, Gibbs JS, Burman J, Gatzoulis MA. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. *J Am Coll Cardiol*. 2006;48:356–365. doi: 10.1016/j.jacc.2006.03.040.
  205. Oechslin E, Mebus S, Schulze-Neick I, Niwa K, Trindade PT, Eicken A, Hager A, Lang I, Hess J, Kaemmerer H. The adult patient with Eisenmenger syndrome: a medical update after Dana Point, part III: specific management and surgical aspects. *Curr Cardiol Rev*. 2010;6:363–372. doi: 10.2174/157340310793566127.
  206. Ammass N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. *J Am Coll Cardiol*. 1996;28:768–772.
  207. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. *Circulation*. 1993;87:1954–1959.
  208. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. *Int J Cardiol*. 2004;97(suppl 1):109–115. doi: 10.1016/j.ijcard.2004.08.015.
  209. Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, Gatzoulis MA. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. *Int J Cardiol*. 2011;151:307–312. doi: 10.1016/j.ijcard.2010.05.066.
  210. Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. *Int J Cardiol*. 2008;127:27–32. doi: 10.1016/j.ijcard.2007.04.078.
  211. Spence MS, Balaratnam MS, Gatzoulis MA. Clinical update: cyanotic adult congenital heart disease. *Lancet*. 2007;370:1530–1532. doi: 10.1016/S0140-6736(07)61647-X.
  212. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. *J Am Coll Cardiol*. 1999;34:223–232.
  213. Ross EA, Perloff JK, Danovitch GM, Child JS, Canobbio MM. Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. *Circulation*. 1986;73:396–400.
  214. Oya H, Nagaya N, Satoh T, Sakamaki F, Kyotani S, Fujita M, Nakanishi N, Miyatake K. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. *Heart*. 2000;84:53–58.
  215. Giglia TM, Massicotte MP, Tweddell JS, Barst RJ, Bauman M, Erickson CC, Feltes TF, Foster E, Hinoki K, Ichord RN, Kreutzer J, McCrindle BW, Newburger JW, Tabbutt S, Todd JL, Webb CL, on behalf of the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association [published correction appears in *Circulation*. 2014;129:e23]. *Circulation*. 2013;128:2622–2703. doi: 10.1161/01.cir.0000436140.77832.7a.
  216. Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ. Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors. *Circulation*. 2015;132:2385–2394. doi: 10.1161/CIRCULATIONAHA.115.01241.
  217. Khairy P, Fernandes SM, Mayer JE Jr, Triedman JK, Walsh EP, Lock JE, Landzberg MJ. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. *Circulation*. 2008;117:85–92. doi: 10.1161/CIRCULATIONAHA.107.738559.
  218. Tomkiewicz-Pajak L, Hoffman P, Trojnarowska O, Lipczyńska M, Podolec P, Undas A. Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. *J Thorac Cardiovasc Surg*. 2014;147:1284–1290. doi: 10.1016/j.jtcvs.2013.06.011.
  219. Varma C, Warr MR, Hendler AL, Paul NS, Webb GD, Therrien J. Prevalence of “silent” pulmonary emboli in adults after the Fontan operation. *J Am Coll Cardiol*. 2003;41:2252–2258.
  220. Valente AM, Bhatt AB, Cook S, Earing MG, Gersony DR, Aboulhosn J, Opatowsky AR, Lui G, Gurvitz M, Graham D, Fernandes SM, Khairy P, Webb G, Gerhard-Herman M, Landzberg MJ; AARCC (Alliance for Adult Research in Congenital Cardiology) Investigators. The CALF (Congenital Heart Disease in Adults Lower Extremity Systemic Venous Health in Fontan Patients) study. *J Am Coll Cardiol*. 2010;56:144–150. doi: 10.1016/j.jacc.2010.02.048.
  221. Idorn L, Jensen AS, Juul K, Reimers JJ, Johansson PI, Sørensen KE, Ostrowski SR, Søndergaard L. Thromboembolic complications in Fontan patients: population-based prevalence and exploration of the etiology. *Pediatr Cardiol*. 2013;34:262–272. doi: 10.1007/s00246-012-0431-4.
  222. Jahangiri M, Ross DB, Redington AN, Lincoln C, Shinebourne EA. Thromboembolism after the Fontan procedure and its modifications. *Ann Thorac Surg*. 1994;58:1409–1413.
  223. McCrindle BW, Manlhiot C, Cochrane A, Roberts R, Hughes M, Szechtman B, Weintraub R, Andrew M, Monagle P; Fontan Anticoagulation Study Group. Factors associated with thrombotic complications after the

- Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. *J Am Coll Cardiol*. 2013;61:346–353. doi: 10.1016/j.jacc.2012.08.1023.
224. Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. *Am J Cardiol*. 2006;98:254–258. doi: 10.1016/j.amjcard.2006.01.083.
  225. Waldman JD, Czapek EE, Paul MH, Schwartz AD, Levin DL, Schindler S. Shortened platelet survival in cyanotic heart disease. *J Pediatr*. 1975;87:77–79.
  226. Ware JA, Reaves WH, Horak JK, Solis RT. Defective platelet aggregation in patients undergoing surgical repair of cyanotic congenital heart disease. *Ann Thorac Surg*. 1983;36:289–294.
  227. Colon-Otero G, Gilchrist GS, Holcomb GR, Ilstrup DM, Bowie EJ. Preoperative evaluation of hemostasis in patients with congenital heart disease. *Mayo Clin Proc*. 1987;62:379–385.
  228. Wedemeyer AL, Edson JR, Krivit W. Coagulation in cyanotic congenital heart disease. *Am J Dis Child*. 1972;124:656–660.
  229. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome: factors relating to deterioration and death. *Eur Heart J*. 1998;19:1845–1855.
  230. Cromme-Dijkhuis AH, Hess J, Hählen K, Henkens CM, Bink-Boelkens MT, Eygelaar AA, Bos E. Specific sequelae after Fontan operation at mid- and long-term follow-up: arrhythmia, liver dysfunction, and coagulation disorders. *J Thorac Cardiovasc Surg*. 1993;106:1126–1132.
  231. Makhija Z, Sharma R. Hematologic alterations in patients with functionally univentricular hearts. *World J Pediatr Congenit Heart Surg*. 2012;3:350–358. doi: 10.1177/2150135112446356.
  232. Takeuchi D, Inai K, Shinohara T, Nakanishi T, Park IS. Blood coagulation abnormalities and the usefulness of D-dimer level for detecting intracardiac thrombosis in adult Fontan patients. *Int J Cardiol*. 2016;224:139–144. doi: 10.1016/j.ijcard.2016.09.017.
  233. Prabhu SP, Mahmood S, Sena L, Lee EY. MDCT evaluation of pulmonary embolism in children and young adults following a lateral tunnel Fontan procedure: optimizing contrast-enhancement techniques. *Pediatr Radiol*. 2009;39:938–944. doi: 10.1007/s00247-009-1304-8.
  234. Sandler KL, Markham LW, Mah ML, Byrum EP, Williams JR. Optimizing CT angiography in patients with Fontan physiology: single-center experience of dual-site power injection. *Clin Radiol*. 2014;69:e562–e567. doi: 10.1016/j.crad.2014.09.011.
  235. Koepke JA, Rodgers JL, Ollivier MJ. Pre-instrumental variables in coagulation testing. *Am J Clin Pathol*. 1975;64:591–596.
  236. Peterson P, Gottfried EL. The effects of inaccurate blood sample volume on prothrombin time (PT) and activated partial thromboplastin time (aPTT). *Thromb Haemost*. 1982;47:101–103.
  237. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. *Am J Clin Pathol*. 1998;109:754–757.
  238. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. *Am J Cardiol*. 2003;92:182–187.
  239. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, Davidson SJ, Bouzas B, Gibbs JS, Burman J, Gatzoulis MA. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. *J Am Coll Cardiol*. 2007;50:634–642. doi: 10.1016/j.jacc.2007.04.056.
  240. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPIC); ESC Committee for Practice Guidelines (CPG). ESC guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J*. 2010;31:2915–2957. doi: 10.1093/eurheartj/ehq249.
  241. Alsaied T, Alsidawi S, Allen CS, Faircloth J, Palumbo JS, Veldtman GR. Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis. *Heart*. 2015;101:1731–1737. doi: 10.1136/heartjnl-2015-307930.
  242. Potter BJ, Leong-Sit P, Fernandes SM, Feifer A, Mayer JE Jr, Triedman JK, Walsh EP, Landzberg MJ, Khairy P. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. *Int J Cardiol*. 2013;168:3940–3943. doi: 10.1016/j.ijcard.2013.06.058.
  243. Avitabile CM, Goldberg DJ, Zemel BS, Brodsky JL, Dodds K, Hayden-Rush C, Whitehead KK, Goldmuntz E, Rychik J, Leonard MB. Deficits in bone density and structure in children and young adults following Fontan palliation. *Bone*. 2015;77:12–16. doi: 10.1016/j.bone.2015.04.012.
  244. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Adesso V, McMahon DJ. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. *Am J Med*. 1997;103:197–207.
  245. Martínez-Quintana E, Rodríguez-González F, Nieto-Lago V. Subclinical hypothyroidism in grown-up congenital heart disease patients. *Pediatr Cardiol*. 2013;34:912–917. doi: 10.1007/s00246-012-0571-6.
  246. Bales CB, Kamath BM, Munoz PS, Nguyen A, Piccolli DA, Spinner NB, Horn D, Shults J, Leonard MB, Grimberg A, Loomes KM. Pathologic lower extremity fractures in children with Alagille syndrome. *J Pediatr Gastroenterol Nutr*. 2010;51:66–70. doi: 10.1097/MPG.0b013e3181cb9629.
  247. Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, Chung B, Cyttrynbaum C, Faghfoury H, Fishman L, García-Miñaur S, George S, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS. Practical guidelines for managing adults with 22q11.2 deletion syndrome. *Genet Med*. 2015;17:599–609. doi: 10.1038/gim.2014.175.
  248. Cassidy SB, Allanson JE. *Management of Genetic Syndromes*. 3rd ed. Hoboken, NJ: Wiley-Blackwell; 2010.
  249. Grover M, Brunetti-Pierri N, Belmont J, Phan K, Tran A, Shypailo RJ, Ellis KJ, Lee BH. Assessment of bone mineral status in children with Marfan syndrome. *Am J Med Genet A*. 2012;158A:2221–2224. doi: 10.1002/ajmg.a.35540.
  250. Bhambhani V, Muenke M. Noonan syndrome. *Am Fam Physician*. 2014;89:37–43.
  251. Conway GS, Band M, Doyle J, Davies MC. How do you monitor the patient with Turner's syndrome in adulthood? *Clin Endocrinol (Oxf)*. 2010;73:696–699. doi: 10.1111/j.1365-2265.2010.03861.x.
  252. Pober BR. Williams-Beuren syndrome [published correction appears in *N Engl J Med*. 2010;362:2142]. *N Engl J Med*. 2010;362:239–252. doi: 10.1056/NEJMra0903074.
  253. Pober BR, Morris CA. Diagnosis and management of medical problems in adults with Williams-Beuren syndrome. *Am J Med Genet C Semin Med Genet*. 2007;145C:280–290. doi: 10.1002/ajmg.c.30139.
  254. Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome [published correction appears in *Pediatrics*. 2011;128:1212]. *Pediatrics*. 2011;128:393–406. doi: 10.1542/peds.2011-1605.
  255. Narayanan DL, Yesodharan D, Kappanayil M, Kuthiroy S, Thampi MV, Hamza Z, Anilkumar A, Nair KM, Sundaram KR, Kumar RK, Nampoothiri S. Cardiac spectrum, cytogenetic analysis and thyroid profile of 418 children with Down syndrome from South India: a cross-sectional study. *Indian J Pediatr*. 2014;81:547–551. doi: 10.1007/s12098-013-1088-6.
  256. Mihçi E, Akçurün G, Eren E, Kardelen F, Akçurün S, Keser I, Ertuğ H. Evaluation of congenital heart diseases and thyroid abnormalities in children with Down syndrome. *Anadolu Kardiyol Derg*. 2010;10:440–445.
  257. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Annerén G. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. *Arch Dis Child*. 1998;79:242–245.
  258. Piran S, Bassett AS, Grewal J, Swaby JA, Morel C, Oechslin EN, Redington AN, Liu PP, Silversides CK. Patterns of cardiac and extracardiac anomalies in adults with tetralogy of Fallot. *Am Heart J*. 2011;161:131–137. doi: 10.1016/j.ahj.2010.09.015.
  259. Fukuda I, Hizuka N, Kurimoto M, Morita J, Tanaka S, Yamakado Y, Takano K. Autoimmune thyroid diseases in 65 Japanese women with Turner syndrome. *Endocr J*. 2009;56:983–986.
  260. Takeuchi D, Honda K, Shinohara T, Inai K, Toyohara K, Nakanishi T. Incidence, clinical course, and risk factors of amiodarone-induced thyroid dysfunction in Japanese adults with congenital heart disease. *Circ J*. 2015;79:1828–1834. doi: 10.1253/circj.CJ-15-0042.
  261. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. *Circulation*. 1999;100:149–154.
  262. Stan MN, Ammash NM, Warnes CA, Brennan MD, Thapa P, Nannenga MR, Bahn RS. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease: a cohort study. *Int J Cardiol*. 2013;167:821–826. doi: 10.1016/j.ijcard.2012.02.015.
  263. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the

- European Thyroid Association. *Clin Endocrinol (Oxf)*. 2004;61:494–502. doi: 10.1111/j.1365-2265.2004.02119.x.
264. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C, Odoguardi L, Love J, Bigalli A, Baschieri L, Pinchera A, Braverman L. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. *Ann Intern Med*. 1984;101:28–34.
265. Tanda ML, Piantanida E, Lai A, Liparulo L, Sassi L, Bogazzi F, Wiersinga WM, Braverman LE, Martino E, Bartalena L. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. *Clin Endocrinol (Oxf)*. 2008;69:812–818. doi: 10.1111/j.1365-2265.2008.03268.x.
266. Stan MN, Hess EP, Bahn RS, Warnes CA, Ammash NM, Brennan MD, Thapa P, Montori VM. A risk prediction index for amiodarone-induced thyrotoxicosis in adults with congenital heart disease. *J Thyroid Res*. 2012;97:2217–2222. doi: 10.1155/2012/210529.
267. Trapp CM, Elder RW, Gerken AT, Sopher AB, Lerner S, Aranoff GS, Rosenzweig EB. Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination. *J Clin Endocrinol Metab*. 2012;97:2217–2222. doi: 10.1210/jc.2012.1109.
268. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JJ, Pessah-Pollack R, Singer PA, Woeber KA; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [published corrections appear in *Thyroid*. 2013;23:129 and *Thyroid*. 2013;23:251]. *Thyroid*. 2012;22:1200–1235. doi: 10.1089/thy.2012.0205.
269. Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E; Practice Guidelines Sub-committee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone: 2007 [published correction appears in *Heart Rhythm*. 2007;4:1590]. *Heart Rhythm*. 2007;4:1250–1259. doi: 10.1016/j.hrthm.2007.07.020.
270. Somerville J. Management of adults with congenital heart disease: an increasing problem. *Annu Rev Med*. 1997;48:283–293. doi: 10.1146/annurev.med.48.1.283.
271. Goldberg DJ, Dodds K, Avitabile CM, Glatz AC, Brodsky JL, Semeao EJ, Rand EB, Mancilla EE, Rychik J. Children with protein-losing enteropathy after the Fontan operation are at risk for abnormal bone mineral density. *Pediatr Cardiol*. 2012;33:1264–1268. doi: 10.1007/s00246-012-0290-z.
272. Avitabile CM, Leonard MB, Zemel BS, Brodsky JL, Lee D, Dodds K, Hayden-Rush C, Whitehead KK, Goldmuntz E, Paridon SM, Rychik J, Goldberg DJ. Lean mass deficits, vitamin D status and exercise capacity in children and young adults after Fontan palliation. *Heart*. 2014;100:1702–1707. doi: 10.1136/heartjnl-2014-305723.
273. Izumi G, Inai K, Shimada E, Nakanishi T. Vitamin D kinetics and parathyroid gland function in patients with congenital heart disease. *Congenit Heart Dis*. 2016;11:700–706. doi: 10.1111/chd.12389.
274. Terrovitis J, Zotos P, Kaldara E, Diakos N, Tselioui E, Vakrou S, Kapelios C, Chalazonitis A, Nanas S, Toumanidis S, Kontoyannis D, Karga E, Nanas J. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. *Eur J Heart Fail*. 2012;14:326–332. doi: 10.1093/eurjhf/hfs002.
275. Petrone LR. Osteoporosis in adults with intellectual disabilities. *South Med J*. 2012;105:87–92. doi: 10.1097/SMJ.0b013e3182427042.
276. Cheung EN, George SR, Costain GA, Andrade DM, Chow EW, Silversides CK, Bassett AS. Prevalence of hypocalcaemia and its associated features in 22q11.2 deletion syndrome. *Clin Endocrinol (Oxf)*. 2014;81:190–196. doi: 10.1111/cen.12466.
277. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewicki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis: 2016. *Endocr Pract*. 2016;22(suppl 4):1–42. doi: 10.4158/EP161435.GL.
278. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA*. 2012;307:491–497. doi: 10.1001/jama.2012.39.
279. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;56:1113–1132. doi: 10.1016/j.jacc.2010.05.034.
280. Moons P, Van Deyk K, Dedroog D, Troost E, Budts W. Prevalence of cardiovascular risk factors in adults with congenital heart disease. *Eur J Cardiovasc Prev Rehabil*. 2006;13:612–616. doi: 10.1097/01.hjr.0000197472.81694.2b.
281. Pemberton VL, McCrindle BW, Barkin S, Daniels SR, Barlow SE, Binns HJ, Cohen MS, Economos C, Faith MS, Gidding SS, Goldberg CS, Kavey RE, Longmuir P, Rocchini AP, Van Horn L, Kaltman JR. Report of the National Heart, Lung, and Blood Institute's Working Group on Obesity and Other Cardiovascular Risk Factors in Congenital Heart Disease. *Circulation*. 2010;121:1153–1159. doi: 10.1161/CIRCULATIONAHA.109.921544.
282. Zaidi AN, Bauer JA, Michalsky MP, Olshove V, Boettner B, Phillips A, Cook SC. The impact of obesity on early postoperative outcomes in adults with congenital heart disease. *Congenit Heart Dis*. 2011;6:241–246. doi: 10.1111/j.1747-0803.2011.00522.x.
283. Wellnitz K, Harris IS, Sapru A, Fineman JR, Radman M. Longitudinal development of obesity in the post-Fontan population. *Eur J Clin Nutr*. 2015;69:1105–1108. doi: 10.1038/ejcn.2015.68.
284. Chung ST, Hong B, Patterson L, Petit CJ, Ham JN. High overweight and obesity in Fontan patients: a 20-year history. *Pediatr Cardiol*. 2016;37:192–200. doi: 10.1007/s00246-015-1265-7.
285. Freud LR, Webster G, Costello JM, Tsao S, Rychlik K, Backer CL, Deal BJ. Growth and obesity among older single ventricle patients presenting for Fontan conversion. *World J Pediatr Congenit Heart Surg*. 2015;6:514–520. doi: 10.1177/2150135115598212.
286. Pinto NM, Marino BS, Wernovsky G, de Ferranti SD, Walsh AZ, Laronde M, Hyland K, Dunn SO Jr, Cohen MS. Obesity is a common comorbidity in children with congenital and acquired heart disease. *Pediatrics*. 2007;120:e1157–e1164. doi: 10.1542/peds.2007-0306.
287. Shustak RJ, McGuire SB, October TW, Phoon CK, Chun AJ. Prevalence of obesity among patients with congenital and acquired heart disease. *Pediatr Cardiol*. 2012;33:8–14. doi: 10.1007/s00246-011-0049-y.
288. Pasquali SK, Marino BS, Pudusseri A, Wernovsky G, Paridon SM, Walker SA, Cohen MS. Risk factors and comorbidities associated with obesity in children and adolescents after the arterial switch operation and Ross procedure. *Am Heart J*. 2009;158:473–479. doi: 10.1016/j.ahj.2009.06.019.
289. Deen JF, Krieger EV, Slee AE, Arslan A, Arterburn D, Stout KK, Portman MA. Metabolic syndrome in adults with congenital heart disease. *J Am Heart Assoc*. 2016;5:e001132. doi: 10.1161/JAHA.114.001132.
290. Moon JR, Song J, Huh J, Kang IS, Park SW, Chang SA, Yang JH, Jun TG. Analysis of cardiovascular risk factors in adults with congenital heart disease. *Korean Circ J*. 2015;45:416–423. doi: 10.4070/kcj.2015.45.5.416.
291. Stefan MA, Hopman WM, Smythe JF. Effect of activity restriction owing to heart disease on obesity. *Arch Pediatr Adolesc Med*. 2005;159:477–481. doi: 10.1001/archpedi.159.5.477.
292. Owens JL, Musa N. Nutrition support after neonatal cardiac surgery. *Nutr Clin Pract*. 2009;24:242–249. doi: 10.1177/0884533609332086.
293. Barker DJ, Osmond C, Forsén TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. *N Engl J Med*. 2005;353:1802–1809. doi: 10.1056/NEJMoa044160.
294. Buelow MW, Earing MG, Hill GD, Cohen SB, Bartz PJ, Tweddell JS, Ginde S. The impact of obesity on postoperative outcomes in adults with congenital heart disease undergoing pulmonary valve replacement. *Congenit Heart Dis*. 2015;10:E197–E202. doi: 10.1111/chd.12266.
295. Martinez SC, Byku M, Novak EL, Cedars AM, Eghtesady P, Ludbrook PA, Billadello JJ. Increased body mass index is associated with congestive heart failure and mortality in adult Fontan patients. *Congenit Heart Dis*. 2016;11:71–79. doi: 10.1111/chd.12296.
296. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129:S100–S202 and *Circulation*. 2015;131:e326]. *Circulation*. 2014;129(suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1.
297. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, Lefevre ML, MacKenzie TD, Oggedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in *JAMA*. 2014;311:1809]. *JAMA*. 2014;311:507–520. doi: 10.1001/jama.2013.284427.

298. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in *Circulation*. 2014;129(suppl 2):S139–S140]. *Circulation*. 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee.
299. US Preventive Services Task Force. *Screening for Lipid Disorders in Adults*. Rockville, MD: US Dept. of Health and Human Services, Agency for Healthcare Research and Quality; 2013.
300. American Diabetes Association. Standards of medical care in diabetes—2014. *Diabetes Care*. 2014;37(suppl 1):S14–S80. doi: 10.2337/dc14-S014.
301. Moyer VA; U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2013;159:342–348. doi: 10.7326/0003-4819-159-5-201309030-00008.
302. Centers for Disease Control and Prevention. *National Diabetes Statistics Report*. Atlanta, GA: US Department of Health and Human Services; 2014.
303. Madsen NL, Marino BS, Woo JG, Thomsen RW, Videboek J, Laursen HB, Olsen M. Congenital heart disease with and without cyanotic potential and the long-term risk of diabetes mellitus: a population-based follow-up study. *J Am Heart Assoc*. 2016;5:e003076. doi: 10.1161/JAHA.115.003076.
304. Ohuchi H, Miyamoto Y, Yamamoto M, Ishihara H, Takata H, Miyazaki A, Yamada O, Yagihara T. High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease. *Am Heart J*. 2009;158:30–39. doi: 10.1016/j.ahj.2009.04.021.
305. Lui GK, Rogers IS, Ding VY, Hedlin HK, MacMillen K, Maron DJ, Sillman C, Romfh A, Dade TC, Haeffele C, Grady SR, McElhinney DB, Murphy DJ, Fernandes SM. Risk estimates for atherosclerotic cardiovascular disease in adults with congenital heart disease. *Am J Cardiol*. 2017;119:112–118. doi: 10.1016/j.amjcard.2016.09.023.
306. Dellborg M, Björk A, Pirozzi Fard MN, Ambring A, Eriksson P, Svensson AM, Gudbjörnsdóttir S. High mortality and morbidity among adults with congenital heart disease and type 2 diabetes. *Scand Cardiovasc J*. 2015;49:344–350. doi: 10.3109/14017431.2015.1085595.
307. Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, Davidson WR Jr, Earing MG, Ghoshhaja BB, Karamlou T, Mital S, Ting J, Tseng ZH; on behalf of the American Heart Association Council on Clinical Cardiology. Congenital heart disease in the older adult: a scientific statement from the American Heart Association [published correction appears in *Circulation*. 2015;131:e510]. *Circulation*. 2015;131:1884–1931. doi: 10.1161/CIR.0000000000000204.
308. Martínez-Quintana E, Rodríguez-González F. Lipoprotein(a) concentrations in adult congenital heart disease patients. *Congenit Heart Dis*. 2014;9:63–68. doi: 10.1111/chd.12093.
309. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129(suppl 2):S46–S48 and *Circulation*. 2015;132:e396]. *Circulation*. 2014;129(suppl 2):S1–45. doi: 10.1161/01.cir.0000437738.63853.7a.
310. Brili S, Tousoulis D, Antonopoulos AS, Antoniadis C, Hatzis G, Bakogiannis C, Papageorgiou N, Stefanadis C. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. *Heart*. 2012;98:325–329. doi: 10.1136/heartjnl-2011-300287.
311. Brili S, Tousoulis D, Antoniadis C, Vasiliadou C, Karali M, Papageorgiou N, Ioakeimidis N, Marinou K, Stefanadi E, Stefanadis C. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. *J Am Coll Cardiol*. 2008;51:742–749. doi: 10.1016/j.jacc.2007.10.036.
312. Gurvitz M, Ionescu-Iltu R, Guo L, Eisenberg MJ, Abrahamawicz M, Pilote L, Marelli AJ. Prevalence of cancer in adults with congenital heart disease compared to the general population. *Am J Cardiol*. 2016;118:1742–1750. doi: 10.1016/j.amjcard.2016.08.057.
313. Lee YS, Chen YT, Jeng MJ, Tsao PC, Yen HJ, Lee PC, Li SY, Liu CJ, Chen TJ, Chou P, Soong WJ. The risk of cancer in patients with congenital heart disease: a nationwide population-based cohort study in Taiwan. *PLoS One*. 2015;10:e0116844. doi: 10.1371/journal.pone.0116844.
314. Beauséjour Ladouceur V, Lawler PR, Gurvitz M, Pilote L, Eisenberg MJ, Ionescu-Iltu R, Guo L, Marelli AJ. Exposure to low-dose ionizing radiation from cardiac procedures in patients with congenital heart disease: 15-year data from a population-based longitudinal cohort. *Circulation*. 2016;133:12–20. doi: 10.1161/CIRCULATIONAHA.115.019137.
315. Altmann AE, Halliday JL, Giles GG. Associations between congenital malformations and childhood cancer: a register-based case-control study. *Br J Cancer*. 1998;78:1244–1249.
316. Narod SA, Hawkins MM, Robertson CM, Stiller CA. Congenital anomalies and childhood cancer in Great Britain. *Am J Hum Genet*. 1997;60:474–485.
317. Mili F, Khoury MJ, Flanders WD, Greenberg RS. Risk of childhood cancer for infants with birth defects, I: a record-linkage study, Atlanta, Georgia, 1968–1988. *Am J Epidemiol*. 1993;137:629–638.
318. Bjørge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer risk in children with birth defects and in their families: a population based cohort study of 5.2 million children from Norway and Sweden. *Cancer Epidemiol Biomarkers Prev*. 2008;17:500–506. doi: 10.1158/1055-9965.EPI-07-2630.
319. Olsen M, Garne E, Sværke C, Søndergaard L, Nissen H, Andersen HØ, Hjortdal VE, Johnsen SP, Videbæk J. Cancer risk among patients with congenital heart defects: a nationwide follow-up study. *Cardiol Young*. 2014;24:40–46. doi: 10.1017/S1047951112002144.
320. Smpokou P, Zand DJ, Rosenbaum KN, Summar ML. Malignancy in Noonan syndrome and related disorders. *Clin Genet*. 2015;88:516–522. doi: 10.1111/cge.12568.
321. Cizmarova M, Kostalova L, Pribilincova Z, Lasabova Z, Hlavata A, Kovacs L, Ilencikova D. Rasopathies: dysmorphic syndromes with short stature and risk of malignancy. *Endocr Regul*. 2013;47:217–222.
322. Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schlüter G, Gencik M, Überlacker B, Liszewski C, Schanze I, Greene MH, Spix C, Zenker M. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. *Br J Cancer*. 2015;112:1392–1397. doi: 10.1038/bjc.2015.75.
323. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes [published correction appears in *Blood Rev*. 2010;24:201]. *Blood Rev*. 2010;24:101–122. doi: 10.1016/j.blre.2010.03.002.
324. Schneider M, Chandler K, Tischkowitz M, Meyer S. Fanconi anaemia: genetics, molecular biology, and cancer: implications for clinical management in children and adults. *Clin Genet*. 2015;88:13–24. doi: 10.1111/cge.12517.
325. Scattone A, Caruso G, Marzullo A, Piscitelli D, Gentile M, Bonadonna L, Balducci G, Digilio MC, Jenkner A, Camassei FD, Boldrini R, Nazzaro P, Pollice L, Serio G. Neoplastic disease and deletion 22q11.2: a multicentric study and report of two cases. *Pediatr Pathol Mol Med*. 2003;22:323–341.
326. Toth G, Zraly CB, Thomson TL, Jones C, Lapetino S, Muraskas J, Zhang J, Dingwall AK. Congenital anomalies and rhabdoid tumor associated with 22q11 germline deletion and somatic inactivation of the SMARCB1 tumor suppressor. *Genes Chromosomes Cancer*. 2011;50:379–388. doi: 10.1002/gcc.20862.
327. Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L. Congenital abnormalities and childhood cancer. *Cancer*. 2005;103:1939–1948. doi: 10.1002/cncr.20985.
328. National Research Council. *Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2*. Washington, DC: The National Academies Press; 2006. <https://www.doi.org/10.17226/11340>. Accessed September 1, 2016.
329. International Commission on Radiological Protection (ICRP). Radiation and your patient: a guide for medical practitioners: a web module produced by Committee 3 of ICRP. 2001. [http://www.icrp.org/docs/Rad\\_for\\_GP\\_for\\_web.pdf](http://www.icrp.org/docs/Rad_for_GP_for_web.pdf). Accessed September 1, 2016.
330. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington



- de González A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *Lancet*. 2012;380:499–505. doi: 10.1016/S0140-6736(12)60815-0.
331. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. *Pediatr Radiol*. 2006;36(suppl 2):121–125. doi: 10.1007/s00247-006-0191-5.
332. Cohen S, Liu A, Gurvitz M, Goossens E, Guo L, Therrien J, Marelli A. Exposure to low-dose ionizing radiation from cardiac procedures and risk of malignancy in adults with congenital heart disease [abstract]. *Circulation*. 2016;134:A20252.
333. Ait-Ali L, Andreassi MG, Foffa I, Spadoni I, Vano E, Picano E. Cumulative patient effective dose and acute radiation-induced chromosomal DNA damage in children with congenital heart disease. *Heart*. 2010;96:269–274. doi: 10.1136/hrt.2008.160309.
334. Johnson JN, Hornik CP, Li JS, Benjamin DK Jr, Yoshizumi TT, Reiman RE, Frush DP, Hill KD. Cumulative radiation exposure and cancer risk estimation in children with heart disease. *Circulation*. 2014;130:161–167. doi: 10.1161/CIRCULATIONAHA.113.005425.
335. Hoffmann A, Engelfriet P, Mulder B. Radiation exposure during follow-up of adults with congenital heart disease. *Int J Cardiol*. 2007;118:151–153. doi: 10.1016/j.ijcard.2006.07.012.
336. Glatz AC, Purrington KS, Klinger A, King AR, Hellinger J, Zhu X, Gruber SB, Gruber PJ. Cumulative exposure to medical radiation for children requiring surgery for congenital heart disease. *J Pediatr*. 2014;164:789–794.e10. doi: 10.1016/j.jpeds.2013.10.074.
337. Andreassi MG, Ait-Ali L, Botto N, Manfredi S, Mottola G, Picano E. Cardiac catheterization and long-term chromosomal damage in children with congenital heart disease. *Eur Heart J*. 2006;27:2703–2708. doi: 10.1093/eurheartj/ehl014.
338. Spengler RF, Cook DH, Clarke EA, Olley PM, Newman AM. Cancer mortality following cardiac catheterization: a preliminary follow-up study on 4,891 irradiated children. *Pediatrics*. 1983;71:235–239.
339. McLaughlin JR, Kreiger N, Sloan MP, Benson LN, Hilditch S, Clarke EA. An historical cohort study of cardiac catheterization during childhood and the risk of cancer. *Int J Epidemiol*. 1993;22:584–591.
340. Modan B, Keinan L, Blumstein T, Sadetzki S. Cancer following cardiac catheterization in childhood. *Int J Epidemiol*. 2000;29:424–428.
341. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. *Proc Natl Acad Sci USA*. 2003;100:13761–13766. doi: 10.1073/pnas.2235592100.
342. Adams FH, Norman A, Bass D, Oku G. Chromosome damage in infants and children after cardiac catheterization and angiocardiography. *Pediatrics*. 1978;62:312–316.
343. Beels L, Bacher K, De Wolf D, Werbrout J, Thierens H. Gamma-H2AX foci as a biomarker for patient X-ray exposure in pediatric cardiac catheterization: are we underestimating radiation risks? *Circulation*. 2009;120:1903–1909. doi: 10.1161/CIRCULATIONAHA.109.880385.
344. Preston DL, Ron E, Tokuda S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958–1998. *Radiat Res*. 2007;168:1–64. doi: 10.1667/RR0763.1.
345. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. *Pediatrics*. 2010;126:746–759. doi: 10.1542/peds.2009-3207.
346. Harbron RW, Chapple CL, O'Sullivan JJ, Best KE, Berrington de González A, Pearce MS. Survival adjusted cancer risks attributable to radiation exposure from cardiac catheterisations in children. *Heart*. 2017;103:341–346. doi: 10.1136/heartjnl-2016-309773.
347. Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. *J Thorac Cardiovasc Surg*. 2005;129:1348–1352. doi: 10.1016/j.jtcvs.2004.10.005.
348. Elder RW, Parekh S, Book WM. More on hepatocellular carcinoma after the Fontan procedure. *N Engl J Med*. 2013;369:490. doi: 10.1056/NEJMc1306854.
349. Saliba T, Dorkhom S, O'Reilly EM, Ludwig E, Gansukh B, Abou-Alfa GK. Hepatocellular carcinoma in two patients with cardiac cirrhosis. *Eur J Gastroenterol Hepatol*. 2010;22:889–891. doi: 10.1097/MEG.0b013e32832e2bec.
350. Schwartz MC, Sullivan L, Cohen MS, Russo P, John AS, Guo R, Guttenberg M, Rand EB. Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study. *J Thorac Cardiovasc Surg*. 2012;143:904–909. doi: 10.1016/j.jtcvs.2011.08.038.
351. Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill AM, Wells RG. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. *Pediatr Cardiol*. 2012;33:1001–1012. doi: 10.1007/s00246-012-0315-7.
352. Opatowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M, Aboulhosn J, Hageman A, Kim Y, Deng LX, Grewal J, Zaidi AN, Almansoori G, Oechslin E, Earing M, Landzberg MJ, Singh MN, Wu F, Vaidya A. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease. *J Clin Endocrinol Metab*. 2015;100:1325–1334. doi: 10.1210/jc.2014-3863.
353. Yamamoto K, Namba N, Kubota T, Usui T, Takahashi K, Kitaoka T, Fujiwara M, Hori Y, Kogaki S, Oue T, Morii E, Ozono K. Pheochromocytoma complicated by cyanotic congenital heart disease: a case report. *Clin Pediatr Endocrinol*. 2016;25:59–65. doi: 10.1297/cpe.25.59.
354. Nissenblatt MJ. Cyanotic heart disease: “low altitude” risk for carotid body tumor? *Johns Hopkins Med J*. 1978;142:18–22.
355. Folger GM Jr, Roberts WC, Mehrizi A, Shah KD, Glancy DL, Carpenter CC, Esterly JR. Cyanotic malformations of the heart with pheochromocytoma: a report of five cases. *Circulation*. 1964;29:750–757.
356. Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. *Hum Pathol*. 1973;4:251–263.
357. King KS, Pacak K. Familial pheochromocytomas and paragangliomas. *Mol Cell Endocrinol*. 2014;386:92–100. doi: 10.1016/j.mce.2013.07.032.
358. Jochmanová I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. *J Natl Cancer Inst*. 2013;105:1270–1283. doi: 10.1093/jnci/djt201.
359. Favier J, Gimenez-Roqueplo AP. Pheochromocytomas: the (pseudo)-hypoxia hypothesis. *Best Pract Res Clin Endocrinol Metab*. 2010;24:957–968. doi: 10.1016/j.beem.2010.10.004.
360. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and Effects of Ionizing Radiation. 2000. [http://www.unsctar.org/docs/reports/2008/09-86753\\_Report\\_2008\\_Annex\\_B.pdf](http://www.unsctar.org/docs/reports/2008/09-86753_Report_2008_Annex_B.pdf). Accessed September 1, 2016.
361. Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in *Arch Intern Med*. 2016;164:448]. *Ann Intern Med*. 2016;164:279–296. doi: 10.7326/M15-2886.
362. Oeffinger KC, Fontham ET, Etzioni R, Herzog A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society [published correction appears in *JAMA*. 2016;315:1406]. *JAMA*. 2015;314:1599–1614. doi: 10.1001/jama.2015.12783.
363. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement [published corrections appear in *JAMA*. 2016;316:545 and *JAMA*. 2017;317:2239]. *JAMA*. 2016;315:2564–2575.
364. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology*. 2008;134:1570–1595. doi: 10.1053/j.gastro.2008.02.002.
365. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2012;157:120–134. doi: 10.7326/0003-4819-157-2-201207170-00459.
366. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin*. 2010;60:70–98. doi: 10.3322/caac.20066.

367. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;160:330–338. doi: 10.7326/M13-2771.
368. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, Walter L, Wolf AM, Brawley OW, Smith RA. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin.* 2013;63:107–117. doi: 10.3322/caac.21172.
369. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;156:880–891, W312. doi: 10.7326/0003-4819-156-12-201206190-00424.
370. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin.* 2012;62:147–172. doi: 10.3322/caac.21139.
371. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res.* 1995;141:259–277.
372. Hildreth NG, Shore RE, Dvoretzky PM. The risk of breast cancer after irradiation of the thymus in infancy. *N Engl J Med.* 1989;321:1281–1284. doi: 10.1056/NEJM198911093211901.
373. Lundell M, Mattsson A, Karlsson P, Holmberg E, Gustafsson A, Holm LE. Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. *Radiat Res.* 1999;151:626–632.
374. Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. *Circulation.* 2009;119:1056–1065. doi: 10.1161/CIRCULATIONAHA.108.191650.
375. Chowdhury UK, Mishra AK, Balakrishnan P, Sharma S, Kabra M, Ray R, Kalaivani M, Gupta R, Govindappa RM, Subramaniam GK. Role of fibrillin-1 genetic mutations and polymorphism in aortic dilatation in patients undergoing intracardiac repair of tetralogy of Fallot. *J Thorac Cardiovasc Surg.* 2008;136:757–766, 766.e1–766.e10. doi: 10.1016/j.jtcvs.2007.12.044.
376. Abiodun A, Moore H, Arif S, Bowater S, Thorne SA, Clift P, Hudsmith L, De Bono J. The burden of AF and stroke in adult congenital heart disease [abstract]. *Heart.* 2016;102:A54–A55.
377. Lin JH, Kean AC, Cordes TM. The risk of thromboembolic complications in Fontan patients with atrial flutter/fibrillation treated with electrical cardioversion. *Pediatr Cardiol.* 2016;37:1351–1360. doi: 10.1007/s00246-016-1441-4.
378. Connolly HM, Huston J 3rd, Brown RD Jr, Warnes CA, Ammash NM, Tajik AJ. Intracranial aneurysms in patients with coarctation of the aorta: a prospective magnetic resonance angiographic study of 100 patients. *Mayo Clin Proc.* 2003;78:1491–1499. doi: 10.4065/78.12.1491.
379. Curtis SL, Bradley M, Wilde P, Aw J, Chakrabarti S, Hamilton M, Martin R, Turner M, Stuart AG. Results of screening for intracranial aneurysms in patients with coarctation of the aorta. *AJNR Am J Neuroradiol.* 2012;33:1182–1186. doi: 10.3174/ajnr.A2915.
380. Donti A, Spinardi L, Brighenti M, Faccioli L, Leoni C, Fabi M, Trossello MP, Gargiulo GD, Bonvicini M. Frequency of intracranial aneurysms determined by magnetic resonance angiography in children (mean age 16) having operative or endovascular treatment of coarctation of the aorta (mean age 3). *Am J Cardiol.* 2015;116:630–633. doi: 10.1016/j.amjcard.2015.05.030.
381. Khairy P, Aboulhosn J, Broberg CS, Cohen S, Cook S, Dore A, Fernandes SM, Fournier A, Kay J, Levesque S, Macle L, Marcotte F, Mondésert B, Mongeon FP, Opatowsky AR, Proietti A, Rivard L, Ting J, Thibault B, Zaidi A, Hamilton R; Anticoagulation Therapy in Congenital Heart Disease (TACTIC) Investigators and the Alliance for Adult Research in Congenital Cardiology (AARCC). Thromboprophylaxis for atrial arrhythmias in congenital heart disease: a multicenter study. *Int J Cardiol.* 2016;223:729–735. doi: 10.1016/j.ijcard.2016.08.223.
382. Attenhofer Jost CH, Connolly HM, Scott CG, Burkhart HM, Ammash NM, Dearani JA. Increased risk of possible paradoxical embolic events in adults with Ebstein anomaly and severe tricuspid regurgitation. *Congenit Heart Dis.* 2014;9:30–37. doi: 10.1111/chd.12068.
383. Bhatt AB, Landzberg MJ, Gerhard-Herman M, Rodriguez-Huertas E, Graham D, Valente AM. Pathophysiology of chronic venous insufficiency in adults with a Fontan circulation (a pre-defined substudy of the CALF investigation). *Int J Cardiol.* 2013;165:41–45. doi: 10.1016/j.ijcard.2011.07.053.
384. Timmers GJ, Falke TH, Rauwerda JA, Huijgens PC. Deep vein thrombosis as a presenting symptom of congenital interruption of the inferior vena cava. *Int J Clin Pract.* 1999;53:75–76.
385. Goldmuntz E, Clark BJ, Mitchell LE, Jawad AF, Cuneo BF, Reed L, McDonald-McGinn D, Chien P, Feuer J, Zackai EH, Emanuel BS, Driscoll DA. Frequency of 22q11 deletions in patients with conotruncal defects. *J Am Coll Cardiol.* 1998;32:492–498.
386. Tan JL, Davlouros PA, McCarthy KP, Gatzoulis MA, Ho SY. Intrinsic histological abnormalities of aortic root and ascending aorta in tetralogy of Fallot: evidence of causative mechanism for aortic dilatation and aortopathy. *Circulation.* 2005;112:961–968. doi: 10.1161/CIRCULATIONAHA.105.537928.
387. Niwa K, Siu SC, Webb GD, Gatzoulis MA. Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. *Circulation.* 2002;106:1374–1378.
388. Kim WH, Seo JW, Kim SJ, Song J, Lee J, Na CY. Aortic dissection late after repair of tetralogy of Fallot. *Int J Cardiol.* 2005;101:515–516. doi: 10.1016/j.ijcard.2004.03.026.
389. Konstantinov IE, Fricke TA, d'Udekem Y, Robertson T. Aortic dissection and rupture in adolescents after tetralogy of Fallot repair. *J Thorac Cardiovasc Surg.* 2010;140:e71–e73. doi: 10.1016/j.jtcvs.2010.06.045.
390. Rathi VK, Doyle M, Williams RB, Yamrozik J, Shannon RP, Biederman RW. Massive aortic aneurysm and dissection in repaired tetralogy of Fallot; diagnosis by cardiovascular magnetic resonance imaging. *Int J Cardiol.* 2005;101:169–170. doi: 10.1016/j.ijcard.2004.05.037.
391. Schwartz ML, Gauvreau K, del Nido P, Mayer JE, Colan SD. Long-term predictors of aortic root dilation and aortic regurgitation after arterial switch operation. *Circulation.* 2004;110(suppl 1):II128–II132. doi: 10.1161/01.CIR.0000138392.68841.d3.
392. Cohen MS, Marino BS, McElhinney DB, Robbers-Visser D, van der Woerd W, Gaynor JW, Spray TL, Wernovsky G. Neo-aortic root dilation and valve regurgitation up to 21 years after staged reconstruction for hypoplastic left heart syndrome. *J Am Coll Cardiol.* 2003;42:533–540.
393. Alsoufi B, Fadel B, Bulbul Z, Al-Ahmadi M, Al-Fayyadh M, Kalloghlian A, Siblini G, Al-Halees Z. Cardiac reoperations following the Ross procedure in children: spectrum of surgery and reoperation results. *Eur J Cardiothorac Surg.* 2012;42:25–30. doi: 10.1093/ejcts/ezr288.
394. Horer J, Hanke T, Stierle U, Takkenberg JJ, Bogers AJ, Hemmer W, Rein JG, Hetzer R, Hubler M, Robinson DR, Sievers HH, Lange R. Neo-aortic root diameters and aortic regurgitation in children after the Ross operation. *Ann Thorac Surg.* 2009;88:594–600.
395. DeFaria Yeh D, Foster E. Is MRI the preferred method for evaluating right ventricular size and function in patients with congenital heart disease?: MRI is not the preferred method for evaluating right ventricular size and function in patients with congenital heart disease. *Circ Cardiovasc Imaging.* 2014;7:198–205. doi: 10.1161/CIRCIMAGING.113.000395.
396. Mivelaz Y, Leung MT, Zadorsky MT, De Souza AM, Potts JE, Sandor GG. Noninvasive assessment of vascular function in postoperative cardiovascular disease (coarctation of the aorta, tetralogy of Fallot, and transposition of the great arteries). *Am J Cardiol.* 2016;118:597–602. doi: 10.1016/j.amjcard.2016.05.055.
397. Cordina RL, Nakhla S, O'Meagher S, Leaney J, Graham S, Celermajer DS. Widespread endotheliopathy in adults with cyanotic congenital heart disease. *Cardiol Young.* 2015;25:511–519. doi: 10.1017/S1047951114000262.
398. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. *Circulation.* 2005;112:1106–1112. doi: 10.1161/CIRCULATIONAHA.105.534073.
399. Radke RM, Diller GP, Duck M, Orwat S, Hartmann D, Thum T, Baumgartner H. Endothelial function in contemporary patients with repaired coarctation of aorta. *Heart.* 2014;100:1696–1701. doi: 10.1136/heartjnl-2014-305739.

400. Vriend JW, de Groot E, de Waal TT, Zijta FM, Kastelein JJ, Mulder BJ. Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: influence of early repair. *Am Heart J*. 2006;151:242–247. doi: 10.1016/j.ahj.2005.02.013.
401. Ou P, Celermajor DS, Jolivet O, Buyens F, Herment A, Sidi D, Bonnet D, Mousseaux E. Increased central aortic stiffness and left ventricular mass in normotensive young subjects after successful coarctation repair. *Am Heart J*. 2008;155:187–193. doi: 10.1016/j.ahj.2007.09.008.
402. Keshavarz-Motamed Z, Rikhtegar Nezami F, Partida RA, Nakamura K, Staziaki PV, Ben-Assa E, Ghoshhajra B, Bhatt AB, Edelman ER. Elimination of transcoarctation pressure gradients has no impact on left ventricular function or aortic shear stress after intervention in patients with mild coarctation. *JACC Cardiovasc Interv*. 2016;9:1953–1965. doi: 10.1016/j.jcin.2016.06.054.
403. De Rita F, Crossland D, Griselli M, Hasan A. Management of the failing Fontan. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu*. 2015;18:2–6. doi: 10.1053/j.pcsu.2015.01.004.
404. Mahle WT, Todd K, Fyfe DA. Endothelial function following the Fontan operation. *Am J Cardiol*. 2003;91:1286–1288.
405. Henaine R, Vergnat M, Bacha EA, Baudet B, Lambert V, Belli E, Serraf A. Effects of lack of pulsatility on pulmonary endothelial function in the Fontan circulation. *J Thorac Cardiovasc Surg*. 2013;146:522–529. doi: 10.1016/j.jtcvs.2012.11.031.
406. Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. *Circulation*. 2003;107:3204–3208. doi: 10.1161/01.CIR.0000074210.49434.40.
407. Lambert E, d'Udekem Y, Cheung M, Sari CI, Inman J, Ahimastos A, Eikelis N, Pathak A, King I, Grigg L, Schlaich M, Lambert G. Sympathetic and vascular dysfunction in adult patients with Fontan circulation. *Int J Cardiol*. 2013;167:1333–1338. doi: 10.1016/j.ijcard.2012.04.015.
408. Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. *J Thorac Cardiovasc Surg*. 2007;134:738–745. doi: 10.1016/j.jtcvs.2007.04.027.
409. Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. *Circulation*. 2013;128:1713–1715. doi: 10.1161/CIRCULATIONAHA.113.004587.
410. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939.
411. Ruiz-Hurtado G, Ruilope LM. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. *Eur Heart J Cardiovasc Pharmacother*. 2015;1:126–131. doi: 10.1093/ehjcvp/pvu023.
412. Bromberg JJ, Beasley PJ, D'Angelo EJ, Landzberg M, DeMaso DR. Depression and anxiety in adults with congenital heart disease: a pilot study. *Heart Lung*. 2003;32:105–110. doi: 10.1067/mhl.2003.26.
413. Horner T, Liberthson R, Jellinek MS. Psychosocial profile of adults with complex congenital heart disease. *Mayo Clin Proc*. 2000;75:31–36. doi: 10.4065/75.1.31.
414. Kovacs AH, Saidi AS, Kuhl EA, Sears SF, Silversides C, Harrison JL, Ong L, Colman J, Oechslin E, Nolan RP. Depression and anxiety in adult congenital heart disease: predictors and prevalence. *Int J Cardiol*. 2009;137:158–164. doi: 10.1016/j.ijcard.2008.06.042.
415. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L; on behalf of the American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation*. 2014;129:1350–1369. doi: 10.1161/CIR.0000000000000019.
416. Ferguson M, Kovacs AH. An integrated adult congenital heart disease psychology service. *Congenit Heart Dis*. 2016;11:444–451. doi: 10.1111/chd.12331.
417. Deng LX, Khan AM, Drajpuch D, Fuller S, Ludmir J, Mascio CE, Partington SL, Qadeer A, Tobin L, Kovacs AH, Kim YY. Prevalence and correlates of post-traumatic stress disorder in adults with congenital heart disease. *Am J Cardiol*. 2016;117:853–857. doi: 10.1016/j.amjcard.2015.11.065.
418. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, Mussatto KA, Uzark K, Goldberg CS, Johnson WH Jr, Li J, Smith SE, Bellinger DC, Mahle WT; on behalf of the American Heart Association Congenital Heart Defects Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Stroke Council. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. *Circulation*. 2012;126:1143–1172. doi: 10.1161/CIR.0b013e318265ee8a.
419. Bellinger DC, Wypij D, Rivkin MJ, DeMaso DR, Robertson RL Jr, Dunbar-Masterson C, Rappaport LA, Wernovsky G, Jonas RA, Newburger JW. Adolescents with d-transposition of the great arteries corrected with the arterial switch procedure: neuropsychological assessment and structural brain imaging. *Circulation*. 2011;124:1361–1369. doi: 10.1161/CIRCULATIONAHA.111.026963.
420. Marino BS, Beebe D, Cassidy A, Riedel M, Burger M, Medek S, Finan S, Andersen C, Uzark K, Ross J, Ittenbach RF, Drotar D. Executive functioning, gross motor ability and mood are key drivers of poorer quality of life in child and adolescent survivors with complex congenital heart disease [abstract]. *J Am Coll Cardiol*. 2011;57:E421.
421. Cassidy AR, White MT, DeMaso DR, Newburger JW, Bellinger DC. Executive function in children and adolescents with critical cyanotic congenital heart disease. *J Int Neuropsychol Soc*. 2015;21:34–49. doi: 10.1017/S1355617714001027.
422. Tyagi M, Austin K, Stygall J, Deanfield J, Cullen S, Newman SP. What do we know about cognitive functioning in adult congenital heart disease? *Cardiol Young*. 2014;24:13–19. doi: 10.1017/S1047951113000747.
423. Wilson WM, Smith-Parrish M, Marino BS, Kovacs AH. Neurodevelopmental and psychosocial outcomes across the congenital heart disease lifespan. *Prog Pediatr Cardiol*. 2015;39:113–118.
424. Utens EM, Verhulst FC, Erdman RA, Meijboom FJ, Duivenvoorden HJ, Bos E, Roelandt JR, Hess J. Psychosocial functioning of young adults after surgical correction for congenital heart disease in childhood: a follow-up study. *J Psychosom Res*. 1994;38:745–758.
425. Utens EM, Bieman HJ, Verhulst FC, Erdman RA, Hess J. Psychopathology in young adults with congenital heart disease: follow-up results. *Eur Heart J*. 1998;19:647–651.
426. Wernovsky G, Stiles KM, Gauvreau K, Gentles TL, duPlessis AJ, Bellinger DC, Walsh AZ, Burnett J, Jonas RA, Mayer JE Jr, Newburger JW. Cognitive development after the Fontan operation. *Circulation*. 2000;102:883–889.
427. Dalfiento L, Mapelli D, Russo G, Scarso P, Limongi F, Iannizzi P, Melendugno A, Mazzotti E, Volpe B. Health related quality of life in adults with repaired tetralogy of Fallot: psychosocial and cognitive outcomes. *Heart*. 2005;91:213–218. doi: 10.1136/hrt.2003.029280.
428. Franklin WJ, Kloudas L, Saraf A, Karlsten M, Parekh D, Schwartz DD. Neurocognitive evaluation of adults with congenital heart disease: the NICHE study [abstract]. *J Am Coll Cardiol*. 2014;63:A489.
429. Claessens P, Moons P, de Casterlé BD, Cannaearts N, Budts W, Gewillig M. What does it mean to live with a congenital heart disease? A qualitative study on the lived experiences of adult patients. *Eur J Cardiovasc Nurs*. 2005;4:3–10. doi: 10.1016/j.ejcnurse.2004.12.003.
430. Pagé MG, Kovacs AH, Irvine J. How do psychosocial challenges associated with living with congenital heart disease translate into treatment interests and preferences? A qualitative approach. *Psychol Health*. 2012;27:1260–1270. doi: 10.1080/08870446.2012.667099.
431. Ong L, Nolan RP, Irvine J, Kovacs AH. Parental overprotection and heart-focused anxiety in adults with congenital heart disease. *Int J Behav Med*. 2011;18:260–267. doi: 10.1007/s12529-010-9112-y.
432. Apers S, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, Sluman MA, Wang JK, Jackson JL, Khairy P, Cook SC, Chidambaraman S, Alday L, Eriksen K, Dellborg M, Berghammer M, Mattsson E, Mackie AS, Menahem S, Caruana M, Veldtman G, Soufi A, Romfh AW, White K, Callus E, Kutty S, Fieuws S, Moons P; APPROACH-IS Consortium and ISACHD. Quality of life of adults with congenital heart disease in 15 countries: evaluating country-specific characteristics. *J Am Coll Cardiol*. 2016;67:2237–2245. doi: 10.1016/j.jacc.2016.03.477.
433. Moons P, Van Deyk K, Marquet K, Raes E, De Bleser L, Budts W, De Geest S. Individual quality of life in adults with congenital heart disease: a paradigm shift. *Eur Heart J*. 2005;26:298–307. doi: 10.1093/eurheartj/ehi054.
434. Geyer S, Norozi K, Buchhorn R, Wessel A. Chances of employment in women and men after surgery of congenital heart disease: comparisons between patients and the general population. *Congenit Heart Dis*. 2009;4:25–33. doi: 10.1111/j.1747-0803.2008.00239.x.

435. Karsenty C, Maury P, Blot-Souletie N, Ladouceur M, Leobon B, Senac V, Mondoly P, Elbaz M, Galinier M, Dulac Y, Carrié D, Acar P, Hascoet S. The medical history of adults with complex congenital heart disease affects their social development and professional activity. *Arch Cardiovasc Dis*. 2015;108:589–597. doi: 10.1016/j.acvd.2015.06.004.
436. Sluman MA, Apers S, Bouma BJ, van Melle JP, Peels CH, Post MC, Waskowsky WM, Moons P, Mulder BJ. Uncertainties in insurances for adults with congenital heart disease. *Int J Cardiol*. 2015;186:93–95. doi: 10.1016/j.ijcard.2015.03.208.
437. Gantt LT. Growing up heartsick: the experiences of young women with congenital heart disease. *Health Care Women Int*. 1992;13:241–248. doi: 10.1080/07399339209515999.
438. Zomer AC, Vaartjes I, Uiterwaal CS, van der Velde ET, Sieswerda GJ, Wajon EM, Plomp K, van Bergen PF, Verheugt CL, Krivka E, de Vries CJ, Lok DJ, Grobbee DE, Mulder BJ. Social burden and lifestyle in adults with congenital heart disease. *Am J Cardiol*. 2012;109:1657–1663. doi: 10.1016/j.amjcard.2012.01.397.
439. Crossland DS, Jackson SP, Lyall R, Hamilton JR, Hasan A, Burn J, O'Sullivan JJ. Patient attitudes to sternotomy and thoracotomy scars. *Thorac Cardiovasc Surg*. 2005;53:93–95. doi: 10.1055/s-2004-830422.
440. Cook SC, Valente AM, Maul TM, Dew MA, Hickey J, Jennifer Burger P, Harmon A, Clair M, Webster G, Cecchin F, Khairy P; Alliance for Adult Research in Congenital Cardiology. Shock-related anxiety and sexual function in adults with congenital heart disease and implantable cardioverter-defibrillators. *Heart Rhythm*. 2013;10:805–810. doi: 10.1016/j.hrthm.2013.02.016.
441. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in *Arch Gen Psychiatry Med*. 2005;62:768]. *Arch Gen Psychiatry*. 2005;62:593–602. doi: 10.1001/archpsyc.62.6.593.
442. Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. *Am Heart J*. 2005;150:193–201. doi: 10.1016/j.ahj.2004.08.025.
443. Kovacs AH, Silversides C, Saidi A, Sears SF. The role of the psychologist in adult congenital heart disease. *Cardiol Clin*. 2006;24:607–618, vi. doi: 10.1016/j.ccl.2006.08.003.
444. Enomoto J, Nakazawa J, Mizuno Y, Shirai T, Ogawa J, Niwa K. Psychosocial factors influencing mental health in adults with congenital heart disease. *Circ J*. 2013;77:749–755.
445. Freitas IR, Castro M, Sarmento SL, Moura C, Viana V, Areias JC, Areias ME. A cohort study on psychosocial adjustment and psychopathology in adolescents and young adults with congenital heart disease. *BMJ Open*. 2013;3:e001138. doi: 10.1136/bmjopen-2012-001138.
446. Rietveld S, Mulder BJ, van Beest I, Lubbers W, Prins PJ, Vioen S, Bennebroek-Everez F, Vos A, Casteelen G, Karsdorp P. Negative thoughts in adults with congenital heart disease. *Int J Cardiol*. 2002;86:19–26.
447. van Rijen EH, Utens EM, Roos-Hesselink JW, Meijboom FJ, van Domburg RT, Roelandt JR, Bogers AJ, Verhulst FC. Longitudinal development of psychopathology in an adult congenital heart disease cohort. *Int J Cardiol*. 2005;99:315–323. doi: 10.1016/j.ijcard.2004.09.004.
448. Callus E, Utens EM, Quadri E, Ricci C, Carminati M, Giamberti A, Chessa M. The impact of actual and perceived disease severity on pre-operative psychological well-being and illness behaviour in adult congenital heart disease patients. *Cardiol Young*. 2014;24:275–282. doi: 10.1017/S1047951113000218.
449. Philip N, Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. *Behav Genet*. 2011;41:403–412. doi: 10.1007/s10519-011-9468-z.
450. Wozniak A, Wolnik-Brzozowska D, Wisniewska M, Glazar R, Materna-Kirylyuk A, Moszura T, Badura-Stronka M, Skolozdrzy J, Krawczynski MR, Zeyland J, Bobkowski W, Slomski R, Latos-Bielenska A, Siwinska A. Frequency of 22q11.2 microdeletion in children with congenital heart defects in western Poland. *BMC Pediatr*. 2010;10:88. doi: 10.1186/1471-2431-10-88.
451. Jackson JL, Misiti B, Bridge JA, Daniels CJ, Vannatta K. Emotional functioning of adolescents and adults with congenital heart disease: a meta-analysis. *Congenit Heart Dis*. 2015;10:2–12. doi: 10.1111/chd.12178.
452. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. *Circulation*. 2008;118:1768–1775. doi: 10.1161/CIRCULATIONAHA.108.190769.
453. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, Levis B, Ziegelstein RC. Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? An updated systematic review. *PLoS One*. 2013;8:e52654. doi: 10.1371/journal.pone.0052654.
454. Kovacs AH, Bendell KL, Colman J, Harrison JL, Oechslin E, Silversides C. Adults with congenital heart disease: psychological needs and treatment preferences. *Congenit Heart Dis*. 2009;4:139–146. doi: 10.1111/j.1747-0803.2009.00280.x.
455. Kovacs AH, Bandyopadhyay M, Grace SL, Kentner AC, Nolan RP, Silversides CK, Irvine MJ. Adult Congenital Heart Disease-Coping And Resilience (ACHD-CARE): rationale and methodology of a pilot randomized controlled trial. *Contemp Clin Trials*. 2015;45(pt B):385–393. doi: 10.1016/j.cct.2015.11.002.
456. Dulfer K, Helbing WA, Duppen N, Utens EM. Associations between exercise capacity, physical activity, and psychosocial functioning in children with congenital heart disease: a systematic review. *Eur J Prev Cardiol*. 2014;21:1200–1215. doi: 10.1177/2047487313494030.
457. Hallgren M, Herring MP, Owen N, Dunstan D, Ekblom Ö, Helgadottir B, Nakitanda OA, Forsell Y. Exercise, physical activity, and sedentary behavior in the treatment of depression: broadening the scientific perspectives and clinical opportunities. *Front Psychiatry*. 2016;7:36. doi: 10.3389/fpsy.2016.00036.
458. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. *Eur Heart J*. 2014;35:1365–1372. doi: 10.1093/eurheartj/eh462.
459. Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: a narrative review. *ARYA Atheroscler*. 2015;11:295–304.
460. Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. *Depress Anxiety*. 2013;30:328–341. doi: 10.1002/da.22051.
461. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL; Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing [published correction appears in *Circulation*. 2009;120:e55–e59]. *Circulation*. 2008;117:2407–2423. doi: 10.1161/CIRCULATIONAHA.107.189473.
462. Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. *J Am Coll Cardiol*. 1999;33:222–227.
463. Rabbitts JA, Groenewald CB, Mauermann WJ, Barbara DW, Burkhart HM, Warnes CA, Oliver WC Jr, Flick RP. Outcomes of general anesthesia for noncardiac surgery in a series of patients with Fontan palliation. *Paediatr Anaesth*. 2013;23:180–187. doi: 10.1111/pan.12020.
464. Warner MA, Lunn RJ, O'Leary PW, Schroeder DR. Outcomes of noncardiac surgical procedures in children and adults with congenital heart disease: Mayo Perioperative Outcomes Group. *Mayo Clin Proc*. 1998;73:728–734.
465. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeyesundera DN. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130:e278–e333. doi: 10.1161/CIR.000000000000106.
466. Maxwell BG, Maxwell TG, Wong JK. Decentralization of care for adults with congenital heart disease in the United States: a geographic analysis of outpatient surgery. *PLoS One*. 2014;9:e106730. doi: 10.1371/journal.pone.0106730.
467. Lowe BS, Therrien J, Ionescu-Iltu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. *J Am Coll Cardiol*. 2011;58:538–546. doi: 10.1016/j.jacc.2011.03.033.
468. van Riel AC, Blok IM, Zwinderman AH, Wajon EM, Sadee AS, Bakker-de Boo M, van Dijk AP, Hoenderman ES, Riezebos RK, Mulder BJ, Bouma BJ. Lifetime risk of pulmonary hypertension for all patients after shunt closure. *J Am Coll Cardiol*. 2015;66:1084–1086. doi: 10.1016/j.jacc.2015.06.1318.
469. van Riel AC, Schuurin MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert CL, Hoorntje JC, Wagenaar LJ, Post MC, van Dijk AP, Hoenderman ES, Mulder BJ, Bouma BJ. Contemporary prevalence of

- pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. *Int J Cardiol.* 2014;174:299–305. doi: 10.1016/j.ijcard.2014.04.072.
470. Maxwell BG, Posner KL, Wong JK, Oakes DA, Kelly NE, Domino KB, Ramamoorthy C. Factors contributing to adverse perioperative events in adults with congenital heart disease: a structured analysis of cases from the Closed Claims Project. *Congenit Heart Dis.* 2015;10:21–29. doi: 10.1111/chd.12188.
471. Raines DE, Liberthson RR, Murray JR. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. *J Clin Anesth.* 1996;8:341–347.
472. Bennett JM, Ehrenfeld JM, Markham L, Eagle SS. Anesthetic management and outcomes for patients with pulmonary hypertension and intracardiac shunts and Eisenmenger syndrome: a review of institutional experience. *J Clin Anesth.* 2014;26:286–293. doi: 10.1016/j.jclinane.2013.11.022.
473. Fleisher LA, Eagle KA. Clinical practice: lowering cardiac risk in noncardiac surgery. *N Engl J Med.* 2001;345:1677–1682. doi: 10.1056/NEJMcp002842.
474. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ, Deal BJ, Dearani JA, de Groot N, Dubin AM, Harris L, Janousek J, Kanter RJ, Karpawich PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP, Warnes CA. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the pediatric and congenital electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). *Heart Rhythm.* 2014;11:e102–e165. doi: 10.1016/j.hrthm.2014.05.009.
475. Harden B, Tian X, Giese R, Nakhleh N, Kureshi S, Francis R, Hanumanthaiah S, Li Y, Swisher M, Kuehl K, Sami I, Olivier K, Jonas R, Lo CW, Leatherbury L. Increased postoperative respiratory complications in heterotaxy congenital heart disease patients with respiratory ciliary dysfunction. *J Thorac Cardiovasc Surg.* 2014;147:1291–1298.e2. doi: 10.1016/j.jtcvs.2013.06.018.
476. Swisher M, Jonas R, Tian X, Lee ES, Lo CW, Leatherbury L. Increased postoperative and respiratory complications in patients with congenital heart disease associated with heterotaxy. *J Thorac Cardiovasc Surg.* 2011;141:637–644, 644.e1–644.e3. doi: 10.1016/j.jtcvs.2010.07.082.
477. Nakhleh N, Francis R, Giese RA, Tian X, Li Y, Zariwala MA, Yagi H, Khalifa O, Kureshi S, Chatterjee B, Sabol SL, Swisher M, Connelly PS, Daniels MP, Srinivasan A, Kuehl K, Kravitz N, Burns K, Sami I, Omran H, Barmada M, Olivier K, Chawla KK, Leigh M, Jonas R, Knowles M, Leatherbury L, Lo CW. High prevalence of respiratory ciliary dysfunction in congenital heart disease patients with heterotaxy. *Circulation.* 2012;125:2232–2242. doi: 10.1161/CIRCULATIONAHA.111.079780.
478. Baum VC, Perloff JK. Anesthetic implications of adults with congenital heart disease. *Anesth Analg.* 1993;76:1342–1358.
479. Rebolledo MA, Perloff JK. Thrombosed pulmonary arterial aneurysm in Eisenmenger's syndrome. *Clin Cardiol.* 1999;22:127.
480. Gannedahl P, Odeberg S, Brodin LA, Sollevi A. Effects of posture and pneumoperitoneum during anaesthesia on the indices of left ventricular filling. *Acta Anaesthesiol Scand.* 1996;40:160–166.
481. Kelman GR, Swapp GH, Smith I, Benzie RJ, Gordon NL. Cardiac output and arterial blood-gas tension during laparoscopy. *Br J Anaesth.* 1972;44:1155–1162.
482. Marshall RL, Jebson PJ, Davie IT, Scott DB. Circulatory effects of carbon dioxide insufflation of the peritoneal cavity for laparoscopy. *Br J Anaesth.* 1972;44:680–684.
483. McClain CD, McGowan FX, Kovatsis PG. Laparoscopic surgery in a patient with Fontan physiology. *Anesth Analg.* 2006;103:856–858. doi: 10.1213/01.ane.0000237294.88298.8e.
484. Councilman-Gonzales LM, Bean-Lijewski JD, McAllister RK. A probable CO<sub>2</sub> embolus during laparoscopic cholecystectomy. *Can J Anaesth.* 2003;50:313. doi: 10.1007/BF03017807.
485. Ishiyama T, Hanagata K, Kashimoto S, Kumazawa T. Pulmonary carbon dioxide embolism during laparoscopic cholecystectomy. *Can J Anaesth.* 2001;48:319–320. doi: 10.1007/BF03019774.
486. Haroun-Bizri S, ElRassi T. Successful resuscitation after catastrophic carbon dioxide embolism during laparoscopic cholecystectomy. *Eur J Anaesthesiol.* 2001;18:118–121.
487. Tiouririne M, de Souza DG, Beers KT, Yemen TA. Anesthetic management of parturients with a Fontan circulation: a review of published case reports. *Semin Cardiothorac Vasc Anesth.* 2015;19:203–209. doi: 10.1177/1089253214566887.

# Circulation

## Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association

George K. Lui, Arwa Saidi, Ami B. Bhatt, Luke J. Burchill, Jason F. Deen, Michael G. Earing, Michael Gewitz, Jonathan Ginns, Joseph D. Kay, Yuli Y. Kim, Adrienne H. Kovacs, Eric V. Krieger, Fred M. Wu, Shi-Joon Yoo and On behalf of the American Heart Association Adult Congenital Heart Disease Committee of the Council on Clinical Cardiology and Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; and Council on Quality of Care and Outcomes Research

*Circulation*. published online October 9, 2017;

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2017 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/content/early/2017/10/06/CIR.0000000000000535>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation* is online at:  
<http://circ.ahajournals.org/subscriptions/>